UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September ~~28,~~26, ~~2019~~2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 0-27078

HENRY SCHEIN, INC.

(Exact name of registrant as specified in its charter)

Delaware	11-3136595
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

135 Duryea Road

Melville, New York

(Address of principal executive offices)

11747

(Zip Code)

(631) 843-5500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.01 per share	HSIC	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☑☒

No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☑☒

No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☑☒		Accelerated filer ☐
Non-accelerated filer ☐		Smaller reporting company ☐
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐

No ☑☒

As of October ~~28, 2019~~26, 2020, there were ~~146,740,149~~142,776,158 shares of the registrant’s common stock outstanding.

HENRY SCHEIN, INC.

~~HENRY SCHEIN, INC.~~
INDEX

		~~Page~~

PART I. FINANCIAL INFORMATION
					Page
ITEM 1.	Consolidated Financial Statements:

		Balance Sheets as of September ~~28, 2019~~26, 2020 and December ~~29, 2018~~28, 2019			3

		Statements of Income for the three and nine months ended
			September 26, 2020 and September 28, 2019 ~~and September 29, 2018~~		4

		Statements of Comprehensive Income for the three and nine months ended
			September 26, 2020 and September 28, 2019 ~~and September 29, 2018~~		5

		Statement of Changes in Stockholders' Equity for the three months ended
			September 26, 2020 and September 28, 2019 ~~and September 29, 2018~~		6

		Statement of Changes in Stockholders' Equity for the nine months ended
			September 26, 2020 and September 28, 2019 ~~and September 29, 2018~~		7

		Statements of Cash Flows for the nine months ended
			September 26, 2020 and September 28, 2019 ~~and September 29, 2018~~		8

		Notes to Consolidated Financial Statements			9
			Note 1 – Basis of Presentation		9
			Note 2 – Discontinued Operations		11
	10
	Note 3 – Critical Accounting Policies, ~~and~~ Accounting Pronouncements Adopted
			and Recently Issued Accounting Standards		1314
			Note 4 – Revenue from Contracts with Customers		15
			Note 5 – Segment Data		16
			Note 6 – Debt		17
			Note 7 – Leases		20
			Note 8 – Redeemable Noncontrolling Interests		22
			Note 9 – Comprehensive Income		23
			Note 10 – Fair Value Measurements		24
			Note 11 – Business Acquisitions		26
	27
	Note 12 – Plans of Restructuring			27
	28
	Note 13 – Earnings Per Share			28
	29
	Note 14 – Income Taxes			29
			Note 15 – Derivatives and Hedging Activities		30
			Note 16 – Stock-Based Compensation		31
			Note 17 – Supplemental Cash Flow Information		33
			Note 18 – Legal Proceedings		33
			Note 19 – ~~Subsequent Events~~Related Party Transactions		3837

ITEM 2.	Management's Discussion and Analysis of
			Financial Condition and Results of Operations		3938


ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk				58
	64

ITEM 4.	Controls and Procedures				59
	65

PART II. OTHER INFORMATION

ITEM 1.	Legal Proceedings				6660

ITEM 1A.	Risk Factors				7160

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds				7163

ITEM 5.	Other Information				63

ITEM 6.	Exhibits				7264

	Signature				7365

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

HENRY SCHEIN, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

September 28,

December 29,

2019

2018

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$
75,256

$
56,885

Accounts receivable, net of reserves of $55,116 and $53,121

1,278,939

1,168,776

Inventories, net

1,356,897

1,415,512

Prepaid expenses and other

404,650

451,033

Assets of discontinued operations

-

1,083,014

Total current assets

3,115,742

4,175,220
Property and equipment, net

311,123

314,221
Operating lease right-of-use assets, net

240,126

-
Goodwill

2,441,175

2,081,029
Other intangibles, net

603,172

376,031
Investments and other

385,744

420,367
Assets of discontinued operations

-

1,133,659

Total assets

$
7,097,082

$
8,500,527

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$
854,658

$
785,756

Bank credit lines

107,841

951,458

Current maturities of long-term debt

109,188

8,280

Operating lease liabilities

67,374

-

Liabilities of discontinued operations

-

577,607

Accrued expenses:

Payroll and related

230,239

242,876

Taxes

111,051

154,613

Other

428,341

498,237

Total current liabilities

1,908,692

3,218,827
Long-term debt

872,229

980,344
Deferred income taxes

68,643

27,218
Operating lease liabilities

182,505

-
Other liabilities

322,378

357,741
Liabilities of discontinued operations

-

62,453

Total liabilities

3,354,447

4,646,583

Redeemable noncontrolling interests

283,325

219,724
Redeemable noncontrolling interests from discontinued operations

-

92,432
Commitments and contingencies

Stockholders' equity:

Preferred stock, $.01 par value, 1,000,000 shares authorized,

NaN outstanding

-

-

Common stock, $.01 par value, 480,000,000 shares authorized,

146,254,864 outstanding on September 28, 2019 and

151,401,668 outstanding on December 29, 2018

1,463

1,514

Additional paid-in capital

65,641

-

Retained earnings

2,957,850

3,208,589

Accumulated other comprehensive loss

(195,426)

(248,771)

Total Henry Schein, Inc. stockholders' equity

2,829,528

2,961,332

Noncontrolling interests

629,782

580,456

Total stockholders' equity

3,459,310

3,541,788

Total liabilities, redeemable noncontrolling interests and stockholders' equity

$
7,097,082

$
8,500,527

				September 26,		December 28,
				2020		2019
				(unaudited)
ASSETS
Current assets:
	Cash and cash equivalents			$	533,495	$	106,097
	Accounts receivable, net of reserves of $86,371 and $60,002				1,407,676		1,246,246
	Inventories, net				1,463,434		1,428,799
	Prepaid expenses and other				464,645		445,360
			Total current assets		3,869,250		3,226,502
Property and equipment, net					334,954		329,645
Operating lease right-of-use assets, net					249,895		231,662
Goodwill					2,488,962		2,462,495
Other intangibles, net					510,395		572,878
Investments and other					356,439		327,919
			Total assets	$	7,809,895	$	7,151,101

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
	Accounts payable			$	1,006,958	$	880,266
	Bank credit lines				507,372		23,975
	Current maturities of long-term debt				110,015		109,849
	Operating lease liabilities				62,914		65,349
	Accrued expenses:
		Payroll and related			250,365		265,206
		Taxes			138,196		165,171
		Other			527,987		528,553
			Total current liabilities		2,603,807		2,038,369
Long-term debt					515,357		622,908
Deferred income taxes					32,408		64,989
Operating lease liabilities					200,611		176,267
Other liabilities					370,745		331,173
			Total liabilities		3,722,928		3,233,706

Redeemable noncontrolling interests					294,700		287,258
Commitments and contingencies

Stockholders' equity:
	Preferred stock, $.01 par value, 1,000,000 shares authorized,
		none outstanding			0		0
	Common stock, $.01 par value, 480,000,000 shares authorized,
		142,456,318 outstanding on September 26, 2020 and
		143,353,459 outstanding on December 28, 2019			1,425		1,434
	Additional paid-in capital				11,044		47,768
	Retained earnings				3,314,136		3,116,215
	Accumulated other comprehensive loss				(171,332)		(167,373)
		Total Henry Schein, Inc. stockholders' equity			3,155,273		2,998,044
	Noncontrolling interests				636,994		632,093
			Total stockholders' equity		3,792,267		3,630,137
		Total liabilities, redeemable noncontrolling interests and stockholders' equity		$	7,809,895	$	7,151,101

See accompanying notes.

Table of Contents

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

(unaudited)

Three Months Ended

Nine Months Ended

September 28,

September 29,

September 28,

September 29,

2019

2018

2019

2018

Net sales

$
2,508,767

$
2,355,565

$
7,316,862

$
6,945,047
Cost of sales

1,747,600

1,633,206

5,036,574

4,785,231

Gross profit

761,167

722,359

2,280,288

2,159,816
Operating expenses:

Selling, general and administrative

574,771

552,051

1,742,597

1,658,988

Litigation settlements

-

38,488

-

38,488

Restructuring costs (credits)

(802)

8,551

15,764

19,723

Operating income

187,198

123,269

521,927

442,617
Other income (expense):

Interest income

3,943

3,928

12,368

11,105

Interest expense

(12,373)

(20,430)

(41,459)

(54,569)

Other, net

(177)

(586)

(2,012)

(1,773)

Income from continuing operations before taxes, equity in

earnings of affiliates and noncontrolling interests

178,591

106,181

490,824

397,380
Income taxes

(41,964)

(16,633)

(117,326)

(86,654)
Equity in earnings of affiliates

6,585

6,699

14,771

14,829
Net income from continuing operations

143,212

96,247

388,269

325,555
Income (loss) from discontinued operations

5,641

30,729

(5,576)

97,561
Net Income

148,853

126,976

382,693

423,116

Less: Net income attributable to noncontrolling interests

(8,296)

(5,477)

(18,187)

(12,615)

Less: Net (income) loss attributable to noncontrolling interests

from discontinued operations

-

(21)

366

(7,593)
Net income attributable to Henry Schein, Inc.

$
140,557

$
121,478

$
364,872

$
402,908
Amounts attributable to Henry Schein Inc.:

Continuing operations

$
134,916

$
90,770

$
370,082

$
312,940
Discontinued operations

5,641

30,708

(5,210)

89,968
Net income attributable to Henry Schein, Inc.

$
140,557

$
121,478

$
364,872

$
402,908

Earnings per share from continuing operations attributable to Henry Schein, Inc.:

Basic

$
0.92

$
0.60

$
2.49

$
2.05

Diluted

$
0.91

$
0.59

$
2.47

$
2.03

Earnings (loss) per share from discontinued operations attributable to Henry Schein, Inc.:

Basic

$
0.04

$
0.20

$
(0.04)

$
0.59

Diluted

$
0.04

$
0.20

$
(0.04)

$
0.58

Earnings per share attributable to Henry Schein, Inc.:

Basic

$
0.96

$
0.80

$
2.46

$
2.63

Diluted

$
0.95

$
0.79

$
2.43

$
2.62

Weighted-average common shares outstanding:

Basic

147,136

152,533

148,603

152,970

Diluted

148,575

153,614

149,920

153,982

				Three Months Ended					Nine Months Ended
				September 26,			September 28,		September 26,		September 28,
				2020			2019		2020		2019

Net sales				$	2,840,146		$	2,508,767	$	6,953,416	$	7,316,862
Cost of sales					2,085,847			1,747,600		4,998,784		5,036,574
		Gross profit			754,299			761,167		1,954,632		2,280,288
Operating expenses:
	Selling, general and administrative				559,636			574,771		1,572,816		1,742,597
	Restructuring costs (credits)				6,992			(802)		27,713		15,764
		Operating income			187,671			187,198		354,103		521,927
Other income (expense):
	Interest income				2,294			3,943		7,481		12,368
	Interest expense				(11,111)			(12,373)		(29,409)		(41,459)
	Other, net				(1,699)			(177)		(2,210)		(2,012)
		Income from continuing operations before taxes,
			equity in earnings of affiliates and noncontrolling interests		177,155			178,591		329,965		490,824
Income taxes					(29,005)			(41,964)		(65,965)		(117,326)
Equity in earnings of affiliates					3,663			6,585		7,808		14,771
Net income from continuing operations					151,813			143,212		271,808		388,269
Income (loss) from discontinued operations, net of tax					(29)			5,641		274		(5,576)
Net income					151,784			148,853		272,082		382,693
	Less: Net income attributable to noncontrolling interests				(10,087)			(8,296)		(10,921)		(18,187)
	Plus: Net loss attributable to noncontrolling interests
			from discontinued operations		0			0		0		366
Net income attributable to Henry Schein, Inc.				$	141,697		$	140,557	$	261,161	$	364,872
Amounts attributable to Henry Schein Inc.:
Continuing operations				$	141,726		$	134,916	$	260,887	$	370,082
Discontinued operations					(29)			5,641		274		(5,210)
Net income attributable to Henry Schein, Inc.				$	141,697		$	140,557	$	261,161	$	364,872

Earnings per share from continuing operations attributable to Henry Schein, Inc.:

	Basic			$	1.00		$	0.92	$	1.83	$	2.49
	Diluted			$	0.99		$	0.91	$	1.82	$	2.47

Earnings (loss) per share from discontinued operations attributable to Henry Schein, Inc.:

	Basic			$	0		$	0.04	$	0	$	(0.04)
	Diluted			$	0		$	0.04	$	0	$	(0.04)

Earnings per share attributable to Henry Schein, Inc.:

	Basic			$	1.00		$	0.96	$	1.83	$	2.46
	Diluted			$	0.99		$	0.95	$	1.82	$	2.43

Weighted-average common shares outstanding:
	Basic				142,362			147,136		142,553		148,603
	Diluted				143,091	��		148,575		143,308		149,920

See accompanying notes.

Table of Contents

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(unaudited)

~~HENRY SCHEIN, INC.~~

~~CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME~~

~~(in thousands)~~

~~(unaudited)~~

				Three Months Ended				Nine Months Ended							Three Months Ended				Nine Months Ended
				September 28,		September 29,		September 28,		September 29,					September 26,		September 28,		September 26,		September 28,
				2019		2018		2019		2018					2020		2019		2020		2019

Net income	Net income			$	148,853	$	126,976	$	382,693	$	423,116	Net income			$	151,784	$	148,853	$	272,082	$	382,693

Other comprehensive income (loss), net of tax:	Other comprehensive income (loss), net of tax:											Other comprehensive income (loss), net of tax:
	Foreign currency translation loss				(60,635)		(10,582)		(43,926)		(106,154)	Foreign currency translation gain (loss)				37,588		(60,635)		(17,316)		(43,926)

	Unrealized gain (loss) from foreign currency hedging											Unrealized gain (loss) from foreign currency hedging
		activities			(1,263)		(379)		(1,586)		674		activities			(7,697)		(1,263)		2,457		(1,586)

	Unrealized investment gain (loss)				2		(1)		8		(2)	Unrealized investment gain (loss)				2		2		(5)		8

	Pension adjustment gain				400		116		832		1,056	Pension adjustment gain (loss)				(338)		400		161		832

Other comprehensive income, net of tax					(61,496)		(10,846)		(44,672)		(104,426)
Other comprehensive income (loss), net of tax												Other comprehensive income (loss), net of tax				29,555		(61,496)		(14,703)		(44,672)
Comprehensive income	Comprehensive income				87,357		116,130		338,021		318,690	Comprehensive income				181,339		87,357		257,379		338,021
	Comprehensive income attributable to noncontrolling											Comprehensive income attributable to noncontrolling
	interests:											interests:
		Net income			(8,296)		(5,498)		(17,821)		(20,208)		Net income			(10,087)		(8,296)		(10,921)		(17,821)
		Foreign currency translation loss			6,014		2,589		4,609		14,844		Foreign currency translation (gain) loss			(1,636)		6,014		10,744		4,609
			Comprehensive income attributable to noncontrolling											Comprehensive income attributable to noncontrolling
			interests		(2,282)		(2,909)		(13,212)		(5,364)			interests		(11,723)		(2,282)		(177)		(13,212)

Comprehensive income attributable to Henry Schein, Inc.	Comprehensive income attributable to Henry Schein, Inc.			$	85,075	$	113,221	$	324,809	$	313,326	Comprehensive income attributable to Henry Schein, Inc.			$	169,616	$	85,075	$	257,202	$	324,809

See accompanying notes.

Table of Contents

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except share and per share data)

(unaudited)

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income/(Loss)
Interests
Equity
Balance, June 29, 2019
147,823,846
$
1,478
$
65,356
$
2,900,387
$
(139,944)
$
618,937
$
3,446,214
Net income (excluding $4,105 attributable to Redeemable

noncontrolling interests from continuing operations)
-

-

-

140,557

-

4,191

144,748
Foreign currency translation loss (excluding loss of $5,748

attributable to Redeemable noncontrolling interests)
-

-

-

-

(54,621)

(266)

(54,887)
Unrealized loss from foreign currency hedging activities,

net of tax benefit of $422
-

-

-

-

(1,263)

-

(1,263)
Unrealized investment gain, net of tax of $1
-

-

-

-

2

-

2
Pension adjustment gain, net of tax of $185
-

-

-

-

400

-

400
Dividends paid
-

-

-

-

-

(84)

(84)
Other adjustments
-

-

1

-

-

-

1
Change in fair value of redeemable securities
-

-

1,667

-

-

-

1,667
Initial noncontrolling interests and related adjustments related

business acquisitions
-

-

-

-

-

7,004

7,004
Repurchase and retirement of common stock
(1,571,909)

(15)

(15,109)

(83,094)

-

-

(98,218)
Stock-based compensation expense
6,028

-

13,338

-

-

-

13,338
Shares withheld for payroll taxes
(3,101)

-

(199)

-

-

-

(199)
Settlement of stock-based compensation awards
-

-

(85)

-

-

-

(85)
Separation of Animal Health business
-

-

672

-

-

-

672
Balance, September 28, 2019
146,254,864
$
1,463
$
65,641
$
2,957,850
$
(195,426)
$
629,782
$
3,459,310

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income/(Loss)
Interests
Equity
Balance, June 30, 2018
153,231,669
$
1,532
$
-
$
3,123,398
$
(211,392)
$
9,371
$
2,922,909
Net income (excluding $2,648 attributable to Redeemable

noncontrolling interests)
-

-

-

121,478

-

2,850

124,328
Foreign currency translation loss (excluding loss of $2,217

attributable to Redeemable noncontrolling interests)
-

-

-

-

(7,993)

(372)

(8,365)
Unrealized loss from foreign currency hedging activities,

net of tax benefit of $27
-

-

-

-

(379)

-

(379)
Unrealized investment loss, net of tax benefit of $0
-

-

-

-

(1)

-

(1)
Pension adjustment gain, net of tax of $23
-

-

-

-

116

-

116
Dividends paid
-

-

-

-

-

(72)

(72)
Other adjustments
-

-

12

-

-

(28)

(16)
Purchase of noncontrolling interests
-

-

-

-

-

8

8
Change in fair value of redeemable securities
-

-

(2,988)

-

-

-

(2,988)
Initial noncontrolling interests and related adjustments related

business acquisitions
-

-

-

-

-

431,824

431,824
Repurchase and retirement of common stock
(751,928)

(7)

(10,625)

(50,119)

-

-

(60,751)
Stock issued upon exercise of stock options
2,000

(1)

55

-

-

-

54
Stock-based compensation expense
(40,017)

-

10,890

-

-

-

10,890
Shares withheld for payroll taxes
(4,044)

-

(421)

-

-

-

(421)
Settlement of stock-based compensation awards
-

-

(420)

-

-

-

(420)
Transfer of charges in excess of capital
-

-

3,497

(3,497)

-

-

-
Balance, September 29, 2018
152,437,680
$
1,524
$
-
$
3,191,260
$
(219,649)
$
443,581
$
3,416,716

									Accumulated
		Common Stock			Additional				Other				Total
		$.01 Par Value			Paid-in		Retained		Comprehensive		Noncontrolling		Stockholders'
		Shares		Amount	Capital		Earnings		Income / (Loss)		Interests		Equity
Balance, June 27, 2020		142,438,127	$	1,424	$	16,475	$	3,172,439	$	(199,251)	$	630,458	$	3,621,545
Net income (excluding $6,092 attributable to Redeemable
	noncontrolling interests from continuing operations)	-		0		0		141,697		0		3,995		145,692
Foreign currency translation gain (excluding gain of $1,277
	attributable to Redeemable noncontrolling interests)	-		0		0		0		35,952		359		36,311
Unrealized loss from foreign currency hedging activities,
	net of tax benefit of $2,793	-		0		0		0		(7,697)		0		(7,697)
Unrealized investment gain, net of tax of $0		-		0		0		0		2		0		2
Pension adjustment loss, net of tax benefit of $133		-		0		0		0		(338)		0		(338)
Dividends paid		-		0		0		0		0		(309)		(309)
Change in fair value of redeemable securities		-		0		(10,724)		0		0		0		(10,724)
Initial noncontrolling interests and adjustments related to
	business acquisitions	-		0		0		0		0		2,491		2,491
Stock-based compensation expense		21,113		0		5,710		0		0		0		5,710
Shares withheld for payroll taxes		(2,922)		1		(194)		0		0		0		(193)
Settlement of stock-based compensation awards		0		0		(223)		0		0		0		(223)
Balance, September 26, 2020		142,456,318	$	1,425	$	11,044	$	3,314,136	$	(171,332)	$	636,994	$	3,792,267

									Accumulated
		Common Stock			Additional				Other				Total
		$.01 Par Value			Paid-in		Retained		Comprehensive		Noncontrolling		Stockholders'
		Shares		Amount	Capital		Earnings		Income / (Loss)		Interests		Equity
Balance, June 29, 2019		147,823,846	$	1,478	$	65,356	$	2,900,387	$	(139,944)	$	618,937	$	3,446,214
Net income (excluding $4,105 attributable to Redeemable
	noncontrolling interests from continuing operations)	-		0		0		140,557		0		4,191		144,748
Foreign currency translation loss (excluding loss of $5,748
	attributable to Redeemable noncontrolling interests)	-		0		0		0		(54,621)		(266)		(54,887)
Unrealized loss from foreign currency hedging activities,
	net of tax benefit of $422	-		0		0		0		(1,263)		0		(1,263)
Unrealized investment gain, net of tax of $1		-		0		0		0		2		0		2
Pension adjustment gain, net of tax of $185		-		0		0		0		400		0		400
Dividends paid		-		0		0		0		0		(84)		(84)
Other adjustments		-		0		1		0		0		0		1
Change in fair value of redeemable securities		-		0		1,667		0		0		0		1,667
Initial noncontrolling interests and adjustments related to
	business acquisitions	-		0		0		0		0		7,004		7,004
Repurchase and retirement of common stock		(1,571,909)		(15)		(15,109)		(83,094)		0		0		(98,218)
Stock-based compensation expense		6,028		0		13,338		0		0		0		13,338
Shares withheld for payroll taxes		(3,101)		0		(199)		0		0		0		(199)
Settlement of stock-based compensation awards		0		0		(85)		0		0		0		(85)
Separation of Animal Health business		-		0		672		0		0		0		672
Balance, September 28, 2019		146,254,864	$	1,463	$	65,641	$	2,957,850	$	(195,426)	$	629,782	$	3,459,310

See accompanying notes.

Table of Contents

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except share and per share data)

(unaudited)

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income/(Loss)
Interests
Equity
Balance, December 29, 2018
151,401,668
$
1,514
$
-
$
3,208,589
$
(248,771)
$
580,456
$
3,541,788
Cumulative impact of adopting new accounting standards
-

-

-

(274)

-

-

(274)
Net income (excluding $10,618 attributable to Redeemable

noncontrolling interests from continuing operations

and ($366) from discontinued operations)
-

-

-

364,872

-

7,569

372,441
Foreign currency translation loss (excluding loss of $4,912

attributable to Redeemable noncontrolling interests

and $592 gain from discontinued operations)
-

-

-

-

(39,317)

(289)

(39,606)
Unrealized loss from foreign currency hedging activities,

net of tax benefit of $ 451
-

-

-

-

(1,586)

-

(1,586)
Unrealized investment gain, net of tax of $2
-

-

-

-

8

-

8
Pension adjustment gain, net of tax of $314
-

-

-

-

832

-

832
Dividends paid
-

-

-

-

-

(299)

(299)
Other adjustments
-

-

(3)

-

-

-

(3)
Change in fair value of redeemable securities
-

-

5,867

-

-

-

5,867
Initial noncontrolling interests and adjustments related to

business acquisitions
-

-

-

-

-

42,345

42,345
Adjustment for Animal Health Spin-off
87,629

1

-

-

-

-

1
Repurchase and retirement of common stock
(5,277,256)

(52)

(51,312)

(273,636)

-

-

(325,000)
Stock issued upon exercise of stock options
2,526

-

34

-

-

-

34
Stock-based compensation expense
218,563

2

33,433

-

-

-

33,435
Shares withheld for payroll taxes
(178,266)

(2)

(10,765)

-

-

-

(10,767)
Settlement of stock-based compensation awards
-

-

303

-

-

-

303
Share Sale related to Animal Health business
-

-

361,090

-

-

-

361,090
Separation of Animal Health business
-

-

(71,549)

(543,158)

93,408

-

(521,299)
Transfer of charges in excess of capital
-

-

(201,457)

201,457

-

-

-
Balance, September 28, 2019
146,254,864
$
1,463
$
65,641
$
2,957,850
$
(195,426)
$
629,782
$
3,459,310


									Accumulated
		Common Stock			Additional				Other				Total
		$.01 Par Value			Paid-in		Retained		Comprehensive		Noncontrolling		Stockholders'
		Shares		Amount	Capital		Earnings		Income / (Loss)		Interests		Equity
Balance, December 28, 2019		143,353,459	$	1,434	$	47,768	$	3,116,215	$	(167,373)	$	632,093	$	3,630,137
Cumulative impact of adopting new accounting standards		-		0		0		(412)		0		0		(412)
Net income (excluding $7,253 attributable to Redeemable
	noncontrolling interests from continuing operations)	-		0		0		261,161		0		3,668		264,829
Foreign currency translation gain (loss) (excluding loss of $10,999
	attributable to Redeemable noncontrolling interests)	-		0		0		0		(6,572)		255		(6,317)
Unrealized gain from foreign currency hedging activities,
	net of tax of $553	-		0		0		0		2,457		0		2,457
Unrealized investment loss, net of tax benefit of $1		-		0		0		0		(5)		0		(5)
Pension adjustment gain, net of tax of $66		-		0		0		0		161		0		161
Dividends paid		-		0		0		0		0		(816)		(816)
Purchase of noncontrolling interests		-		0		(1,597)		0		0		(701)		(2,298)
Change in fair value of redeemable securities		-		0		(5,141)		0		0		0		(5,141)
Initial noncontrolling interests and adjustments related to
	business acquisitions	-		0		0		0		0		2,495		2,495
Repurchase and retirement of common stock		(1,200,000)		(12)		(10,949)		(62,828)		0		0		(73,789)
Stock-based compensation expense (credit)		535,556		5		(6,653)		0		0		0		(6,648)
Shares withheld for payroll taxes		(232,697)		(2)		(14,197)		0		0		0		(14,199)
Settlement of stock-based compensation awards		0		0		164		0		0		0		164
Separation of Animal Health business		-		0		1,649		0		0		0		1,649
Balance, September 26, 2020		142,456,318	$	1,425	$	11,044	$	3,314,136	$	(171,332)	$	636,994	$	3,792,267

									Accumulated														Accumulated
		Common Stock			Additional				Other				Total			Common Stock			Additional				Other				Total
		$.01 Par Value			Paid-in		Retained		Comprehensive		Noncontrolling		Stockholders'			$.01 Par Value			Paid-in		Retained		Comprehensive		Noncontrolling		Stockholders'
		Shares		Amount	Capital		Earnings		Income/(Loss)		Interests		Equity			Shares		Amount	Capital		Earnings		Income / (Loss)		Interests		Equity
Balance, December 30, 2017		153,690,146	$	1,537	$	-	$	2,940,029	$	(130,067)	$	12,911	$	2,824,410
Balance, December 29, 2018															Balance, December 29, 2018	151,401,668	$	1,514	$	0	$	3,208,589	$	(248,771)	$	580,456	$	3,541,788
Cumulative impact of adopting new accounting standards	Cumulative impact of adopting new accounting standards	-		-		-		2,594		-		-		2,594	Cumulative impact of adopting new accounting standards	-		0		0		(274)		0		0		(274)
Net income (excluding $17,019 attributable to Redeemable
Net income (excluding $10,618 attributable to Redeemable															Net income (excluding $10,618 attributable to Redeemable
	noncontrolling interests)	-		-		-		402,908		-		3,189		406,097	noncontrolling interests from continuing operations
Foreign currency translation loss (excluding loss of $13,752
	attributable to Redeemable noncontrolling interests)	-		-		-		-		(91,310)		(1,092)		(92,402)	and ($366) from discontinued operations)	-		0		0		364,872		0		7,569		372,441
Unrealized gain from foreign currency hedging activities,
Foreign currency translation loss (excluding loss of $4,912															Foreign currency translation loss (excluding loss of $4,912
	net of tax of $405	-		-		-		-		674		-		674	attributable to Redeemable noncontrolling interests
Unrealized investment loss, net of tax benefit of $0		-		-		-		-		(2)		-		(2)
Pension adjustment gain, including tax of $393		-		-		-		-		1,056		-		1,056
															and $592 gain from discontinued operations)	-		0		0		0		(39,317)		(289)		(39,606)
Unrealized loss from foreign currency hedging activities,															Unrealized loss from foreign currency hedging activities,
															net of tax benefit of $451	-		0		0		0		(1,586)		0		(1,586)
Unrealized investment gain, net of tax of $2															Unrealized investment gain, net of tax of $2	-		0		0		0		8		0		8
Pension adjustment gain, net of tax of $314															Pension adjustment gain, net of tax of $314	-		0		0		0		832		0		832
Dividends paid	Dividends paid	-		-		-		-		-		(396)		(396)	Dividends paid	-		0		0		0		0		(299)		(299)
Other adjustments	Other adjustments	-		-		(11)		-		-		712		701	Other adjustments	-		0		(3)		0		0		0		(3)
Purchase of noncontrolling interests		-		-		-		-		-		(207)		(207)
Change in fair value of redeemable securities	Change in fair value of redeemable securities	-		-		(119,695)		-		-		-		(119,695)	Change in fair value of redeemable securities	-		0		5,867		0		0		0		5,867
Initial noncontrolling interests and adjustments related to	Initial noncontrolling interests and adjustments related to														Initial noncontrolling interests and adjustments related to
	business acquisitions	-		-		-		-		-		428,464		428,464	business acquisitions	-		0		0		0		0		42,345		42,345
Adjustment for Animal Health Spin-off															Adjustment for Animal Health Spin-off	87,629		1		0		0		0		0		1
Repurchase and retirement of common stock	Repurchase and retirement of common stock	(1,521,208)		(15)		(20,865)		(93,226)		-		-		(114,106)	Repurchase and retirement of common stock	(5,277,256)		(52)		(51,312)		(273,636)		0		0		(325,000)
Stock issued upon exercise of stock options	Stock issued upon exercise of stock options	153,516		1		3,075		-		-		-		3,076	Stock issued upon exercise of stock options	2,526		0		34		0		0		0		34
Stock-based compensation expense	Stock-based compensation expense	379,428		4		34,231		-		-		-		34,235	Stock-based compensation expense	218,563		2		33,433		0		0		0		33,435
Shares withheld for payroll taxes	Shares withheld for payroll taxes	(267,573)		(3)		(18,107)		-		-		-		(18,110)	Shares withheld for payroll taxes	(178,266)		(2)		(10,765)		0		0		0		(10,767)
Settlement of stock-based compensation awards	Settlement of stock-based compensation awards	3,371		-		(642)		-		-		-		(642)	Settlement of stock-based compensation awards	0		0		303		0		0		0		303
Deferred tax benefit arising from acquisition of
	noncontrolling interest in partnership	-		-		60,969		-		-		-		60,969
Share Sale related to Animal Health business															Share Sale related to Animal Health business	-		0		361,090		0		0		0		361,090
Separation of Animal Health business															Separation of Animal Health business	-		0		(71,549)		(543,158)		93,408		0		(521,299)
Transfer of charges in excess of capital	Transfer of charges in excess of capital	-		-		61,045		(61,045)		-		-		-	Transfer of charges in excess of capital	-		0		(201,457)		201,457		0		0		0
Balance, September 29, 2018		152,437,680	$	1,524	$	-	$	3,191,260	$	(219,649)	$	443,581	$	3,416,716
Balance, September 28, 2019															Balance, September 28, 2019	146,254,864	$	1,463	$	65,641	$	2,957,850	$	(195,426)	$	629,782	$	3,459,310

See accompanying notes.

Table of Contents

~~HENRY SCHEIN, INC.~~

~~CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~(in thousands, unaudited)~~

Nine Months Ended

September 28,

September 29,

2019

2018
Cash flows from operating activities:

Net income

$
382,693

$
423,116

Income (loss) from discontinued operations

(5,576)

97,561

Income from continuing operations

388,269

325,555

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

136,210

106,930

Stock-based compensation expense

33,110

30,570

Provision for losses on trade and other accounts receivable

7,576

7,400

Benefit from deferred income taxes

(3,468)

(3,768)

Equity in earnings of affiliates

(14,771)

(14,829)

Distributions from equity affiliates

67,913

14,585

Changes in unrecognized tax benefits

3,535

2,853

Other

(2,122)

503

Changes in operating assets and liabilities, net of acquisitions:

Accounts receivable

(115,384)

(141,017)

Inventories

75,093

(59,794)

Other current assets

(70,348)

(58,856)

Accounts payable and accrued expenses

19,567

59,263
Net cash provided by operating activities from continuing operations

525,180

269,395
Net cash provided by (used in) operating activities from discontinued operations

(163,653)

121,359
Net cash provided by operating activities

361,527

390,754

Cash flows from investing activities:

Purchases of fixed assets

(48,956)

(49,319)

Payments for equity investments and business

acquisitions, net of cash acquired

(657,093)

(38,996)

Proceeds from sale of equity investment

10,500

-

Proceeds/(payments) for loan to affiliate

16,448

(24,200)

Other

(12,248)

(11,557)
Net cash used in investing activities from continuing operations

(691,349)

(124,072)
Net cash used in investing activities from discontinued operations

(2,064)

(22,285)
Net cash used in investing activities

(693,413)

(146,357)

Cash flows from financing activities:

Proceeds from (repayments of) bank borrowings

(843,846)

404,098

Proceeds from issuance of debt

741

115,000

Principal payments for long-term debt

(10,252)

(24,483)

Debt issuance costs

(391)

(395)

Proceeds from issuance of stock upon exercise of stock options

34

3,076

Payments for repurchases of common stock

(325,000)

(114,106)

Payments for taxes related to shares withheld for employee taxes

(10,751)

(17,903)

Distribution received related to Animal Health Spin-off

1,120,000

-

Proceeds related to Animal Health Share Sale

361,090

-

Proceeds from (distributions to) noncontrolling stockholders

53,429

(6,142)

Acquisitions of noncontrolling interests in subsidiaries

(2,358)

(286,233)

Payments to Henry Schein Animal Health Business

(166,557)

(292,806)
Net cash provided by (used in) financing activities from continuing operations

176,139

(219,894)
Net cash provided by (used in) financing activities from discontinued operations

144,633

(98,622)
Net cash provided by (used in) financing activities

320,772

(318,516)

Effect of exchange rate changes on cash and cash equivalents-continuing operations

8,401

14,505
Effect of exchange rate changes on cash and cash equivalents-discontinued operations

(2,240)

4,696
Net change in cash and cash equivalents from continuing operations

18,371

(60,066)
Net change in cash and cash equivalents from discontinued operations

(23,324)

5,148
Cash and cash equivalents, beginning of period

56,885

158,002
Cash and cash equivalents, end of period

$
75,256

$
97,936

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except per share data)

(unaudited)

					September 26,		September 28,
					2020		2019
Cash flows from operating activities:
	Net income				$	272,082	$	382,693
	Income (loss) from discontinued operations					274		(5,576)
	Income from continuing operations					271,808		388,269
	Adjustments to reconcile net income to net cash provided by operating activities:
			Depreciation and amortization			140,664		136,210
			Stock-based compensation (credit) expense			(6,648)		33,110
			Provision for losses on trade and other accounts receivable			34,590		7,576
			Benefit from deferred income taxes			(48,193)		(3,468)
			Equity in earnings of affiliates			(7,808)		(14,771)
			Distributions from equity affiliates			10,053		67,913
			Changes in unrecognized tax benefits			(18,365)		3,535
			Other			4,794		(2,122)
			Changes in operating assets and liabilities, net of acquisitions:
				Accounts receivable		(199,858)		(115,384)
				Inventories		(25,830)		75,093
				Other current assets		(51,746)		(70,348)
				Accounts payable and accrued expenses		144,953		19,567
Net cash provided by operating activities from continuing operations						248,414		525,180
Net cash provided by (used in) operating activities from discontinued operations						648		(163,653)
Net cash provided by operating activities						249,062		361,527

Cash flows from investing activities:
	Purchases of fixed assets					(37,799)		(48,956)
	Payments related to equity investments and business
		acquisitions, net of cash acquired				(52,208)		(657,093)
	Proceeds from sale of equity investment					12,000		10,500
	Proceeds from (repayments to) loan to affiliate					(1,451)		16,448
	Other					(14,498)		(12,248)
Net cash used in investing activities from continuing operations						(93,956)		(691,349)
Net cash used in investing activities from discontinued operations						0		(2,064)
Net cash used in investing activities						(93,956)		(693,413)

Cash flows from financing activities:
	Net change in bank borrowings					484,139		(843,846)
	Proceeds from issuance of long-term debt					501,421		741
	Principal payments for long-term debt					(610,457)		(10,252)
	Debt issuance costs					(3,683)		(391)
	Debt extinguishment costs					(401)		0
	Proceeds from issuance of stock upon exercise of stock options					0		34
	Payments for repurchases of common stock					(73,789)		(325,000)
	Payments for taxes related to shares withheld for employee taxes					(14,007)		(10,751)
	Distribution received related to Animal Health Spin-off					0		1,120,000
	Proceeds related to Animal Health Share Sale					0		361,090
	Proceeds from (distributions to) noncontrolling shareholders					(3,995)		53,429
	Acquisitions of noncontrolling interests in subsidiaries					(14,934)		(2,358)
	Proceeds from (payments to) Henry Schein Animal Health Business					139		(166,557)
Net cash provided by financing activities from continuing operations						264,433		176,139
Net cash provided by (used in) financing activities from discontinued operations						(648)		144,633
Net cash provided by financing activities						263,785		320,772
Effect of exchange rate changes on cash and cash equivalents from continuing operations						8,507		8,401
Effect of exchange rate changes on cash and cash equivalents from discontinued operations						0		(2,240)
Net change in cash and cash equivalents from continuing operations						427,398		18,371
Net change in cash and cash equivalents from discontinued operations						0		(23,324)
Cash and cash equivalents, beginning of period						106,097		56,885
Cash and cash equivalents, end of period					$	533,495	$	75,256

See accompanying notes.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 1 – Basis of Presentation

Our consolidated financial statements include our accounts, as well as those of our wholly-owned and majority-owned subsidiaries. Certain prior period amounts have been reclassified to conform to the current period presentation.

Our accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements.

We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary beneficiary. The VIE is a trade accounts receivable securitization. We are the primary beneficiary because we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are included in our consolidated financial statements.

For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At September ~~28, 2019~~26, 2020 and December ~~29, 2018,~~28, 2019, trade accounts receivable that can only be used to settle obligations of this VIE were ~~$419~~$0 million and ~~$422~~$127 million, respectively, and the liabilities of the VIE where the creditors have recourse to us were ~~$350~~$0 million and ~~$350~~$100 million, respectively.

The consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December ~~29, 2018.~~28, 2019.

On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”~~) (the “Merger”~~). All financial information within this Form 10-Q presents the Henry Schein Animal Health Business as a discontinued operation.

The preparation of financial statements in conformity with ~~U.S. GAAP~~accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the nine months ended September ~~28, 2019~~26, 2020 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December ~~28, 2019.~~26, 2020.

In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020.Demand increased in the third quarter resulting in growth over the prior year driven by sales of personal protective equipment (PPE) and COVID-19 related products.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and indefinite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; vendor rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in the future. In addition, the impact of COVID-19 had a material adverse effect on our business, results of operations and cash flows in the second quarter of 2020. In the latter half of the second quarter, dental and medical practices began to re-open worldwide, and continued to do so during the third quarter. However, patient volumes remain below pre-COVID-19 levels and certain regions in the U.S. and internationally are experiencing an increase in COVID-19 cases. As such, there is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 2 – Discontinued Operations

Animal Health Spin-off

On the Distribution Date, we completed the Separation and subsequent Merger of the Henry Schein Animal Health Business with Vets First Choice. This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus (“Merger Sub”). In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors (the “Share Sale Investors”) for $361.1 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”). After the Share Sale and Animal Health Spin-off, Merger Sub consummated the Merger whereby it merged with and into Vets First Choice, with Vets First Choice surviving the Merger as a wholly owned subsidiary of Covetrus. Immediately following the consummation of the Merger, on a fully diluted basis, (i) approximately 63% of the shares of Covetrus common stock were (a) owned by our stockholders and the Share Sale Investors, and (b) held by certain employees of the Henry Schein Animal Health Business (in the form of certain equity awards), and (ii) approximately 37% of the shares of Covetrus common stock were (a) owned by stockholders of Vets First Choice immediately prior to the Merger, and (b) held by certain employees of Vets First Choice (in the form of certain equity awards). After the Separation and the Merger, we no longer beneficially owned any shares of Covetrus common stock and, following the Distribution Date, will not consolidate the financial results of Covetrus for the purpose of our financial reporting. Following the Separation and the Merger, Covetrus was an independent, publicly traded company on the Nasdaq Global Select Market.

In connection with the completion of the Animal Health Spin-off, we entered into a transition services agreement with Covetrus under which we have agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services.

As a result of the Separation, the financial position and results of operations of the Henry Schein Animal Health Business are presented as discontinued operations and have been excluded from continuing operations and segment results for all periods presented. The accompanying Notes to the Consolidated Financial Statements have been revised to reflect the effect of the Separation and all prior year balances have been revised accordingly to reflect continuing operations only. The historical statements of Comprehensive Income (Loss) and Shareholders' Equity have not been revised to reflect the Separation and instead reflect the Separation as an adjustment to the balances at September 28, 2019.

1011

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Summarized financial information for our discontinued operations is as follows:

	Three Months Ended				Nine Months Ended				Three Months Ended				Nine Months Ended
	September 28,		September 29,		September 28,		September 29,		September 26,		September 28,		September 26,		September 28,
	2019		2018		2019		2018		2020		2019		2020		2019

Net sales	$	-	$	924,114	$	319,522	$	2,881,747	$	0	$	0	$	0	$	319,522
Cost of goods sold										0		0		0		260,097
Gross profit		-		166,201		59,425		525,408		0		0		0		59,425
Operating income (loss)		(1,063)		42,657		(8,588)		130,800
Income tax expense (benefit)		(6,704)		12,767		(2,023)		37,430
Selling, general and administrative										326		1,063		782		68,013
Operating loss										(326)		(1,063)		(782)		(8,588)
Income tax benefit										(297)		(6,704)		(1,056)		(2,023)
Income (loss) from discontinued operations		5,641		30,729		(5,576)		97,561		(29)		5,641		274		(5,576)
Net (income) loss attributable to noncontrolling interests		-		(21)		366		(7,593)
Net loss attributable to noncontrolling interests										0		0		0		366
Net income (loss) from discontinued operations
attributable to Henry Schein, Inc.		5,641		30,708		(5,210)		89,968		(29)		5,641		274		(5,210)

The operating loss from discontinued operations for the three and nine months ended September 26, 2020 was primarily attributable to costs directly related to the Animal Health Spin-off. See Note 19-Related Party Transactions

for additional information.

The net income from discontinued operations for the nine months ended September 26, 2020 was primarily attributable to a tax refund received during Q2 2020 by a holding company previously part of our Animal Health legal structure.

The September 28, 2019 financial information above represents activity of the discontinued operations during the quarter and year-to-date through the Distribution Date.

The operating income (loss) from discontinued operations for the three and nine months ended September 28, 2019 was primarily attributable to the inclusion of approximately $0.3 million and $23.4 million, respectively, of transaction costs directly related to the Animal Health Spin-off.

The income from discontinued operations for the three months ended September 28, 2019 was primarily attributable to a change in estimate of the tax deductibility of transaction costs incurred that were directly related to the Animal Health Spin-off. The loss from discontinued operations for the nine months ended September 28, 2019 was primarily attributable to the inclusion of the transaction costs directly related to the Animal Health Spin-off.

1112

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

The following are the amounts of assets and liabilities that were transferred to Covetrus as of February 7, 2019 and December 29, 2018.

February 7,

December 29,

2019

2018

(unaudited)

(unaudited)

Cash and cash equivalents

$
6,815

$
23,324
Accounts receivable, net

432,812

434,935
Inventories, net

536,637

555,230
Prepaid expenses and other

120,546

69,525

Total current assets of discontinued operations

1,096,810

1,083,014
Property and equipment, net

69,790

68,177
Operating lease right-of-use asset, net

57,012

-
Goodwill

742,931

739,266
Other intangibles, net

205,793

208,213
Investments and other

120,518

118,003

Total long-term assets of discontinued operations

1,196,044

1,133,659
Total assets of discontinued operations

$
2,292,854

$
2,216,673

Accounts payable

$
316,162

$
441,453
Current maturities of long-term debt

657

675
Operating lease liabilities

18,951

-
Accrued expenses:

Payroll and related

36,847

36,888

Taxes

24,060

17,552

Other

80,400

81,039

Total current liabilities of discontinued operations

477,077

577,607
Long-term debt

1,176,105

23,529
Deferred income taxes

17,019

4,352
Operating lease liabilities

38,668

-
Other liabilities

29,209

34,572

Total long-term liabilities of discontinued operations

1,261,001

62,453
Total liabilities of discontinued operations

$
1,738,078

$
640,060
Redeemable noncontrolling interests

$
28,270

$
92,432

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~Note 3 – Critical Accounting Policies and Accounting Pronouncements Adopted~~

~~Critical Accounting Policies~~

Except for the accounting policy for leases appearing below, implemented as a result of adopting Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), there have been no material changes in our critical accounting policies during the nine months ended September 28, 2019, as compared to the critical accounting policies described in Item 7 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 29, 2018.

~~Leases~~

We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in Operating lease right-of-use (“ROU”) assets, Operating lease liabilities, and Non-current operating lease liabilities in our consolidated balance sheet. Finance leases are included in ~~Property and equipment~~, ~~Current maturities of long-term debt, and~~ ~~Long-term debt~~ ~~in our consolidated balance sheet.~~

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we use our incremental borrowing rate based on the information available at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Leases with a lease term of 12 months or less are not capitalized.

We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.

~~Accounting Pronouncements Adopted~~

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02 “Leases (Topic 842)” related to leases requiring the recognition of ROU assets and lease liabilities on the balance sheet. Most significant among the changes in the standard is the recognition of ROU assets and lease liabilities by lessors for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.

~~We adopted the standard on December 30, 2018 using a~~ ~~modified retrospective~~ approach utilizing a transition relief expedient method whereby we continue to apply existing lease guidance during the comparative periods and apply the new lease requirements through a cumulative-effect adjustment in the period of adoption, rather than in the earliest period presented without adjusting historical financial statements. We elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Information related to leases as of September 28, 2019~~is presented under Topic 842, while prior period amounts are not adjusted and continue to be reported under legacy guidance in Topic 840.~~

			February 7,		December 29,
			2019		2018


Cash and cash equivalents			$	6,815	$	23,324
Accounts receivable, net				432,812		434,935
Inventories, net				536,637		555,230
Prepaid expenses and other				120,546		69,525
		Total current assets of discontinued operations		1,096,810		1,083,014
Property and equipment, net				69,790		68,177
Operating lease right-of-use asset, net				57,012		0
Goodwill				742,931		739,266
Other intangibles, net				205,793		208,213
Investments and other				120,518		118,003
		Total long-term assets of discontinued operations		1,196,044		1,133,659
Total assets of discontinued operations			$	2,292,854	$	2,216,673

Accounts payable			$	316,162	$	441,453
Current maturities of long-term debt				657		675
Operating lease liabilities				18,951		0
Accrued expenses:
	Payroll and related			36,847		36,888
	Taxes			24,060		17,552
	Other			80,400		81,039
		Total current liabilities of discontinued operations		477,077		577,607
Long-term debt				1,176,105		23,529
Deferred income taxes				17,019		4,352
Operating lease liabilities				38,668		0
Other liabilities				29,209		34,572
		Total long-term liabilities of discontinued operations		1,261,001		62,453
Total liabilities of discontinued operations			$	1,738,078	$	640,060
Redeemable noncontrolling interests			$	28,270	$	92,432

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

~~The most significant impact was the recognition of ROU assets~~

Note 3 – Critical Accounting Policies, Accounting Pronouncements Adopted and ~~lease liabilities for operating leases, while our accounting for finance leases remained substantially unchanged.~~Recently Issued Accounting Standards

~~Adoption of~~Critical Accounting Policies

There have been no material changes in our critical accounting policies during the ~~new standard resulted~~nine months ended September 26, 2020, as compared to the critical accounting policies described in Item 8 to the ~~recording of additional net operating lease assets of $259.9 million and operating lease liabilities of $267.3 million, and a decrease of $1.1 million and $8.5 million~~consolidated financial statements included in ~~prepaid rent and deferred rent liabilities, respectively. The standard did not materially impact~~ our ~~consolidated net income and had no impact~~Annual Report on ~~cash flows.~~Form 10-K for the year ended December 28, 2019, except as follows:

Accounting Pronouncements Adopted

In ~~February 2018,~~January 2017, the ~~FASB~~Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2017-04, “Intangibles-Goodwill and Other” (Topic 350) (“ASU No. 2018-02, "Treatment of Stranded Tax Effects in Accumulated Other Comprehensive Income Resulting From the Tax Cuts and Jobs Act of 2017," which allows the reclassification from accumulated comprehensive income to retained earnings the income tax effects resulting2017-04”). ASU 2017-04 eliminates step two from the ~~Tax Cuts and Jobs Act~~goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of ~~2017 (the “Tax Act”). This~~a reporting unit. ASU ~~is effective for interim and~~2017-04 requires us to perform our annual goodwill impairment test by comparing the fair value of our reporting ~~periods beginning after December 15, 2018. The~~units to the carrying value of those units. If the carrying value exceeds the fair value, we will be required to recognize an impairment charge; however, the impairment charge should not exceed the amount of goodwill allocated to such reporting unit. Our adoption of ~~this~~ ASU 2017-04 on December 29, 2019 did not have a material impact on our consolidated financial statements.

In ~~August 2017,~~June 2016, the FASB issued ASU No. ~~2017-12, “Derivatives and Hedging”~~2016-13, "Financial Instruments-Credit Losses (Topic ~~815)~~326): Measurement of Credit Losses on Financial Instruments" (“ASU 2016-13”), which ~~simplified~~requires the ~~requirements~~measurement and recognition of expected credit losses for ~~hedge accounting, more closely aligns hedge accounting risk with risk management activities~~financial assets held at amortized cost. We adopted ASU 2016-13 using the modified-retrospective method and ~~increases transparency~~recorded an immaterial cumulative-effect adjustment to the opening balance of retained earnings. Based upon the ~~scope~~level and ~~results of hedging activities. This ASU amends the presentation and disclosure requirements and changes how we can assess the effectiveness~~makeup of our ~~hedging relationships. This~~financial asset portfolio, including accounts receivable, past loan loss activity and current known activity regarding our outstanding loans, the adoption of ASU 2016-13 on December 29, 2019 resulted in a decrease of $0.4 million to retained earnings.

Recently Issued Accounting Standards

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will ~~make more financial~~simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and ~~nonfinancial hedging strategies eligible~~simplify U.S. GAAP for ~~hedge accounting. This~~other areas of Topic 740 by clarifying and amending existing guidance. ASU 2017-04 is effective for ~~interim and annual reporting periods~~fiscal years beginning after December 15, ~~2018. The adoption~~2020. We do not expect that the requirements of this ASU ~~did not~~will have a material impact on our consolidated financial statements.

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options” (Subtopic 470-20) and “Derivatives and Hedging— in Entity’s Own Equity” (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments. In addition to eliminating certain accounting models, this ASU includes improvements to the disclosures for convertible instruments and earnings-per-share (EPS) guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. We do not expect that the requirements of this ASU will have a material impact on our consolidated financial statements.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 4 – Revenue from Contracts with Customers

Revenue is recognized in accordance with policies disclosed in Item 78 of our Annual Report on ~~form~~Form 10-K for the year ended December ~~29, 2018.~~28, 2019.

Disaggregation of Revenue

The following table disaggregates our revenue by segment and geography:

			Three Months Ended						Nine Months Ended								Three Months Ended						Nine Months Ended
			September 28, 2019						September 28, 2019								September 26, 2020						September 26, 2020
			North America		International		Global		North America		International		Global				North America		International		Global		North America		International		Global
Revenues:	Revenues:														Revenues:
Health care distribution															Health care distribution
	Health care distribution														Dental		$	1,008,836	$	641,017	$	1,649,853	$	2,413,154	$	1,653,067	$	4,066,221
		Dental	$	951,796	$	594,188	$	1,545,984	$	2,850,762	$	1,843,041	$	4,693,803	Medical			1,002,741		24,405		1,027,146		2,377,357		68,287		2,445,644
		Medical		784,349		19,360		803,709		2,125,002		59,925		2,184,927		Total health care distribution		2,011,577		665,422		2,676,999		4,790,511		1,721,354		6,511,865
		Total health care distribution		1,736,145		613,548		2,349,693		4,975,764		1,902,966		6,878,730
	Technology and value-added services			120,197		17,134		137,331		327,618		50,273		377,891
	Total excluding Corporate TSA revenues ⁽¹⁾			1,856,342		630,682		2,487,024		5,303,382		1,953,239		7,256,621
	Corporate TSA revenues ⁽¹⁾			1,077		20,666		21,743		4,098		56,143		60,241
Technology and value-added services															Technology and value-added services			120,949		17,406		138,355		327,374		48,173		375,547
Total excluding Corporate TSA revenues ⁽¹⁾															Total excluding Corporate TSA revenues ⁽¹⁾			2,132,526		682,828		2,815,354		5,117,885		1,769,527		6,887,412
Corporate TSA revenues ⁽¹⁾															Corporate TSA revenues ⁽¹⁾			0		24,792		24,792		0		66,004		66,004
		Total revenues	$	1,857,419	$	651,348	$	2,508,767	$	5,307,480	$	2,009,382	$	7,316,862		Total revenues	$	2,132,526	$	707,620	$	2,840,146	$	5,117,885	$	1,835,531	$	6,953,416

			Three Months Ended						Nine Months Ended								Three Months Ended						Nine Months Ended
			September 29, 2018						September 29, 2018								September 28, 2019						September 28, 2019
			North America		International		Global		North America		International		Global				North America		International		Global		North America		International		Global
Revenues:	Revenues:														Revenues:
Health care distribution															Health care distribution
	Health care distribution														Dental		$	951,792	$	594,189	$	1,545,981	$	2,850,669	$	1,843,042	$	4,693,711
		Dental	$	951,199	$	563,126	$	1,514,325	$	2,830,384	$	1,844,150	$	4,674,534	Medical			784,349		19,360		803,709		2,125,002		59,925		2,184,927
		Medical		702,758		19,184		721,942		1,915,944		60,423		1,976,367		Total health care distribution		1,736,141		613,549		2,349,690		4,975,671		1,902,967		6,878,638
		Total health care distribution		1,653,957		582,310		2,236,267		4,746,328		1,904,573		6,650,901
	Technology and value-added services			103,955		15,343		119,298		245,761		48,385		294,146
	Total excluding Corporate TSA revenues ⁽¹⁾			1,757,912		597,653		2,355,565		4,992,089		1,952,958		6,945,047
	Corporate TSA revenues ⁽¹⁾			-		-		-		-		-		-
		Total revenues	$	1,757,912	$	597,653	$	2,355,565	$	4,992,089	$	1,952,958	$	6,945,047
Technology and value-added services															Technology and value-added services			120,199		17,135		137,334		327,709		50,274		377,983
Total excluding Corporate TSA revenues ⁽¹⁾															Total excluding Corporate TSA revenues ⁽¹⁾			1,856,340		630,684		2,487,024		5,303,380		1,953,241		7,256,621
Corporate TSA revenues ⁽¹⁾															Corporate TSA revenues ⁽¹⁾			1,077		20,666		21,743		4,098		56,143		60,241
																Total revenues	$	1,857,417	$	651,350	$	2,508,767	$	5,307,478	$	2,009,384	$	7,316,862

~~(1)~~	Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which we expect to continue through August 2020.														Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered
~~(1)~~															into in connection with the Animal Health Spin-off, which has been substantially completed as of October 2020.

At December ~~29, 2018,~~28, 2019, the current portion of contract liabilities of ~~$65.3~~$70.8 million was reported in Accrued expenses: Other, and ~~$5.0~~$6.2 million related to non-current contract liabilities ~~was~~were reported in Other liabilities. During the nine months ended September ~~28, 2019,~~26, 2020, we recognized in revenue ~~$55.0~~$60.0 million of the amounts that were previously deferred at December ~~29, 2018.~~28, 2019. At September ~~28, 2019,~~26, 2020, the current and non-current portion of contract liabilities were ~~$58.2~~$58.3 million and ~~$4.9~~$6.8 million, respectively.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 5 – Segment Data

We conduct our business through 2 reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base.

The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. Our global dental group serves office-based dental practitioners, dental laboratories, schools and other institutions. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental and medical groups serve practitioners in 3231 countries worldwide.

Our global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Our technology group offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners.

The following tables present information about our reportable and operating segments:

			Three Months Ended				Nine Months Ended						Three Months Ended				Nine Months Ended
			September 28,		September 29,		September 28,		September 29,				September 26,		September 28,		September 26,		September 28,
			2019		2018		2019		2018				2020		2019		2020		2019
Net Sales:	Net Sales:										Net Sales:
	Health care distribution ^(1):										Health care distribution ⁽¹⁾
		Dental	$	1,545,984	$	1,514,325	$	4,693,803	$	4,674,534		Dental	$	1,649,853	$	1,545,981	$	4,066,221	$	4,693,711
		Medical		803,709		721,942		2,184,927		1,976,367		Medical		1,027,146		803,709		2,445,644		2,184,927
		Total health care distribution		2,349,693		2,236,267		6,878,730		6,650,901		Total health care distribution		2,676,999		2,349,690		6,511,865		6,878,638
	Technology and value-added services ⁽²⁾			137,331		119,298		377,891		294,146	Technology and value-added services ⁽²⁾			138,355		137,334		375,547		377,983
		Total excluding Corporate TSA revenue		2,487,024		2,355,565		7,256,621		6,945,047		Total excluding Corporate TSA revenue		2,815,354		2,487,024		6,887,412		7,256,621
	Corporate TSA revenues ⁽³⁾			21,743		-		60,241		-	Corporate TSA revenues ⁽³⁾			24,792		21,743		66,004		60,241
		Total	$	2,508,767	$	2,355,565	$	7,316,862	$	6,945,047		Total	$	2,840,146	$	2,508,767	$	6,953,416	$	7,316,862

(1)											Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

~~(3)~~(2)	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which we expect to continue through August 2020.										Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.


(3)											Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which has been substantially completed as of October 2020.


			Three Months Ended				Nine Months Ended						Three Months Ended				Nine Months Ended
			September 28,		September 29,		September 28,		September 29,				September 26,		September 28,		September 26,		September 28,
			2019		2018		2019		2018				2020		2019		2020		2019
Operating Income:	Operating Income:										Operating Income:
	Health care distribution		$	149,497	$	91,306	$	429,026	$	358,978	Health care distribution		$	148,657	$	149,495	$	271,477	$	428,934
	Technology and value-added services			37,701		31,963		92,901		83,639	Technology and value-added services			39,014		37,703		82,626		92,993
		Total	$	187,198	$	123,269	$	521,927	$	442,617		Total	$	187,671	$	187,198	$	354,103	$	521,927

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 6 – Debt

Bank Credit Lines

Bank credit lines consisted of the following:

		September 28,		December 29,			September 26,		December 28,
		2019		2018			2020		2019
Revolving credit agreement	Revolving credit agreement	$	75,000	$	175,000	Revolving credit agreement	$	0	$	0
364-day credit agreement						364-day credit agreement		500,000		0
Other short-term bank credit lines	Other short-term bank credit lines		32,841		376,458	Other short-term bank credit lines		7,372		23,975
Committed loan associated with Animal Health Spin-off			-		400,000
Total	Total	$	107,841	$	951,458	Total	$	507,372	$	23,975

The increase in the level of borrowings under our bank credit lines as of September 26, 2020 was attributable to potential cash requirements due to the impact of the COVID-19 pandemic.

Revolving Credit Agreement

On April 18, 2017, we entered into a $750 million revolving credit agreement (the “Credit Agreement”)~~. This facility,~~, which matures in April 2022~~, replaced our $500 million revolving credit facility, which was scheduled to mature in~~ ~~September 2019~~. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. We expect ~~that~~ the LIBOR rate ~~will~~to be discontinued at some point during ~~2021. We expect~~2021, which will require an amendment to ~~work with our lenders to identify a suitable replacement rate and amend~~ our debt agreements to reflect ~~this~~a new reference ~~rate accordingly.~~rate. We do not ~~believe that~~expect the discontinuation of LIBOR as a reference rate in our debt agreements ~~will~~to have a material adverse effect on our financial position or to materially affect our interest expense. ~~Additionally, the~~The Credit Agreement ~~provides,~~also requires, among other things, that we ~~are required to~~ maintain maximum leverage ~~ratios, and~~ratios. Additionally, the Credit Agreement contains customary representations, warranties and affirmative ~~covenants. The Credit Agreement also contains~~covenants as well as customary negative covenants, subject to negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of September ~~28, 2019~~26, 2020 and December ~~29, 2018,~~28, 2019, the borrowings on this revolving credit facility were $~~75.0~~0.0 million and ~~$175.0~~$0.0 million, respectively. As of September 26, 2020 and December 28, 2019, ~~and December 29, 2018,~~ there were ~~$9.6~~$9.5 million and ~~$11.2~~$9.6 million of letters of credit, respectively, provided to third parties under the credit facility.

~~Other Short-Term~~On April 17, 2020, we amended the Credit ~~Lines~~Agreement to, among other things, (i) modify the financial covenant from being based on total leverage ratio to net leverage ratio, (ii) adjust the pricing grid to reflect the net leverage ratio calculation, and (iii) increase the maximum maintenance leverage ratio through March 31, 2021.

As of September 28, 2019 and December 29, 2018, we had various other short-term bank credit lines available, of which $32.8 million and $376.5 million, respectively, were outstanding. At September 28, 2019 and December 29, 2018, borrowings under all of our credit lines had a weighted average interest rate of 2.94% and 3.30%, respectively.

~~Committed Loan Associated with Animal Health Spin-off~~364-Day Credit Agreement

On ~~May 21, 2018,~~April 17, 2020, we ~~obtained~~entered into a ~~$400~~new $700 million ~~committed loan which matured~~364-day credit agreement, with JPMorgan Chase Bank, N.A. and U.S. Bank National Association as joint lead arrangers and joint bookrunners. This facility matures on April 16, 2021. As of September 26, 2020, the ~~earlier of (i) March 31, 2019 and (ii)~~borrowings on this credit facility were $500 million. We have the ~~consummation of~~ability to borrow the Animal Health Spin-off. The proceeds of this loan were used, among other things, to fund our purchase of all of the equity interests in Butler Animal Health Holding Company, LLC (“BAHHC”) directly or indirectly owned by Darby Group Companies, Inc. (“Darby”) and certain other sellers pursuantremaining $200 million on a revolving basis as needed, subject to the terms and conditions of ~~that certain Amendment to Put Rights Agreements, dated as of April 20, 2018, by and among us, Darby, BAHHC and~~ the ~~individual sellers party thereto~~credit agreement. The interest rate for ~~an aggregate purchase price of $365 million. As of December 29, 2018, the balance outstanding~~borrowings under this facility will fluctuate based on ~~this loan was $400 million and is included within the “Bank credit lines” caption within~~ our ~~consolidated balance sheet.~~net leverage ratio. At ~~December 29, 2018,~~September 26, 2020, the interest rate on this ~~loan~~facility was ~~3.38%~~2.81%. ~~Concurrent with the completion~~The proceeds from this facility can be used for working capital requirements and general corporate purposes, including, but not limited to, permitted refinancing of ~~the Animal Health Spin-off on February 7, 2019, we re-paid the balance of this loan.~~existing indebtedness.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Other Short-Term Credit Lines

As of September 26, 2020 and December 28, 2019, we had various other short-term bank credit lines available, of which $7.4 million and $24 million, respectively, were outstanding. At September 26, 2020 and December 28, 2019, borrowings under all of these credit lines had a weighted average interest rate of 2.82% and 3.45%, respectively.

The decrease during the quarter ended September 26, 2020 in the weighted average interest rate under all of our credit lines was attributable to the Federal Reserve lowering borrowing rates during March 2020 in response to the COVID-19 pandemic.

Long-term debt

Long-term debt consisted of the following:

		September 28,		December 29,			September 26,		December 28,
		2019		2018			2020		2019
Private placement facilities	Private placement facilities	$	621,217	$	628,189	Private placement facilities	$	613,549	$	621,274
U.S. trade accounts receivable securitization	U.S. trade accounts receivable securitization		350,000		350,000	U.S. trade accounts receivable securitization		0		100,000
Various collateralized and uncollateralized loans payable with interest
Note payable due in 2025 with an interest rate of 3.1%						Note payable due in 2025 with an interest rate of 3.1%
						at September 26, 2020		1,438		0
Various collateralized and uncollateralized loans payable with interest,						Various collateralized and uncollateralized loans payable with interest,
	in varying installments through 2024 at interest rates					in varying installments through 2023 at interest rates
	ranging from 2.56% to 10.5% at September 28,2019 and					ranging from 2.62% to 4.22% at September 26, 2020 and
	ranging from 2.61% to 4.17% at December 29, 2018		5,995		6,491	ranging from 2.56% to 10.5% at December 28, 2019		4,273		6,089
Finance lease obligations payable through 2029 with interest rates
Finance lease obligations (see Note 7)						Finance lease obligations (see Note 7)		6,112		5,394
	ranging from 1.64% to 19.13% at September 28,2019 and					Total		625,372		732,757
	ranging from 1.45% to 6.00% at December 29, 2018		4,205		3,944
Total			981,417		988,624
Less current maturities	Less current maturities		(109,188)		(8,280)	Less current maturities		(110,015)		(109,849)
	Total long-term debt	$	872,229	$	980,344	Total long-term debt	$	515,357	$	622,908

Private Placement Facilities

On September 15, 2017, we increased our available private placement facilities with three insurance companies to a total facility amount of $1 ~~billion, and extended~~billion. On June 23, 2020, the expiration date ~~to September 15, 2020.~~for our private placement facilities was extended through June 23, 2023. These facilities are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through ~~September 15, 2020.~~June 23, 2023. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. On June 29, 2018, we amended and restated the above private placement facilities to, among other things, (i) permit the consummation of the Animal Health Spin-off and (ii) provide for the issuance of notes in Euros, British Pounds and Australian Dollars, in addition to U.S. Dollars. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

four-quarter period ending on or after June 30, 2021 showing compliance with the total leverage ratio requirement, and (iii) make certain other changes conforming to the Credit Agreement, dated as of April 18, 2017.

The components of our private placement facility borrowings as of September ~~28, 2019~~26, 2020 are presented in the following table (in thousands):


		Amount of						Amount of
		Borrowing		Borrowing				Borrowing		Borrowing
Date of Borrowing		Outstanding		Rate		Due Date		Outstanding		Rate		Due Date
September 2, 2010		$	100,000	3.79	%	September 2, 2020
January 20, 2012(1)			50,000	3.45		January 20, 2024		$	14,286	3.09	%	January 20, 2022
January 20, 2012			21,429	3.09		January 20, 2022			50,000	3.45		January 20, 2024
December 24, 2012			50,000	3.00		December 24, 2024			50,000	3.00		December 24, 2024
June 2, 2014			100,000	3.19		June 2, 2021			100,000	3.19		June 2, 2021
June 16, 2017			100,000	3.42		June 16, 2027			100,000	3.42		June 16, 2027
September 15, 2017			100,000	3.52		September 15, 2029			100,000	3.52		September 15, 2029
January 2, 2018			100,000	3.32		January 2, 2028			100,000	3.32		January 2, 2028
September 2, 2020 (2)									100,000	2.35		September 3, 2030
Less: Deferred debt issuance costs			(212)						(737)
		$	621,217					$	613,549


(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.	(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.						(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.
(2) On September 2, 2020, we refinanced our $100 million private placement borrowing at 3.79%, originally due on September 2, 2020, with a similar 10-year borrowing at 2.35% maturing on September 2, 2030.							(2) On September 2, 2020, we refinanced our $100 million private placement borrowing at 3.79%, originally due on September 2, 2020, with a similar 10-year borrowing at 2.35% maturing on September 2, 2030.

U.S. Trade Accounts Receivable Securitization

We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. Our current facility, which has a purchase limit of $350 million, ~~and~~ was ~~previously~~ scheduled to expire on April 29, 2022. On June 22, 2020, ~~has been~~the expiration date for this facility was extended to ~~April 29, 2022. The~~June 12, 2023. As of September 26, 2020 and December 28, 2019, the borrowings outstanding under this securitization facility were ~~$350~~$0 million ~~as of both September 28, 2019~~ and ~~December 29, 2018,~~$100 million, respectively. At September 26, 2020, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.22% plus 0.95%, for a combined rate of 1.17%. At December 28, 2019, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate ~~of2.21 %~~of 1.90% plus 0.75%, for a combined rate of ~~2.96%~~2.65%. ~~At December 29, 2018, the interest rate on borrowings~~

If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility ~~was based on the asset-backed commercial paper rate of 2.66% plus 0.75%, for a combined rate of 3.41%.~~may be reduced.

We are required to pay a commitment fee of 3025 to 45 basis points on the daily balance of the unused portion of the facility if our usage is greater than or equal to 50% of the facility limit or a commitment fee of 35 basis points on the daily balance of the unused portion of the facility if our usage is less than 50% of the facility limit.depending upon program utilization.

Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance ~~sheet.~~sheets.

On June 22, 2020 we amended this facility to adjust certain covenant levels, in particular for the second and third quarters of 2020.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 7 – Leases

Leases

Three Months Ended

Nine Months Ended

September 28,

September 28,

2019

2019
Operating lease cost:⁽¹⁾

$
21,840

$
68,273
Finance lease cost:

Amortization of right-of-use assets

290

798

Interest on lease liabilities

31

88
Total finance lease cost

$
321

$
886

(1)
Includes variable lease expenses.

Supplemental balance sheet information related to leases is as follows:

September 28,

2019

Operating Leases:

Operating lease right-of-use assets

$
240,126

Current operating lease liabilities

67,374

Non-current operating lease liabilities

182,505

Total operating lease liabilities

$
249,879

Finance Leases:

Property and equipment, at cost

$
10,826

Accumulated depreciation

(6,115)

Property and equipment, net of accumulated depreciation

$
4,711

Current maturities of long-term debt

$
1,092

Long-term debt

3,113

Total finance lease liabilities

$
4,205

Weighted Average Remaining Lease Term in Years:

Operating leases

5.5

Finance leases

6.1

Weighted Average Discount Rate:

Operating leases

3.4
%

Finance leases

2.2
%

		Three Months Ended				Nine Months Ended
		September 26,		September 28,		September 26,		September 28,
		2020		2019		2020		2019
Operating lease cost:^{(1) (2)}		$	21,343	$	21,840	$	65,413	$	68,273
Finance lease cost:
Amortization of right-of-use assets			434		290		1,148		798
Interest on lease liabilities			29		31		86		88
Total finance lease cost		$	463	$	321	$	1,234	$	886

(1)	Includes variable lease expenses.
(2)	Operating lease (credit) cost for three months and nine months ended September 26, 2020, includes amortization of right-of-use assets of $(0.1) and $ 0.40 million, respectively, related to facility leases recorded in “Restructuring costs” within our consolidated statements of income.


Supplemental balance sheet information related to leases is as follows:

		September 26,			December 28,
		2020			2019
Operating Leases:
Operating lease right-of-use assets		$	249,895		$	231,662

Current operating lease liabilities			62,914			65,349
Non-current operating lease liabilities			200,611			176,267
	Total operating lease liabilities	$	263,525		$	241,616

Finance Leases:
Property and equipment, at cost		$	10,457		$	10,268
Accumulated depreciation			(4,030)			(4,581)
Property and equipment, net of accumulated depreciation		$	6,427		$	5,687

Current maturities of long-term debt		$	2,348		$	1,736
Long-term debt			3,764			3,658
	Total finance lease liabilities	$	6,112		$	5,394

Weighted Average Remaining Lease Term in Years:
	Operating leases		7.1			5.5
	Finance leases		4.3			5.0

Weighted Average Discount Rate:
	Operating leases		3.0	%		3.4	%
	Finance leases		2.0	%		2.2	%

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Supplemental cash flow information related to leases is as follows:	Supplemental cash flow information related to leases is as follows:			Supplemental cash flow information related to leases is as follows:

						Nine Months Ended
		September 28,			September 26,		September 28,
		2019			2020		2019
Cash paid for amounts included in the measurement of lease liabilities:	Cash paid for amounts included in the measurement of lease liabilities:			Cash paid for amounts included in the measurement of lease liabilities:
	Operating cash flows for operating leases	$	60,275	Operating cash flows for operating leases	$	57,666	$	60,275
	Operating cash flows for finance leases		67	Operating cash flows for finance leases		76		67
	Financing cash flows for finance leases		862	Financing cash flows for finance leases		1,515		862
Right-of-use assets obtained in exchange for lease obligations:	Right-of-use assets obtained in exchange for lease obligations:			Right-of-use assets obtained in exchange for lease obligations:
	Operating leases ⁽¹⁾	$	281,373	Operating leases	$	66,082	$	290,166
	Finance leases		1,149	Finance leases		2,489		1,149


(1)	Includes leases that commenced during the nine months ended September 28, 2019, as well as balances related to leases in existence as of the date of the adoption of Topic 842.

Maturities of lease liabilities are as follows:	Maturities of lease liabilities are as follows:					Maturities of lease liabilities are as follows:
			September 28,
			2019					September 26, 2020
			Operating		Finance			Operating		Finance
			Leases		Leases			Leases		Leases
2019 (excluding the nine months ended September 28, 2019)		$	21,149	$	453
2020	2020		69,052		1,135	2020	$	18,423	$	747
2021	2021		54,082		846	2021		65,955		2,272
2022	2022		37,886		434	2022		49,257		1,365
2023	2023		26,051		295	2023		32,363		495
2024						2024		22,298		315
Thereafter	Thereafter		67,075		1,372	Thereafter		103,765		1,163
Total future lease payments	Total future lease payments		275,295		4,535	Total future lease payments		292,061		6,357
Less imputed interest	Less imputed interest		(25,416)		(330)	Less imputed interest		(28,536)		(245)
Total	Total	$	249,879	$	4,205	Total	$	263,525	$	6,112

As of September ~~28, 2019~~26, 2020, we have additional operating leases with total lease payments of ~~$6.8~~$12.7 million for buildings and vehicles that have not yet commenced. These operating leases will commence ~~during 2019~~subsequent to September 26, 2020, with lease terms of ~~two~~13 months to 10 years.

As previously disclosed in our December 29, 2018 Form 10-K and under the previous lease accounting standard, future minimum lease payments under non-cancelable operating leases and capital leases as of December 29, 2018 were as follows (in thousands):

Operating

Finance

Leases

Leases
2019

$
62,535

$
976
2020

47,686

801
2021

34,633

501
2022

25,626

305
2023

19,560

283
Thereafter

62,918

1,430
Total minimum lease payments

$
252,958

4,296
Less imputed interest (Capital leases only)

(352)
Total present value of minimum lease payments

$
3,944

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 8 – Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. ~~ASC~~Accounting Standards Codification (“ASC”) Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the nine months ended September ~~28, 2019~~26, 2020 and the year ended December ~~29, 2018~~28, 2019 are presented in the following table:

September 28,

December 29,

2019

2018
Balance, beginning of period

$
219,724

$
465,585
Decrease in redeemable noncontrolling interests due to

redemptions

(2,270)

(287,767)
Increase in redeemable noncontrolling interests due to business

acquisitions

73,975

4,655
Net income attributable to redeemable noncontrolling interests

10,618

15,327
Dividends declared

(7,943)

(8,206)
Effect of foreign currency translation loss attributable to

redeemable noncontrolling interests

(4,912)

(11,330)
Change in fair value of redeemable securities

(5,867)

41,460
Balance, end of period

$
283,325

$
219,724

Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are adjusted at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a floor amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.

		September 26,		December 28,
		2020		2019
Balance, beginning of period		$	287,258	$	219,724
Decrease in redeemable noncontrolling interests due to
	redemptions		(12,636)		(2,270)
Increase in redeemable noncontrolling interests due to business
	acquisitions		25,955		74,865
Net income attributable to redeemable noncontrolling interests			7,253		14,838
Dividends declared			(7,272)		(10,264)
Effect of foreign currency translation loss attributable to
	redeemable noncontrolling interests		(10,999)		(2,335)
Change in fair value of redeemable securities			5,141		(7,300)
Balance, end of period		$	294,700	$	287,258

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 9 – Comprehensive Income

Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity.

The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of:

			September 28,		December 29,				September 26,		December 28,
			2019		2018				2020		2019
Attributable to Redeemable noncontrolling interests:	Attributable to Redeemable noncontrolling interests:						Attributable to Redeemable noncontrolling interests:
		Foreign currency translation adjustment	$	(22,915)	$	(18,595)		Foreign currency translation adjustment	$	(31,337)	$	(20,338)

Attributable to noncontrolling interests:	Attributable to noncontrolling interests:						Attributable to noncontrolling interests:
		Foreign currency translation adjustment	$	(715)	$	(426)		Foreign currency translation adjustment	$	(276)	$	(531)

Attributable to Henry Schein, Inc.:	Attributable to Henry Schein, Inc.:						Attributable to Henry Schein, Inc.:
	Foreign currency translation loss		$	(180,267)	$	(234,799)	Foreign currency translation adjustment		$	(149,744)	$	(143,172)
	Unrealized loss from foreign currency hedging activities			(1,742)		(156)	Unrealized loss from foreign currency hedging activities			(1,575)		(4,032)
	Unrealized investment gain (loss)			2		(6)	Unrealized investment gain			1		6
	Pension adjustment loss			(13,419)		(13,810)	Pension adjustment loss			(20,014)		(20,175)
		Accumulated other comprehensive loss	$	(195,426)	$	(248,771)		Accumulated other comprehensive loss	$	(171,332)	$	(167,373)

Total Accumulated other comprehensive loss	Total Accumulated other comprehensive loss		$	(219,056)	$	(267,792)	Total Accumulated other comprehensive loss		$	(202,945)	$	(188,242)

The following table summarizes the components of comprehensive income, net of applicable taxes as follows:

Three Months Ended

Nine Months Ended

September 28,

September 29,

September 28,

September 29,

2019

2018

2019

2018
Net income

$
148,853

$
126,976

$
382,693

$
423,116

Foreign currency translation loss

(60,635)

(10,582)

(43,926)

(106,154)
Tax effect

-

-

-

-
Foreign currency translation loss

(60,635)

(10,582)

(43,926)

(106,154)

Unrealized gain (loss) from foreign currency hedging

activities

(1,685)

(406)

(2,037)

1,079
Tax effect

422

27

451

(405)
Unrealized gain (loss) from foreign currency hedging

activities

(1,263)

(379)

(1,586)

674

Unrealized investment gain (loss)

3

(1)

10

(2)
Tax effect

(1)

-

(2)

-
Unrealized investment gain (loss)

2

(1)

8

(2)

Pension adjustment gain

585

139

1,146

1,449
Tax effect

(185)

(23)

(314)

(393)
Pension adjustment gain

400

116

832

1,056
Comprehensive income

$
87,357

$
116,130

$
338,021

$
318,690

	Three Months Ended				Nine Months Ended
	September 26,		September 28,		September 26,		September 28,
	2020		2019		2020		2019
Net income	$	151,784	$	148,853	$	272,082	$	382,693

Foreign currency translation gain (loss)		37,588		(60,635)		(17,316)		(43,926)
Tax effect		0		0		0		0
Foreign currency translation gain (loss)		37,588		(60,635)		(17,316)		(43,926)

Unrealized gain (loss) from foreign currency hedging
activities		(10,490)		(1,685)		3,010		(2,037)
Tax effect		2,793		422		(553)		451
Unrealized gain (loss) from foreign currency hedging
activities		(7,697)		(1,263)		2,457		(1,586)

Unrealized investment gain (loss)		2		3		(6)		10
Tax effect		0		(1)		1		(2)
Unrealized investment gain (loss)		2		2		(5)		8

Pension adjustment gain (loss)		(471)		585		227		1,146
Tax effect		133		(185)		(66)		(314)
Pension adjustment gain (loss)		(338)		400		161		832
Comprehensive income	$	181,339	$	87,357	$	257,379	$	338,021

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

~~During~~The change in the unrealized gain (loss) from foreign currency hedging activities during the three months and year ended September 28, 2019 and September 29, 2018, we recognized, as a component of our comprehensive income, a foreign currency translation loss of $60.6 million and $10.6 million, respectively, due to changes in foreign exchange rates from the beginning of the period26, 2020, compared to the ~~end of the period. During the nine months ended September 28, 2019~~comparable prior year period, was primarily attributable to a net investment hedge that was entered into during 2019. See Note 15-Derivatives and September 29, 2018, we recognized, as a component of our comprehensive income, a foreign currency translation loss of $43.9 million and $106.2 million, respectively, due to changes in foreign exchange rates from the beginning of the period to the end of the period. Hedging Activities

for further information.

Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive ~~income (loss).~~income. The foreign currency translation gain (loss) during the ~~three~~nine months ended September 26, 2020 and nine months ended September 28, 2019 ~~and September 29, 2018~~ was primarily impacted by changes in foreign currency exchange rates of the Euro, British Pound, Brazilian Real, ~~British Pound~~Australian Dollar and ~~Australian~~Canadian Dollar.

The following table summarizes our total comprehensive income, net of applicable taxes, as follows:

		Three Months Ended				Nine Months Ended					Three Months Ended				Nine Months Ended
		September 28,		September 29,		September 28,		September 29,			September 26,		September 28,		September 26,		September 28,
		2019		2018		2019		2018			2020		2019		2020		2019
Comprehensive income attributable to	Comprehensive income attributable to									Comprehensive income attributable to
	Henry Schein, Inc.	$	85,075	$	113,221	$	324,809	$	313,326	Henry Schein, Inc.	$	169,616	$	85,075	$	257,202	$	324,809
Comprehensive income attributable to	Comprehensive income attributable to									Comprehensive income attributable to
	noncontrolling interests		3,924		2,478		7,280		2,097	noncontrolling interests		4,354		3,924		3,923		7,280
Comprehensive income (loss) attributable to	Comprehensive income (loss) attributable to									Comprehensive income (loss) attributable to
	Redeemable noncontrolling interests		(1,642)		431		5,932		3,267	Redeemable noncontrolling interests		7,369		(1,642)		(3,746)		5,932
Comprehensive income	Comprehensive income	$	87,357	$	116,130	$	338,021	$	318,690	Comprehensive income	$	181,339	$	87,357	$	257,379	$	338,021

Note 10 – Fair Value Measurements

~~ASC Topic 820 “Fair Value Measurements and Disclosures” (“ASC Topic 820”) provides a framework for measuring fair~~Fair value ~~in generally accepted accounting principles.~~

~~ASC Topic 820 defines fair value~~is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ~~ASC Topic 820 establishes a fair value~~The hierarchy for determining that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy ~~under ASC Topic 820~~ are described as follows:

• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

• Level 3— Inputs that are unobservable for the asset or liability.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

The following section describes the ~~valuation~~fair values of our financial instruments and the methodologies that we used to measure ~~different financial instruments at~~their fair ~~value.~~values.

Investments and notes receivable

There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair ~~value.~~value based on the interest rates in the applicable markets.

Debt

The fair value of our debt ~~including~~(including bank credit ~~lines,~~lines) is classified as Level 3 within the fair value hierarchy as of September ~~28, 2019~~26, 2020 and December ~~29, 2018~~28, 2019 was estimated at ~~$1,089.3~~$1,132.7 million and ~~$1,940.1~~$756.7 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads.

Derivative contracts

Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, ~~and~~ certain forecasted inventory purchase commitments with ~~suppliers.~~foreign suppliers, foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges and a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan and our deferred compensation plan.

The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy. See Note 15-Derivatives and Hedging Activities for further information.

Redeemable noncontrolling interests

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value based on third-party valuations. The primary factor affecting the future value of redeemable noncontrolling interests is expected earnings and, if such earnings are not achieved, the value of the redeemable noncontrolling interests might be impacted. The noncontrolling interests subject to put options are adjusted to their estimated redemption amounts each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share. The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value ~~hierarchy. The details~~hierarchy and are based on recent transactions and/or implied multiples of ~~the changes in~~ earnings. See Note 8–Redeemable ~~noncontrolling interests are presented in Note 8.~~Noncontrolling Interests

for additional information.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September ~~28, 2019~~26, 2020 and December ~~29, 2018:~~28, 2019:

September 28, 2019

Level 1

Level 2

Level 3

Total

Assets:

Derivative contracts

$
-

$
5,620

$
-

$
5,620

Total assets

$
-

$
5,620

$
-

$
5,620

Liabilities:

Derivative contracts

$
-

$
3,629

$
-

$
3,629

Total liabilities

$
-

$
3,629

$
-

$
3,629

Redeemable noncontrolling interests

$
-

$
-

$
283,325

$
283,325

December 29, 2018

Level 1

Level 2

Level 3

Total

Assets:

Derivative contracts

$
-

$
12,533

$
-

$
12,533

Total assets

$
-

$
12,533

$
-

$
12,533

Liabilities:

Derivative contracts

$
-

$
1,708

$
-

$
1,708

Total liabilities

$
-

$
1,708

$
-

$
1,708

Redeemable noncontrolling interests

$
-

$
-

$
219,724

$
219,724

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

			September 26, 2020
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	0	$	32,107	$	0	$	32,107
		Total assets	$	0	$	32,107	$	0	$	32,107

Liabilities:
	Derivative contracts		$	0	$	4,175	$	0	$	4,175
	Total return swaps			0		2,406		0		2,406
		Total liabilities	$	0	$	6,581	$	0	$	6,581

Redeemable noncontrolling interests			$	0	$	0	$	294,700	$	294,700


			December 28, 2019
				Level 1		Level 2		Level 3		Total

Assets:
	Derivative contracts		$	0	$	567	$	0	$	567
		Total assets	$	0	$	567	$	0	$	567

Liabilities:
	Derivative contracts		$	0	$	5,795	$	0	$	5,795
		Total liabilities	$	0	$	5,795	$	0	$	5,795

Redeemable noncontrolling interests			$	0	$	0	$	287,258	$	287,258

Note 11 – Business Acquisitions

Acquisitions

The operating results of all acquisitions are reflected in our financial statements from their respective acquisition dates.

~~During the nine months ended September 28, 2019 we completed the following acquisitions:~~

On March 4, 2019, we announced that we acquired North American Rescue (“NAR”), a leading provider of survivability and casualty-care medical products to the defense and public-safety markets. NAR has annual sales of approximately $184 million. As of September 28, 2019, we have recorded $168.9 million of goodwill related to this acquisition.

On March 18, 2019, we announced that our Henry Schein One subsidiary acquired Lighthouse 360, a provider of easy-to-use dental practice management and patient communication software. Lighthouse 360 has annual sales of approximately $50 million. As of September 28, 2019, we have recorded $143.4 million of goodwill related to this acquisition.

We completed ~~certain other~~ acquisitions during the nine months ended September ~~28, 2019~~26, 2020 which were immaterial to our financial statements ~~individually~~individually. In the aggregate, these transactions resulted in consideration of $47.1 million during the nine months ended September 26, 2020 related to business combinations, for net assets amounting to $16.9 million. As of September 26, 2020, we had recorded $29.1 million of identifiable intangibles, $34.7 million of goodwill and ~~in the aggregate.~~$24.2 million of non-controlling interest, related to these acquisitions.

Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018,~~28, 2019, there were no material adjustments recorded in our consolidated ~~statement~~statements of income relating to changes in estimated contingent purchase price liabilities.

2726

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 12 – Plans of Restructuring

On July 9, 2018, we committed to an initiative to rationalize our operations and provide expense efficiencies. These actions ~~have~~ allowed us to execute on our plan to reduce our cost structure and fund new initiatives that ~~are expected to~~ drive ~~future~~ growth under our 2018 to 2020 strategic plan. This initiative has resulted in the elimination of approximately 4% of our workforce and the closing of certain facilities.

On November 20, 2019, we committed to a contemplated initiative, intended to mitigate stranded costs associated with the Animal Health Spin-off and to rationalize operations and to provide expense efficiencies. These activities were originally expected to be completed by the end of 2020. We are re-assessing that timeline in light of the current business environment brought on by the COVID-19 pandemic.

During the three ~~and nine~~ months ended September 26, 2020 and September 28, 2019, we recorded restructuring costs (credits) of $7.0 million and $(0.8) million. During the nine months ended September 26, 2020 and September 28, 2019, we recorded restructuring costs of ~~$(0.8)~~$27.7 million and $15.8 ~~million, respectively.~~million. The restructuring ~~credits in the three months ended September 28, 2019 were attributable to a reduction in previously recorded estimated restructuring~~ costs ~~as of June 29, 2019. The total 2018~~for these periods included costs ~~associated with the actions to complete this restructuring were $54.4 million from continuing operations, consisting primarily of~~for severance ~~costs. As of June 29, 2019, the restructuring activities under this initiative are complete~~benefits and ~~we do not expect to incur any additional restructuring charges for the remainder of 2019.~~facility exit costs. The costs associated with ~~this restructuring~~these restructurings are included in a separate line item, “Restructuring costs” within our consolidated statements of income.

The following table shows the net amounts expensed and paid for restructuring costs that were incurred during the nine months ended September ~~28, 2019~~26, 2020 and during our ~~2018~~2019 fiscal year and the remaining accrued balance of restructuring costs as of September ~~28, 2019,~~26, 2020, which is included in Accrued expenses: Other within our consolidated balance ~~sheet:~~sheets:

				Facility									Facility
		Severance		Closing							Severance		Closing
		Costs		Costs		Other		Total			Costs		Costs		Other		Total
Balance, December 30, 2017		$	3,087	$	1,315	$	24	$	4,426
Balance, December 29, 2018										Balance, December 29, 2018	$	29,964	$	1,603	$	158	$	31,725
Provision	Provision		50,197		3,153		1,017		54,367	Provision		13,741		937		27		14,705
Payments and other adjustments	Payments and other adjustments		(23,320)		(2,865)		(883)		(27,068)	Payments and other adjustments		(30,794)		(1,714)		(112)		(32,620)
Balance, December 29, 2018		$	29,964	$	1,603	$	158	$	31,725
Balance, December 28, 2019										Balance, December 28, 2019	$	12,911	$	826	$	73	$	13,810
Provision	Provision		14,733		945		86		15,764	Provision		23,127		4,348		238		27,713
Payments			(26,313)		(1,575)		(110)		(27,998)
Balance, September 28, 2019		$	18,384	$	973	$	134	$	19,491
Payments and other adjustments										Payments and other adjustments		(21,404)		(4,609)		(247)		(26,260)
Balance, September 26, 2020										Balance, September 26, 2020	$	14,634	$	565	$	64	$	15,263

The following table shows, by reportable segment, the net amounts expensed and paid for restructuring costs that were incurred during the nine months ended September ~~28, 2019~~26, 2020 and during our ~~2018~~2019 fiscal year and the remaining accrued balance of restructuring costs as of September ~~28, 2019:~~26, 2020:

				Technology and							Technology and
		Health Care		Value-Added					Health Care		Value-Added
		Distribution		Services		Total			Distribution		Services		Total
Balance, December 30, 2017		$	4,426	$	-	$	4,426
Balance, December 29, 2018								Balance, December 29, 2018	$	30,291	$	1,434	$	31,725
Provision	Provision		50,824		3,543		54,367	Provision		13,935		770		14,705
Payments and other adjustments	Payments and other adjustments		(24,959)		(2,109)		(27,068)	Payments and other adjustments		(30,853)		(1,767)		(32,620)
Balance, December 29, 2018		$	30,291	$	1,434	$	31,725
Balance, December 28, 2019								Balance, December 28, 2019	$	13,373	$	437	$	13,810
Provision	Provision		14,966		798		15,764	Provision		26,621		1,092		27,713
Payments			(26,349)		(1,649)		(27,998)
Balance, September 28, 2019		$	18,908	$	583	$	19,491
Payments and other adjustments								Payments and other adjustments		(25,175)		(1,085)		(26,260)
Balance, September 26, 2020								Balance, September 26, 2020	$	14,819	$	444	$	15,263

2827

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 13 – Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested restricted stock and restricted stock units, ~~and upon exercise of stock options,~~ using the treasury stock method in periods in which they have a dilutive effect.

A reconciliation of shares used in calculating earnings per basic and diluted share follows:

		Three Months Ended		Nine Months Ended			Three Months Ended		Nine Months Ended
		September 28,	September 29,	September 28,	September 29,		September 26,	September 28,	September 26,	September 28,
		2019	2018	2019	2018		2020	2019	2020	2019
Basic	Basic	147,136	152,533	148,603	152,970	Basic	142,362	147,136	142,553	148,603
Effect of dilutive securities:	Effect of dilutive securities:					Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,439	1,081	1,317	1,012	Restricted stock and restricted stock units	729	1,439	755	1,317
	Diluted	148,575	153,614	149,920	153,982	Diluted	143,091	148,575	143,308	149,920

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 14 – Income Taxes

For the nine months ended September ~~28, 2019,~~26, 2020, our effective tax rate was ~~23.9~~% 20.0% compared to ~~21.8~~% 23.9% for the prior year period. The difference between our effective tax ~~rates~~rate and the federal statutory tax rate for the nine months ended September 26, 2020, was primarily due to a U.S. federal income tax settlement reached during the third quarter, which lowered income tax expense by approximately $15.6 million, as well as state and foreign income taxes and interest. The difference between our effective tax rate and the federal statutory tax rate for the nine months ended September 28, 2019 primarily relates to state and foreign income taxes and interest expense.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The ~~difference between our effective~~CARES Act includes, but is not limited to, certain income tax ~~rates~~provisions that modify the Section 163(j) limitation of business interest and Net Operating Loss (“NOL”) carryover and carryback rules. The modifications to Section 163(j) increase the ~~federal statutory~~allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income for years beginning in 2019 and 2020. The CARES Act eliminated the NOL income limitation for years beginning before 2021 and it extended the carryback period to five years for year losses incurred in 2018, 2019 and 2020. We have analyzed the income tax ~~rate~~provisions of the CARES Act and have accounted for the impact in the nine months ended September ~~29, 2018 primarily relates~~26, 2020, which did not have a material impact on our consolidated financial statements. There are certain other non-income tax benefits available to ~~a provisional transition tax benefit of $10 million related to~~us under the ~~Tax~~CARES Act ~~as well as state and foreign income taxes and interest expense.~~that require further clarification or interpretation that may affect our consolidated financial statements in the future.

On ~~December 22, 2017,~~July 20, 2020, the ~~U.S. government passed the Tax Act. The Tax Act is comprehensive tax legislation that implemented complex changes~~U.S Internal Revenue Service (the “IRS”) issued final regulations related to the ~~U.S. tax code including, but not limited to,~~2017 Tax Cuts and Jobs Act (“Tax Act”). The final regulations concern the ~~reduction of the~~ ~~corporate tax rate from 35% to 21%, modification of accelerated depreciation, the repeal of the domestic manufacturing deduction and changes to the~~ limitations of the deductibility of interest. Additionally, the Tax Act moved from a global tax regime to a modified territorial regime, which requires U.S. companies to pay a mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The transition tax is payable over eight years. The Tax Act also included provisions to tax global intangible low-taxed income (“GILTI”)~~, a beneficial tax rate foreign Derived Intangible Income (“FDII”), a base erosion~~ and anti-abuse tax (“BEAT”) that imposes tax on certain foreign related-party payments, and IRC Section 163(j) interest limitation (Interest Limitation). We became subject to the GILTI, FDII, BEAT and Interest Limitation provisions effective January 1, 2018.

The FASB Staff Q&A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. We elected to recognize the tax on GILTI as a period expense in the period the tax is incurred. For the BEAT, FDII and Interest Limitation computations, we have not recorded an estimate in our effective tax rate for the nine~~months ended September 28, 2019 because we have concluded that these~~subpart F income provisions of the Tax ~~Act will~~Act. To provide flexibility to taxpayers, the IRS is permitting the application of these final regulations to prior tax years, if the taxpayer elects to do so. We have analyzed the final regulations, which do not ~~apply~~have a material impact to ~~us in 2019.~~our consolidated financial statements.

The total amount of unrecognized tax benefits, which are included in “Other liabilities” within our consolidated balance sheets, as of September ~~28, 2019~~ 26, 2020 was approximately ~~$107.6~~$90.5 million, of which ~~$86.5~~$76.7 million would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our consolidated ~~statement~~statements of income.

The tax years subject to examination by major tax jurisdictions include the years 2012 and forward by the IRS, as well as the years 2008 and forward for certain states and certain foreign jurisdictions. All tax returns audited by the IRS are officially closed through 2011. We are currently under audit for the years 2012 and 2013. In the quarter ended December 28, 2019, we reached a settlement with the U.S. Competent Authority to resolve certain transfer pricing issues related to 2012 and 2013. For all remaining outstanding issues for 2012 and 2013, we have provided all necessary documentation to the Appellate Division to date and we currently expect resolution in the fourth quarter of 2020. We do not believe the final resolution will have a material impact to our consolidated financial statements. During the quarter ended September 26, 2020 we finalized negotiations with the Advance Pricing Division and reached an agreement on an appropriate transfer pricing methodology for the years 2014-2025. The objective of this resolution is to mitigate future transfer pricing audit adjustments.

The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest expense (credit) was approximately $(1.1) million for the nine months ended September 26, 2020, and $2.6 million for the nine months ended September 28, 2019. The total amount of accrued interest is included in “Other liabilities”, and was approximately $16.2 million as of September 26, 2020 and $18.0 million as of December 28, 2019. NaN penalties were accrued for the periods presented.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

~~The total amounts of interest and penalties, which are classified as a component of the provision for income taxes and included in “Other liabilities”, were approximately~~ ~~$18.3 million and $0, respectively, as of~~ ~~September 28, 2019~~.

The tax years subject to examination by major tax jurisdictions include the years 2012 and forward by the U.S. Internal Revenue Service (“IRS”), as well as the years 2008 and forward for certain states and certain foreign jurisdictions. During the quarter ended December 31, 2016 we filed a Mutual Agreement Procedure request with the IRS for assistance from the U.S. Competent Authority for an open Transfer Pricing issue which resulted in a partial settlement during the quarter ended December 30, 2017. We received a 30 Day Letter from the IRS during the quarter ended April 1, 2017 for the remaining open audit issues for the years 2012 and 2013. We filed a Protest with the Appellate Division regarding these issues during the second quarter of 2017. We had an initial Appeals Conference during the third quarter of 2018, of which we are awaiting a final settlement. During the quarter ended December 29, 2018, we submitted the first draft of our proposed Advanced Pricing Agreement covering tax years 2014-2024 to the IRS in which Henry Schein, Inc. and the IRS would agree on an appropriate transfer pricing methodology. We have provided all necessary documentation to the Appellate Division and the Advance Pricing and Mutual Agreement Program to date and are waiting for responses.

Note 15 – Derivatives and Hedging Activities

We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital.

During 2019 we entered into foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. These net investment hedges offset the change in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates. Gains and losses related to these net investment hedges are recorded in Accumulated other comprehensive loss within our consolidated balance sheets. Amounts excluded from the assessment of hedge effectiveness are included in interest expense within our consolidated statements of income. The aggregate notional value of this net investment hedge, which matures on November 16, 2023, is approximately €200 million. During the three and nine months ended September 26, 2020 we recognized approximately $1.2 million and $3.6 million, respectively, of interest savings as a result of this net investment hedge.

On March 20, 2020, we entered into a total return swap for the purpose of economic hedging our unfunded non-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset changes in our SERP and DCP liabilities. At the inception, the notional value of the investments in these plans was $43.4 million. At September 26, 2020, the notional value of the investments in these plans was $58.8 million. At September 26, 2020 the financing rate for this swap is based on LIBOR of 0.16% plus 0.38%, for a combined rate of 0.54%. From March 20, 2020, the effective date of the swap, to September 26, 2020, we have recorded a gain, within the selling, general and administrative line item in our consolidated statement of income, of approximately $3.8 million and $14.2 million, respectively, net of transaction costs, related to this undesignated swap for the three and nine months ended September 26, 2020. This gain was offset by the change in fair value adjustment in deferred compensation, resulting in a neutral impact to our results of operations. This swap is expected to be renewed on an annual basis.

Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC ~~Topic~~ 815 have been omitted.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

N~~ote~~Note 16 – Stock-Based Compensation

Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $5.7 million ($4.1 million after-tax) and a credit of $6.6 million ($5.3 million after-tax) for the three and nine months ended September 26, 2020, respectively. For the three and nine months ended September 28, 2019 we recorded pre-tax share-based compensation expense of $13.3 million ($10.2 million after-tax) and $33.1 million ($25.2 million after-tax), respectively. The $6.6 million credit for share-based compensation during the ~~three and~~ nine months ended September ~~28,~~26, 2020 reflects our reduced estimate in expected achievement of performance-based targets resulting from the impact of COVID-19. Due to the significantly lower projected earnings in 2020, we are currently estimating that 0 performance shares granted under our 2018, 2019 ~~respectively, and $9.5 million ($7.6 million after-tax) and $30.6 million ($23.4 million after-tax)~~or 2020 Long-Term Incentive Programs under our employee stock incentive plan will ultimately vest.

Our accompanying consolidated statements of cash flows present our stock-based compensation expense (credit) as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the ~~three and~~accompanying consolidated statements of cash flows, there were 0 benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the nine months ended September ~~29, 2018,~~26, 2020 and September 28, 2019, respectively.

Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income.

Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2020 Stock Incentive Plan (formerly known as the 2013 Stock Incentive ~~Plan, as amended,~~Plan), and our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors. ~~Prior to March 2009,~~Equity-based awards ~~under the Plans principally included a combination of at-the-money stock options and restricted stock/units. Since March 2009, equity-based awards have been~~are granted solely in the form of restricted ~~stock/~~stock units, with the exception of providing stock options to employees pursuant to certain pre-existing contractual obligations.

Grants of restricted ~~stock/~~stock units are stock-based awards granted to recipients with specified vesting provisions. ~~In the case of restricted stock, common stock is delivered on the date of grant, subject to vesting conditions.~~ In the case of restricted stock units, common stock is generally delivered on or following satisfaction of vesting conditions. We issue restricted ~~stock/~~stock units that vest solely based on the recipient’s continued service over time (primarily ~~four-year~~four year cliff vesting, except for grants made under the 2015 Non-Employee Director Stock Incentive Plan, which are primarily ~~12-month~~12 month cliff vesting) and restricted ~~stock/~~stock units that vest based on our achieving specified performance measurements and the recipient’s continued service over time (primarily three~~-year~~ year cliff vesting).

With respect to time-based restricted ~~stock/~~stock units, we estimate the fair value on the date of grant based on our closing stock price. With respect to performance-based restricted ~~stock/~~stock units, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee of the Board of Directors. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based restricted ~~stock/~~stock units based on our closing stock price at time of grant.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

The Plans provide for adjustments to the performance-based restricted ~~stock/~~stock units targets for significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), restructuring costs, if any, certain litigation settlements or payments, if any, changes in tax rates in certain countries, changes in accounting principles or in applicable laws or regulations and foreign exchange fluctuations. Over the performance period,, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans.

As a result of the Separation, the number of our unvested (as of the date of the Separation) equity-based awards from previous grants ~~to our remaining employees~~made under our Long-term Incentive Program under the Plans was increased ~~in accordance with the provisions in the Plans. This was based on~~by a factor of approximately 1.2633,~~, corresponding~~ along with a corresponding decrease in our price per share.

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Total unrecognized compensation cost related to unvested awards as of September ~~28, 2019~~26, 2020 was ~~$97.5~~$50.6 million, which is expected to be recognized over a weighted-average period of approximately ~~2.2~~2.4 years.

~~The following table summarizes stock option activity under the Plans during the nine months ended September 28, 2019:~~

Weighted

Average

Weighted

Remaining

Average

Contractual

Aggregate

Exercise

Life in

Intrinsic

Shares

Price

Years

Value
Outstanding at beginning of period

3

$
13.63

Granted

-

-

Exercised

(3)

13.63

Forfeited

-

-

Outstanding at end of period

-

$
-

-

$
-

Options exercisable at end of period

-

$
-

-

$
-

The following tables summarize the activity of our unvested restricted stock/units for the nine months ended September ~~28, 2019:~~26, 2020:

	Time-Based Restricted Stock/Units					Time-Based Restricted Stock/Units
		Weighted Average					Weighted Average
		Grant Date Fair		Intrinsic Value			Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share		Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,513	$	57.94			1,417	$	58.72
Granted	449		59.47			379		60.02
Vested	(338)		55.57			(297)		65.93
Forfeited	(204)		60.39			(47)		59.87
Outstanding at end of period	1,420	$	58.66	$	62.58	1,452	$	57.55	$	58.79

	Performance-Based Restricted Stock/Units					Performance-Based Restricted Stock/Units
		Weighted Average					Weighted Average
		Grant Date Fair		Intrinsic Value			Grant Date Fair		Intrinsic Value
	Shares/Units	Value Per Share		Per Share		Shares/Units	Value Per Share		Per Share
Outstanding at beginning of period	1,163	$	40.26			1,459	$	61.41
Granted	656		60.04			(1,092)		55.89
Vested	(185)		66.52			(326)		67.51
Forfeited	(155)		61.37			(40)		57.84
Outstanding at end of period	1,479	$	61.41	$	62.58	1	$	52.10	$	58.79

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 17 – Supplemental Cash Flow Information

Cash paid for interest and income taxes was:

	Nine Months Ended				Nine Months Ended
	September 28,		September 29,		September 26,		September 28,
	2019		2018		2020		2019
Interest	$	45,543	$	49,959	$	29,551	$	45,543
Income taxes		138,068		197,943		164,575		138,068

During the nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018,~~28, 2019, we had a ~~$2.0~~$3.0 million and $(2.0) million of non-cash net unrealized ~~loss related to foreign currency hedging activities and a $1.1 million non-cash net unrealized~~ gain (loss) related to foreign currency hedging activities, respectively.

Note 18 – Legal Proceedings

Beginning in January 2016, purported class action complaints were filed against Patterson Companies, Inc. (“Patterson”), Benco Dental Supply Co. (“Benco”) and Henry Schein, Inc. Although there were factual and legal variations among these complaints, each of these complaints alleges, among other things, that defendants conspired to fix prices, allocate customers and foreclose competitors by boycotting manufacturers, state dental associations and others that deal with defendants’ competitors. On February 9, 2016, the U.S. District Court for the Eastern District of New York ordered all of these actions, and all other actions filed thereafter asserting substantially similar claims against defendants, consolidated for pre-trial purposes. On February 26, 2016, a consolidated class action complaint was filed by Arnell Prato, D.D.S., P.L.L.C., d/b/a Down to Earth Dental, Evolution Dental Sciences, LLC, Howard M. May, DDS, P.C., Casey Nelson, D.D.S., Jim Peck, D.D.S., Bernard W. Kurek, D.M.D., Larchmont Dental Associates, P.C., and Keith Schwartz, D.M.D., P.A. (collectively, “putative class representatives”) in the U.S. District Court for the Eastern District of New York, entitled In re Dental Supplies Antitrust Litigation, Civil Action No. 1:16-CV-00696-BMC-GRB. In the consolidated class action complaint, putative class representatives allege a nationwide agreement among Henry Schein, Benco, Patterson and non-party Burkhart Dental Supply Company, Inc. (“Burkhart”) not to compete on price. The consolidated class action complaint asserts a single count under Section 1 of the Sherman Act, and seeks equitable relief, compensatory and treble damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On September 28, 2018, the parties executed a settlement agreement that proposes, subject to court approval, a full and final settlement of the lawsuit on a classwide basis. Subject to certain exceptions, the settlement class consists of all persons or entities that purchased dental products directly from Henry Schein, Patterson, Benco, Burkhart, or any combination thereof, during the period August 31, 2008 through and including March 31, 2016. As a result, in our third quarter of fiscal 2018, we recorded a charge of $38.5 million, which was paid into a settlement fund in January 2019. On June 25, 2019, the district court granted final approval to the settlement, and entered final judgment dismissing the case. On July 16, 2019, Dr. William Roe, an unnamed class member that had objected to the settlement, filed a notice of appeal appealing the district court’s Final Judgment and Order Granting Motion for Final Approval of Class Settlement. On October 8, 2019, the class plaintiffs and the objector filed notice indicating that they had reached a settlement concerning the objection, which, once approved by the court, would resolve the objection. On October 24, 2019 the court approved the agreement between the objector and the plaintiffs.

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Archer alleges ~~aconspiracy~~a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights. On August 1, 2017, Archer filed an amended complaint, adding Patterson Companies, Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”) as defendants, and alleging that Henry Schein, Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer. Archer seeks damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally, as well as injunctive relief. On October 30, 2017, Archer filed a second amended complaint, to add additional allegations that it believes support its claims. The named parties and causes of action are the same as the August 1, 2017 amended complaint.

On October 1, 2012, we filed a motion for an order: (i) compelling Archer to arbitrate its claims against us; (2) staying all proceedings pending arbitration; and (3) joining the Danaher Defendants’ motion to arbitrate and stay. On May 28, 2013, the Magistrate Judge granted the motions to arbitrate and stayed proceedings pending arbitration. On June 10, 2013, Archer moved for reconsideration before the District Court judge. On December 7, 2016, the District Court Judge granted Archer’s motion for reconsideration and lifted the stay. Defendants appealed the District Court’s order. On December 21, 2017, the U.S. Court of Appeals for the Fifth Circuit affirmed the District Court’s order denying the motions to compel arbitration. On June 25, 2018, the Supreme Court of the United States granted defendants’ petition for writ of certiorari. On October 29, 2018, the Supreme Court heard oral arguments. On January 8, 2019, the Supreme Court issued its published decision vacating the judgment of the Fifth Circuit and remanding the case to the Fifth Circuit for further proceedings consistent with the Supreme Court’s opinion. On April 2, 2019, the District Court stayed the proceeding in the trial court pending resolution by the Fifth Circuit. The Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated. The Fifth Circuit issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel arbitration. Defendants filed a petition for rehearing en banc before the Fifth Circuit. The Fifth Circuit ~~has not ruled on~~denied that petition. On October 1, 2019, the District Court set the case for trial on February 3, 2020, which was subsequently moved to January 29, 2020. ~~We intend~~On January 24, 2020 the Supreme Court granted our motion to ~~defend ourselves vigorously against this action.~~

On August 17, 2017, IQ Dental Supply, Inc. (“IQ Dental”) filed a complaint in the U.S. District Court for the Eastern District of New York, entitled IQ Dental Supply, Inc. v. Henry Schein, Inc., Patterson Companies, Inc. and Benco Dental Supply Company, Case No. 2:17-cv-4834. Plaintiff alleges that it is a distributor of dental supplies and equipment, and sells dental products through an online dental distribution platform operated by SourceOne Dental (“SourceOne”). SourceOne had previously brought an antitrust lawsuit against Henry Schein, Patterson and Benco, which Henry Schein settled in the second quarter of 2017 and which is described in our prior filings with the SEC.

IQ Dental alleges, among other things, that defendants conspired to suppress competition from IQ Dental and SourceOne for the marketing, distribution and sale of dental supplies and equipment in the United States, and that defendants unlawfully agreed with one another to boycott dentists, manufacturers and state dental associations that deal with, or considered dealing with, plaintiff and SourceOne. Plaintiff claims that this alleged conduct constitutes unreasonable restraint of trade in violation of Section 1 of the Sherman Act, New York’s Donnelly Act and the New Jersey Antitrust Act, and also makes pendant state law claims for tortious interference with prospective business relations, civil conspiracy and aiding and abetting. Plaintiff seeks injunctive relief, compensatory, treble and punitive damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On December 21, 2017,stay the District Court ~~granted~~proceedings, pending the ~~defendants’ motion to dismiss. On~~disposition of our petition for writ of certiorari, which was filed on January ~~19, 2018, IQ Dental appealed the District Court’s order. On May 10, 2019, the U.S. Court of Appeals~~31, 2020. Archer conditionally cross petitioned for the Second Circuit affirmed in part and reversed in part the District Court’s dismissal of the Complaint, holding that IQ Dental lacks antitrust standing to challenge the alleged boycott of SourceOne and state dental associations, but that it has standing to challenge injury related to the alleged direct boycott of its business.certiorari on an arbitration issue on March 2, 2020. On June ~~29, 2019,~~15, 2020, the ~~Second Circuit denied IQ Dental’s~~Supreme Court granted our petition for ~~rehearing or rehearing en banc. Proceedings in~~writ of certiorari, and denied Archer’s conditional petition for certiorari, and thus the District Court ~~are ongoing. We intend to defend ourselves vigorously against this action.~~proceedings remain stayed. The case is scheduled for argument before the Supreme Court in December 2020. Patterson and the Danaher Defendants settled with Archer and they have been dismissed from the

3433

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

~~On February 12, 2018, the United States Federal Trade Commission (“FTC”)~~case with prejudice. Benco is still a defendant and filed a ~~complaint against Benco Dental Supply Co.,~~notice of joinder in Henry ~~Schein, Inc. and Patterson Companies, Inc. The FTC alleges, among other things, that defendants violated U.S. antitrust laws by conspiring, and entering into an agreement,~~Schein’s motion to ~~refuse to provide discounts to or otherwise serve buying groups representing dental practitioners. The FTC alleges that defendants conspired in violation of Section 5 of~~compel arbitration with the ~~FTC Act. The complaint seeks equitable relief only and does not seek monetary damages.~~District Court. We ~~deny the allegation that we conspired to refuse to provide discounts to or otherwise serve dental buying groups and~~ intend to defend ourselves vigorously against this action. A hearing before an administrative law judge began on October 16, 2018 and the hearing record was closed on February 21, 2019. On October 7, 2019, the administrative law judge issued his Initial Decision, finding in relevant part that the “evidence fails to prove a conspiracy involving Schein,” and dismissing the Complaint as to Schein. The Initial Decision will become the decision of the Commission on or about November 7, 2019 unless the Commission places the case on its own docket for review or stays the effective date of the decision.~~We believe this matter will not have a material adverse effect on our consolidated financial position, liquidity or results of operations.~~

On March 7, 2018, Joseph Salkowitz, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Stanley M. Bergman and Steven Paladino in the U.S. District Court for the Eastern District of New York, Case No. 1:18-cv-01428. The complaint sought to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased Henry Schein securities from March 7, 2013 through February 12, 2018 (the “Class Period”). The complaint alleged, among other things, that the defendants had made materially false and misleading statements about Henry Schein’s business, operations and prospects during the Class Period, ~~including matters relating to the issues in the antitrust class action and the FTC action described above,~~ thereby causing the plaintiff and members of the purported class to pay artificially inflated prices for Henry Schein securities. Those alleged statements included matters relating to the issues in the In re Dental Supplies Antitrust Litigation, which Henry Schein settled and which the court dismissed in June 2019, and in the United States Federal Trade Commission (“FTC”) administrative proceeding, in which an administrative law judge ruled in Henry Schein’s favor in October 2019 after a trial, as described in our prior filings with the SEC. The complaint sought unspecified monetary damages and a jury trial. Pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), the court appointed lead plaintiff and lead counsel on June 22, 2018 and recaptioned the putative class action as In re Henry Schein, Inc. Securities Litigation, under the same case number. Lead plaintiff filed a consolidated class action complaint on September 14, 2018. The consolidated class action complaint ~~asserts~~asserted similar claims against the same defendants (plus Timothy Sullivan) on behalf of the same putative class of purchasers during the Class Period. It ~~alleges~~alleged that Henry Schein’s stock price ~~was~~had been inflated during that period because Henry Schein had misleadingly portrayed its dental-distribution business “as successfully producing excellent profits while operating in a highly competitive environment” even though, “in reality, [Henry Schein] had engaged for years in collusive and anticompetitive practices in order to maintain Schein’s margins, profits, and market share.” The complaint ~~alleges~~alleged that the stock price started to fall from August 8, 2017, when the company announced below-expected financial performance that allegedly “revealed that Schein’s poor results were a product of abandoning prior attempts to inflate sales volume and margins through anticompetitive collusion,” through February 13, 2018, after the FTC filed a complaint against Benco, Henry Schein and Patterson alleging that they violated U.S. antitrust laws. The complaint ~~alleges~~alleged violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 and Section 20(a) of the Exchange Act. On September 27, 2019, the court issued a decision partially granting and partially denying defendants’ motion to dismiss the securities action. The court dismissed all claims against Messrs. Bergman and Paladino as well as the Section 10(b) claim against Henry Schein to the extent that that claim relied on the Company’s financial results and margins to allege a material misstatement or ~~omission, and~~omission. The court also dismissed the Section 10(b) claim against Henry Schein to the extent that it relied on the Company’s August 8, 2017 disclosure to allege loss causation. The court otherwise denied the motion as to Henry Schein and Mr. Sullivan. ~~We intend to defend ourselves vigorously against this action.~~ Henry Schein ~~has also received~~and Mr. Sullivan moved for partial reconsideration of the court’s decision. Pursuant to all parties’ request, the court temporarily took the motion off the calendar after it was fully briefed. The parties later agreed to resolve this matter in exchange for a ~~request under 8 Del. C. § 220 to inspect corporate books~~cash payment of $35 million, which would be covered by the Company’s insurance and ~~records relating~~would have no earnings impact to the ~~issues raised in~~Company. The Court held a fairness hearing on the ~~securities class action~~proposed settlement on September 16, 2020 and approved it later that day. The order and judgment approving the ~~antitrust matters discussed above.~~settlement have become final.

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Becton, Dickinson, and Co. (“Becton”); Premier, Inc. (“Premier”), Vizient, Inc. (“Vizient”), Cardinal Health, Inc. (“Cardinal”), Owens & Minor Inc. (“O&M”), Henry Schein, Inc., and Unnamed Becton ~~DistributorCo-Conspirators.~~Distributor Co-Conspirators. The complaint ~~alleges~~alleged that the defendants entered into a vertical conspiracy to force health care providers into long-term exclusionary contracts that restrain trade in the nationwide markets for conventional and safety syringes and safety IV catheters and inflate the prices of certain Becton products to above-competitive levels. The named plaintiffs ~~seek~~sought to represent three separate classes consisting of all health care providers that purchased (i) Becton’s conventional syringes, (ii) Becton’s safety syringes, or (iii) Becton’s safety catheters directly from Becton, Premier, Vizient, Cardinal, O&M or Henry Schein on or after May 3, 2014. The complaint ~~asserts~~asserted a

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

single count under Section 1 of the Sherman Act, and ~~seeks~~sought equitable relief, treble damages, reasonable attorneys’ fees and costs and expenses, and pre-judgment and post-judgment interest. On June 15, 2018, an amended complaint was filed asserting the same allegations against the same parties and adding McKesson Medical-Surgical, Inc. as a defendant. On November 30, 2018, the District Court granted defendants’ motion to dismiss and entered a final judgment, dismissing plaintiffs’ complaint with prejudice. On December 27, 2018, plaintiffs appealed the District Court’s decision to the Seventh Circuit Court of Appeals. The parties argued the appeal on September 27, ~~2019 and are currently awaiting~~2019. On March 5, 2020, the Seventh ~~Circuit’s ruling.~~Circuit Court of Appeals reversed the District Court’s decision. The Seventh Circuit held that plaintiffs failed to adequately allege the necessary conspiracy by the defendants, but should be provided an opportunity to amend their complaint. The Seventh Circuit vacated the District Court’s judgment, and remanded the case for further proceedings consistent with its opinion. Plaintiffs subsequently dropped Henry Schein as a defendant in their amended complaint.

On May 29, 2018, an amended complaint was filed in the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) in an action entitled The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al., Civil Action No. 1:18-op-45090-DAP (“County of Summit Action”), in the U.S. District Court for the Northern District of Ohio, adding Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants. Summit County ~~alleges~~alleged that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, ~~will establish and donate~~donated $1 million to a ~~Pain Management Education Foundation dedicated to making grants to programs within Summit County focused on (I) supporting~~foundation and aggregating research around best practices for pain management, including the prescription of opioids and alternatives: (II) educating dentists and physicians, clinical associates, patients and patient networks on those best practices along with the risks of opioid addiction and alternative pain management treatment options for key indications; and ‎(III) offering grants to develop and offer training to dentists and physicians or other qualified professionals to qualify a practitioner for a waiver to prescribe or dispense buprenorphine medications. Henry Schein will paypaid $250,000 of Summit County’s ~~expenses.~~expenses, as described in our prior filings with the SEC.

In addition to the County of Summit Action, Henry Schein and/or one or more of its affiliated companies have ~~currently~~ been named as a defendant in multiple lawsuits (currently less than one-hundred ~~(100)~~and fifty (150)), which allege claims similar to those alleged in the County of Summit Action. ~~None of these other cases have been set for trial.~~ These actions consist of some that have been consolidated within the MDL and are currently abated for discovery purposes, and others which remain pending in state courts and are proceeding independently and outside of the MDL. On October 9, 2020, the Circuit Court of the 17th Judicial Circuit in and for Broward County, Florida, Case No. CACE19018882, granted Henry Schein’s motion to dismiss the claims brought against it in the action filed by North Broward Hospital District et. al. The Florida court gave plaintiffs until October 29, 2020 to replead their claims against Henry Schein. The plaintiffs have asked the Florida court for an additional 20 days to replead their claims. An action filed by Tucson Medical Center et al. was previously scheduled for trial beginning on June 1, 2021 but the court has vacated that trial date. At this time, the only case set for trial is the action filed by West Virginia University Hospitals, Inc. et al., which is currently scheduled for a non-jury liability trial on Plaintiffs’ public nuisance claims on November 1, 2021. Of Henry Schein’s ~~2018~~2019 revenue of ~~$9.4~~approximately $10 billion from continuing operations, sales of opioids represented less than one-tenth of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions.

~~Table of Contents~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Bus. and Prof. Code § 16720) and the Unfair Competition Act (Cal. Bus. and Prof. Code § 17200), and seeks a permanent injunction, actual damages to be determined at trial, trebled, reasonable attorneys’ fees and costs, and pre- and post-judgment interest. On December 7, 2018, an amended complaint was filed asserting the same claims against the same parties. On June 28, 2019, the court granted Defendants’ motions to dismiss with leave to amend. The parties subsequently stipulated to dismissal of the action with prejudice, pursuant to a settlement in which Henry Schein agreed to pay the plaintiff a de minimis amount. The court entered the stipulation of dismissal with prejudice and terminated the case on August 2, 2019.

On January 29, 2019, a purported class action complaint was filed by R. Lawrence Hatchett, M.D. against Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and unnamed co-conspirators in the U.S. District Court for the Southern District of Illinois. The complaint alleges that members of the proposed class suffered antitrust injury due to an unlawful boycott, price-fixing or otherwise anticompetitive conspiracy among Henry Schein, Patterson and Benco. The complaint alleges that the alleged conspiracy overcharged Illinois dental practices, orthodontic practices and dental laboratories on their purchase of dental supplies, which in turn passed on some or all of such overcharges to members of the class. Subject to certain exclusions, the complaint defines the class as “all persons residing in Illinois purchasing and/or reimbursing for dental care provided by independent Illinois dental practices purchasing dental supplies from the defendants, or purchasing from buying groups purchasing these supplies from the defendants, on or after January 29, 2015.” The complaint alleges violations of the Illinois Antitrust Act, 740 Ill. Comp. Stat. §§ 10/3(2), 10/7(2), and seeks a permanent injunction, actual damages to be determined at trial, trebled, reasonable attorneys’ fees and costs, and pre- and post-judgment interest. We intend to defend ourselves vigorously against this action.

On September 30, 2019, the City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively) in the U.S. District Court for the Eastern District of New York, Case No. 2:19-cv-05530-FB-RLM. The complaint seeks to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February 8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein Animal Health Business with Vets First Choice in February 2019. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Henry Schein, and understated the impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly large customer in North America just before the Separation and Merger. The complaint seeks unspecified monetary damages and a jury trial. Pursuant to the provisions of the PSLRA, the court appointed lead plaintiff and lead counsel on December 23, 2019. Lead plaintiff filed a Consolidated Class Action Complaint on February 21, 2020. Lead plaintiff added Steve Paladino, our Chief Financial Officer, as a defendant in the action. Lead plaintiff filed an Amended Consolidated Class Action Complaint on May 21, 2020, in which it added a claim that Mr. Paladino is a “control person” of Covetrus. We intend to defend ourselves vigorously against this action.

On November 15, 2019, Frank Finazzo filed a putative shareholder derivative action on behalf of Henry Schein, Inc. against various present and former directors and officers of Henry Schein in the U.S. District Court for the Eastern District of New York, Case No. 1:19-cv-6485-LDH-JO. The named defendants in the action are Stanley M. Bergman, Steven Paladino, Timothy J. Sullivan, Barry J. Alperin, Lawrence S. Bacow, Gerald A. Benjamin, James P. Breslawski, Paul Brons, Shira Goodman, Joseph L. Herring, Donald J. Kabat, Kurt Kuehn, Philip A. Laskawy, Anne H. Margulies, Karyn Mashima, Norman S. Matthews, Mark E. Mlotek, Carol Raphael, E. Dianne Rekow, Bradley T. Sheares, and Louis W. Sullivan, with Henry Schein named as a nominal defendant. The Complaint asserts claims under the federal securities laws and state law relating to the allegations in the antitrust actions, the In re Henry Schein, Inc. Securities Litigation, and the City of Hollywood securities class action described above. The complaint seeks declaratory, injunctive, and monetary relief on behalf of Henry Schein. On January 6, 2020, counsel who filed the Finazzo case filed another, virtually identical putative shareholder derivative action on behalf of Henry Schein against the same defendants, asserting the same claims and seeking the same relief. That case, captioned Mark Sloan v. Stanley M. Bergman, et al., is also pending in the U.S. District Court for the Eastern District of New York, Case No. 1:20-cv-0076. On January 24, 2020, the court consolidated the Finazzo and Sloan cases under the new caption In re Henry Schein, Inc. Derivative Litigation, No. 1:19-cv-06485-LDH-JO, and appointed the counsel in these cases as co-lead counsel for the consolidated action. The parties agreed to a resolution of this matter subject to various conditions, including court approval. The contemplated settlement, if finally approved, would involve the adoption of certain procedures but would not involve the payment of any money except a fee to the plaintiffs’ attorneys that is immaterial. The Court preliminarily approved the proposed settlement on June 10, 2020, and scheduled a fairness hearing for September 22, 2020. On September 9, 2020, the Court issued an order referring the motion for final settlement approval and fairness hearing to a Magistrate Judge for a report and recommendation. On September 10, 2020, the Magistrate Judge issued an order adjourning the September 22, 2020 fairness hearing without setting a new date. The parties have consented to the cases being assigned to the Magistrate Judge for all purposes.

From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations.

As of September ~~28, 2019,~~26, 2020, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

3736

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 19 – ~~Subsequent Events~~Related Party Transactions

~~On October 1, 2019,~~ In connection with the ~~Company sold an equity investment in Hu-Friedy Mfg. Co., LLC, a manufacturer~~completion of ~~dental instruments and infection prevention solutions. Our investment was non-controlling, we were not involved in running~~ the ~~business and had no representation on the board of directors. We estimate that in the fourth quarter of~~Animal Health Spin-off during our fiscal year 2019, we ~~will record~~entered into a ~~pretax gain~~transition services agreement with Covetrus under which we have agreed to provide certain transition services for up to 24 months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services. During the three and nine months ended September 26, 2020, we recorded approximately $3.9 million and $12.7 million, respectively, of fees for these services. During the three and nine months ended September 28, 2019, we recorded approximately $4.7 million and $13.0 million, respectively, of fees for these services. Covetrus also purchases certain products from us pursuant to the transition services agreement. During the three and nine months ended September 26, 2020, net sales to Covetrus were approximately $24.8 million and $66.0 million, respectively. During the three and nine months ended September 28, 2019, net sales to Covetrus were approximately $21.8 million and $60.2 million, respectively. Sales to Covetrus under the transition services agreement have been substantially completed as of October 2020. At September 26, 2020 we had $4.2 million of receivables due from Covetrus and $0.4 million payable to Covetrus under this ~~sale in the range of $~~transition services agreement.

~~225 million to $275 million. Our final calculation of the gain will take into account the accounting treatment of contingent consideration associated~~

In connection with the ~~transaction~~formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $31.0 million annually for the use of their intellectual property. During the three and nine months ended September 26, 2020, we recorded $7.8 million and $23.4 million, respectively in connection with costs related to this royalty agreement. During the three and nine months ended September 28, 2019, we recorded $7.8 million and $23.4 million, respectively in connection with costs related to this royalty agreement. As of September 26, 2020 and December 28, 2019, Henry Schein One, LLC had a net receivable balance due from Internet Brands of $13.5 million and $9.8 million, respectively, comprised of amounts related to results of operations and the ~~appropriate income tax treatment.~~royalty agreement.

During our normal course of business, we have interests in entities that we account for under the equity accounting method. During the three and nine months ended September 26, 2020, we recorded net sales of $10.0 million and $33.1 million, respectively, to such entities. During the three and nine months ended September 28, 2019, we recorded net sales of $28.6 million and $74.4 million, respectively, to such entities. During the three and nine months ended September 26, 2020, we purchased $2.9 million and $7.7 million, respectively, from such entities. During the three and nine months ended September 28, 2019, we purchased $3.2 million and $9.0 million, respectively, from such entities. At September 26, 2020 and December 28, 2019, we had in aggregate $34.3 million and $30.8 million, due from our equity affiliates, and $6.9 million and $4.9 million due to our equity affiliates, respectively.

3837

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Quarterly Report on Form 10-Q, and in particular the risks discussed under the caption “Risk Factors” in Item 1A of this report and those discussed in other documents we file with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K. Forward looking statements include the overall impact of the Novel Coronavirus Disease 2019 (COVID-19) on the Company, its results of operations, liquidity, and financial condition (including any estimates of the percentage impact on these items), the rate and consistency with which dental and other practices resume normal operations in the United States and internationally, expectations regarding PPE and other COVID-19 related product sales and inventory levels and whether one or more resurgences of the virus will adversely impact the resumption of normal operations, as well as more generally current expectations regarding performance in current and future periods. Forward looking statements also include the Company’s ability to make additional testing available, the nature of those tests and the number of tests intended to be made available and the timing for availability, the nature of the target market, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not been, or will not have been, independently verified under normal FDA procedures.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive and consolidating market; increased competition by third party online commerce sites; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic conditions; risks associated with currency fluctuations; risks associated with political and economic uncertainty; disruptions in financial markets; volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; risks associated with COVID-19, as well as other disease outbreaks, epidemics, pandemics, or similar wide spread public health concerns and other natural disasters; risks associated with the United Kingdom’s withdrawal from the European Union; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; financial and tax risks associated with acquisitions, dispositions and joint ventures; litigation risks; new or unanticipated litigation developments and the status of litigation matters; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence on third parties for certain technologically advanced components; ~~increased competition by third party online commerce sites;~~ risks from disruption to our information systems; cyberattacks or other privacy or data security breaches; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

Table of Contents

Where You Can Find Important Information

We may disclose important information through one or more of the following channels: SEC filings, public conference calls and webcasts, press releases, the investor relations page of our website (www.henryschein.com) and the social media channels identified on the Newsroom page of our website.

~~Table of Contents~~

Recent Developments

~~On October 1,~~COVID-19 Pandemic

In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a pandemic. The COVID-19 pandemic has negatively impacted the ~~Company sold an~~global economy, disrupted global supply chains and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020.Demand increased in the third quarter resulting in growth over the prior year driven by sales of personal protective equipment (PPE) and COVID-19 related products.

Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and indefinite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; vendor rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in ~~Hu-Friedy Mfg. Co., LLC,~~the future. In addition, the impact of COVID-19 had a ~~manufacturer~~material adverse effect on our business, results of operations and cash flows in the second quarter of 2020. In the latter half of the second quarter, dental ~~instruments~~ and ~~infection prevention solutions. Our investment was non-controlling, we were not involved~~medical practices began to re-open worldwide, and continued to do so during the third quarter. However, patient volumes remain below pre-COVID-19 levels and certain regions in ~~running~~ the U.S. and internationally are experiencing an increase in COVID-19 cases. As such, there is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time.

As part of a broad-based effort to support plans for the long-term health of our business and ~~had no representation on~~to strengthen our financial flexibility, we implemented cost reduction measures that included certain reductions in payroll, substantially decreased capital expenditures, reduced corporate spending and elimination of certain non-strategic targeted expenditures. As our markets have begun to recover we have ended most of those temporary expense-reduction initiatives during the board of directors. We estimate that in the fourth quarter of 2019 we will record a pretax gain from this sale in the range of $225 million to $275 million. Our final calculation of the gain will take into account the accounting treatment of contingent consideration associated with the transaction and the appropriate income tax treatment.third quarter.

Corporate Transactions

On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”) (the “Merger”). This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus (“Merger Sub”). In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors (the “Share Sale Investors”) for $361.1 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”). After the Share Sale and Animal Health Spin-off, Merger Sub consummated the

Table of Contents

Merger whereby it merged with and into Vets First Choice, with Vets First Choice surviving the Merger as a wholly owned subsidiary of Covetrus. Immediately following the consummation of the Merger, on a fully diluted basis, (i) approximately 63% of the shares of Covetrus common stock were (a) owned by our stockholders and the Share Sale Investors, and (b) held by certain employees of the Henry Schein Animal Health Business (in the form of certain equity awards), and (ii) approximately 37% of the shares of Covetrus common stock were (a) owned by stockholders of Vets First Choice immediately prior to the Merger, and (b) held by certain employees of Vets First Choice (in the form of certain equity awards). After the Separation and the Merger, we no longer beneficially owned any shares of Covetrus common stock and, following the Distribution Date, will not consolidate the financial results of Covetrus for the purpose of our financial reporting. Following the Separation and the Merger, Covetrus was an independent, publicly traded company on the Nasdaq Global Select Market.

Executive-Level Overview

We believe we are the ~~world's~~world’s largest provider of health care products and services primarily to office-based dental and medical practitioners. We serve more than 1one million customers worldwide including dental practitioners and laboratories and physician practices, as well as government, institutional health care clinics and other alternate care clinics. We believe that we have a strong brand identity due to our more than 8788 years of experience distributing health care products.

We are headquartered in Melville, New York, employ ~~approximately~~more than 19,000 people (of which ~~approximately 8,800~~more than 9,500 are based outside the United States) and have operations or affiliates in 3231 countries, including the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR, Ireland, Israel, Italy, Japan, Liechtenstein, Luxembourg, Malaysia, the Netherlands, New Zealand, Poland, Portugal, Singapore, ~~Slovakia,~~ South Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates and the United Kingdom.

~~Table of Contents~~

We have established strategically located distribution centers to enable us to better serve our customers and increase our operating efficiency. This infrastructure, together with broad product and service offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of supply for our customers’ needs. Our infrastructure also allows us to provide convenient ordering and rapid, accurate and complete order fulfillment.

We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base.

Industry Overview

In recent years, the health care industry has increasingly focused on cost ~~containment.~~containment and on value-based reimbursement arrangements that condition payment to health care providers on the achievement of cost savings and quality targets. This trend has benefited distributors capable of providing a broad array of products and services at low prices. It also has accelerated the growth of ~~HMOs,~~ group practices, ~~other~~ managed care ~~accounts~~arrangements and collective buying groups, which, in addition to their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing specialized management information support. We believe that the trend towards cost containment and value-based reimbursement has the potential to favorably affect demand for

Table of Contents

technology solutions, including software, which can enhance the efficiency and facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies and transactions that we undertook to expand our business, domestically and internationally, in part to address significant changes in the health care industry, including consolidation of health care distribution companies, health care reform, trends toward managed care, cuts in Medicare and collective purchasing arrangements.

Our current and future results have been and could continue to be adversely impacted by the COVID-19 pandemic, the current economic environment and uncertainty, particularly impacting overall demand for our products and services.

Industry Consolidation

The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented and diverse. The industry ranges from sole practitioners working out of relatively small offices to group practices or service organizations ranging in size from a few practitioners to a large number of practitioners who have combined or otherwise associated their practices.

Due in part to the inability of office-based health care practitioners to store and manage large quantities of supplies in their offices, the distribution of health care supplies and small equipment to office-based health care practitioners has been characterized by frequent, small quantity orders, and a need for rapid, reliable and substantially complete order fulfillment. The purchasing decisions within an office-based health care practice are typically made by the practitioner or an administrative assistant. Supplies and small equipment are generally purchased from more than one distributor, with one generally serving as the primary supplier.

~~Table of Contents~~

The trend of consolidation extends to our customer base. Health care practitioners are increasingly seeking to partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician hospital organizations. In many cases, purchasing decisions for consolidated groups are made at a centralized or professional staff level; however, orders are delivered to the practitioners’ offices.

We believe that consolidation within the industry will continue to result in a number of distributors, particularly those with limited financial, operating and marketing resources, seeking to combine with larger companies that can provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire companies that can enhance their current product and service offerings or provide opportunities to serve a broader customer base.

Our trend with regard to acquisitions and joint ventures has been to expand our role as a provider of products and services to the health care industry. This trend has resulted in our expansion into service areas that complement our existing operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired businesses.

As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe we have the ability to support increased sales through our existing infrastructure, although there can be no assurances that we will be able to successfully accomplish this. We also have invested in expanding our sales/marketing infrastructure to include a focus on building relationships with decision makers who do not reside in the office-based practitioner setting.

As the health care industry continues to change, we continually evaluate possible candidates for merger and joint venture or acquisition and intend to continue to seek opportunities to expand our role as a provider of products and services to the health care industry. There can be no assurance that we will be able to successfully pursue any such opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or consummated, we would incur merger and/or acquisition-related costs, and there can be no assurance that the integration efforts associated with any such transaction would be successful. In response to the COVID-19 pandemic, we had taken a range of actions to preserve cash, including the temporary suspension of significant acquisition activity. During the third quarter of 2020, as global conditions improved, we resumed our acquisition strategy.

Table of Contents

Aging Population and Other Market Influences

The health care products distribution industry continues to experience growth due to the aging population, increased health care awareness, the proliferation of medical technology and testing, new pharmacology treatments and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance coverage. In addition, the physician market continues to benefit from the shift of procedures and diagnostic testing from acute care settings to alternate-care sites, particularly physicians’ offices.

According to the U.S. Census Bureau’s International Data Base, in ~~2018~~2020 there were more than six and a half` million Americans aged 85 years or older, the segment of the population most in need of long-term care and elder-care services. By the year 2050, that number is projected to nearly triple to approximately 19 million. The population aged 65 to 84 years is projected to increase ~~over 44%~~by approximately 36% during the same time period.

As a result of these market dynamics, annual expenditures for health care services continue to increase in the United States. We believe that demand for our products and services will grow, while continuing to be impacted by current and future operating, economic and industry conditions. The Centers for Medicare and Medicaid Services, or CMS, published “National Health Expenditure Projections ~~2017-2026”~~2019-2028” indicating that total national health care spending reached approximately ~~$3.7~~$3.6 trillion in 2018, or ~~18.2%~~17.7% of the nation’s gross domestic product, the benchmark measure for annual production of goods and services in the United States. Health care spending is projected to reach approximately ~~$5.7~~$6.2 trillion in ~~2026,~~2028, approximately 19.7% of the nation’s projected gross domestic product.

Government

Certain of our businesses involve the distribution, importation and sale of pharmaceuticals and medical devices, and in this regard we are subject to extensive local, state, federal and foreign governmental laws and regulations applicable to the distribution and sale of pharmaceuticals and medical devices. Additionally, government and private insurance programs fund a large portion of the total cost of medical care, and there has been an emphasis on efforts to control medical costs,

~~Table of Contents~~

including laws and regulations lowering reimbursement rates for pharmaceuticals, medical devices, and/or medical treatments or services. Also, many of these laws and regulations are subject to change and may impact our financial performance. For example, certain laws and regulations restricting medical supply sales in the United States have been temporarily modified or waived in response to the COVID-19 pandemic. In addition, our businesses are generally subject to numerous other laws and regulations that could impact our financial performance, including securities, antitrust, anti-bribery and anti-kickback, customer interaction transparency, data privacy, data security, price gouging and other laws and ~~regulations.~~regulations, and some of the related rules have been temporarily modified in response to the COVID-19 pandemic. Failure to comply with law or regulations could have a material adverse effect on our business.

~~Health Care Reform~~

The United States Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, each enacted in March 2010 (the “Health Care Reform Law”), increased federal oversight A more detailed discussion of private health insurance plans and included a number of provisions designed to reduce Medicare expenditures and the cost of health care generally, to reduce fraud and abuse, and to provide access to increased health coverage.

The Health Care Reform Law requirements include a 2.3% excise tax on domestic sales of many medical devices by manufacturers and importers that began in 2013 and a fee on branded prescription drugs and biologics that was implemented in 2011, both of which may affect sales. However, with respect to the medical device excise tax, a two-year moratorium was imposed under the Consolidated Appropriations Act, 2016, suspending the imposition of the tax on device sales during the period beginning January 1, 2016 and ending on December 31, 2017, and on January 22, 2018 an additional two-year moratorium was imposed under Public Law No. 115-120, suspending the imposition of the tax on device sales during the period beginning January 1, 2018 and ending on December 31, 2019. The Health Care Reform Law has also materially expanded the number of individuals in the United States with health insurance. The Health Care Reform Law has faced ongoing legal challenges, including litigation seeking to invalidate some of or all of the law or the manner in which it has been implemented. In addition, the President is seeking to repeal and replace the Health Care Reform Law and has taken a number of administrative actions to materially weaken it, which efforts are being challenged in various judicial proceedings. On December 22, 2017, the President signed into law the Tax Cuts and Jobs Act (the “Tax Act”), which contains a broad range of tax reform provisions that impact the individual and corporate tax rates, international tax provisions, income tax add-back provisions and deductions, and which also repealed the individual mandate of the Health Care Reform Law. Further, in December 2018, a Texas federal court struck down the entire Health Care Reform Law, a ruling which is being appealed, and, if upheld, could have a significant impact on the U.S. health care industry. The uncertain status of the Health Care Reform Law affects our ability to plan.

A Health Care Reform Law provision, generally referred to as the Physician Payment Sunshine Act or Open Payments Program, imposes annual reporting and disclosure requirements for drug and device manufacturers and distributors with regard to payments or other transfers of value made to certain covered recipients (including physicians, dentists and teaching hospitals), and for such manufacturers and distributors and for group purchasing organizations, with regard to certain ownership interests held by physicians in the reporting entity. CMS publishes information from these reports on a publicly available website, including amounts transferred and physician, dentist and teaching hospital identities. Effective January 1, 2022, payments or other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives must also be reported, and this new requirement will be effective for data collected beginning in calendar year 2021.

Under the Physician Payment Sunshine Act, we are required to collect and report detailed information regarding certain financial relationships we have with covered recipients such as physicians, dentists and teaching hospitals. We believe that we are substantially compliant with applicable Physician Payment Sunshine Act requirements. The Physician Payment Sunshine Act pre-empts similar state reporting laws, although we or our subsidiaries may be required to report under certain state transparency laws that address circumstances not covered by the Physician Payment Sunshine Act, and some of these state laws, as well as the federal law, can be ambiguous. We are also subject to foreign regulations requiring transparency of certain interactions between suppliers and their customers. While we believe we have substantially compliant programs and controls in place to comply with these requirements, our compliance with these rules imposes additional costs on us.

~~Table of Contents~~

Another notable Medicare health care reform initiative, the Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”), enacted on April 16, 2015, established a new payment framework, called the Quality Payment Program, which modifies certain Medicare payments to “eligible clinicians,” including physicians, dentists and other practitioners. Under MACRA, certain eligible clinicians are required to participate in Medicare through the Merit-Based Incentive Payment System (“MIPS”) or Advanced Alternative Payment Models (“APMs”). MIPS generally consolidated three programs; the physician quality reporting system, the value-based payment modifier and the Medicare electronic health record (“EHR”) program, into a single program in which Medicare reimbursement to eligible clinicians includes both positive and negative payment adjustments that take into account quality, promoting interoperability, cost and improvement activities. Advanced APMs generally involve higher levels of financial and technology risk. The first MIPS performance year was 2017, and the data collected in the first performance year determines payment adjustments that began January 1, 2019. MACRA represents a fundamental change in physician reimbursement that is expected to provide substantial financial incentives for physicians to participate in risk contracts, and to increase physician information technology and reporting obligations. MIPS and APM performance measures and other program requirements continue to evolve. For example, in a Proposed Rule for the 2020 Medicare Physician Fee Schedule, published August 14, 2019, CMS proposed instituting a new MIPS framework, to be called the MIPS Value Pathways (MVPs), which would apply beginning with the 2021 performance year, and involve a new approach to measures and standards to be focused on clinical episodes of care. The implications of the implementation of MACRA are uncertain and will depend on future regulatory activity and physician activity in the marketplace. MACRA may encourage physicians to move from smaller practices to larger physician groups or hospital employment, leading to a consolidation of a portion of our customer base. Although we believe that we are positioned to capitalize on this consolidation trend, there can be no assurances that we will be able to successfully accomplish this.

In 2019, there has been increased scrutiny on drug pricing and concurrent efforts to control or reduce drug costs by Congress, the President, and various states. Several related bills have been introduced at the federal level, and such legislation could have the potential to impose additional costs on our business.

~~Health Care Fraud~~

Certain of our businesses are subject to federal and state (and similar foreign) health care fraud and abuse, referral and reimbursement laws and regulations with respect to their operations. Some of these laws, referred to as “false claims laws,” prohibit the submission or causing the submission of false or fraudulent claims for reimbursement to federal, state and other health care payers and programs. Other laws, referred to as “anti-kickback laws,” prohibit soliciting, offering, receiving or paying remuneration in order to induce the referral of a patient or ordering, purchasing, leasing or arranging for, or recommending ordering, purchasing or leasing of, items or services that are paid for by federal, state and other health care payers and programs.

The fraud and abuse laws and regulations have been subject to varying interpretations, as well as heightened enforcement activity over the past few years, and significant enforcement activity has been the result of “relators,” who serve as whistleblowers by filing complaints in the name of the United States (and if applicable, particular states) under federal and state false claims laws and who may receive up to 30% of total government recoveries. Penalties under fraud and abuse laws may be severe. For example, under the federal False Claims Act, violations may result in treble damages, plus civil penalties of up to $22,927 per claim, as well as exclusion from federal health care programs and criminal penalties. Most states have adopted similar state false claims laws, and these state laws have their own penalties which may be in addition to federal False Claims Act penalties. With respect to “anti-kickback laws,” violations of the federal Anti-Kickback Law may result in civil penalties of up to $100,000 for each violation, plus up to three times the total amount of remuneration offered, paid, solicited or received, as well as exclusion from federal health care programs and criminal penalties. Notably, effective October 24, 2018, a new federal anti-kickback law (the “Eliminating Kickbacks in Recovery Act of 2018”) enacted in connection with broader addiction services legislation, may impose criminal penalties for kickbacks involving clinical laboratory services, regardless of whether the services at issue involved addiction services, and regardless of whether the services were reimbursed by a federal health care program or by a commercial insurer. Furthermore, the Health Care Reform Law significantly strengthened the federal False Claims Act and the federal Anti-Kickback Law provisions, clarifying that a federal Anti-Kickback Law violation can be a basis for federal False Claims Act liability.

~~Table of Contents~~

With respect to measures of this type, the United States government (among others) has expressed concerns about financial relationships between suppliers on the one hand and physicians and dentists on the other. As a result, we regularly review and revise our marketing practices as necessary to facilitate compliance.

We also are subject to certain United States and foreign laws and regulations concerning the conduct of our foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German anti-corruption laws and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records, which have been the focus of increasing enforcement activity globally in recent years.

Failure to comply with fraud and abuse laws and regulations could result in significant civil and criminal penalties and costs, including the loss of licenses and the ability to participate in federal and state health care programs, and could have a material adverse effect on our business. Also, these measures may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations or incur substantial defense and settlement expenses. Even unsuccessful challenges by regulatory authorities or private relators could result in reputational harm and the incurring of substantial costs. In addition, many of these laws are vague or indefinite and have not been interpreted by the courts, and have been subject to frequent modification and varied interpretation by prosecutorial and regulatory authorities, increasing the risk of noncompliance.

While we believe that we are substantially compliant with applicable fraud and abuse laws and regulations, and have adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict whether changes in applicable law, or interpretation of laws, or changes in our services or marketing practices in response to changes in applicable law or interpretation of laws, could have a material adverse effect on our business.

~~Operating, Security and Licensure Standards~~

~~Certain of our businesses involve the distribution of pharmaceuticals and medical devices, and in this regard we are subject to various local, state, federal and foreign~~ governmental laws and regulations applicable to the distribution of pharmaceuticals and medical devices. Among the United States federal laws applicable to us are the Controlled Substances Act, the Federal Food, Drug, and Cosmetic Act, as amended (“FDC Act”), and Section 361 of the Public Health Service Act. We are also subject to comparable foreign regulations.

The FDC Act and similar foreign laws generally regulate the introduction, manufacture, advertising, labeling, packaging, storage, handling, reporting, marketing and distribution of, and record keeping for, pharmaceuticals and medical devices shippedis included in interstate commerce, and states may similarly regulate such activities within the state. Section 361 of the Public Health Service Act, which provides authority to prevent the introduction, transmission or spread of communicable diseases, serves as the legal basisManagement’s Discussion & Analysis, contained in our Annual Report on Form 10-K for the ~~United States Food and Drug Administration’s (“FDA”) regulation of human cells, tissues and cellular and tissue-based products, also known as “HCT/P products.”~~

The Federal Drug Quality and Security Act of 2013 brought about significant changes with respect to pharmaceutical supply chain requirements. Title II of this measure, known as the Drug Supply Chain Security Act (“DSCSA”), is being phased in over a period of ten years, and is intended to build a national electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States. The law’s track and trace requirements applicable to manufacturers, wholesalers, repackagers and dispensers (e.g., pharmacies) of prescription drugs took effect in January 2015, and continues to be implemented. The DSCSA product tracing requirements replace the former FDA drug pedigree requirements and pre-empt certain state requirements that are inconsistent with, more stringent than, or in addition to, the DSCSA requirements.

The DSCSA also establishes certain requirements for the licensing and operation of prescription drug wholesalers and third party logistics providers (“3PLs”), and includes the eventual creation of national wholesaler and 3PL licenses in cases where states do not license such entities. The DSCSA requires that wholesalers and 3PLs distribute drugs in accordance with certain standards regarding the recordkeeping, storage and handling of prescription drugs. According to FDA guidance, states are pre-empted from imposing any licensing requirementsfiscal year ended December 28 2019, filed on February 20, 2020.

~~Table of Contents~~

that are inconsistent with, less stringent than, directly related to, or covered by the standards established by federal law in this area. Current state licensing requirements concerning wholesalers will remain in effect until the FDA issues new regulations as directed by the DSCSA.

~~We believe that we are substantially compliant with applicable DSCSA requirements.~~

The Food and Drug Administration Amendments Act of 2007 and the Food and Drug Administration Safety and Innovation Act of 2012 amended the FDC Act to require the FDA to promulgate regulations to implement a unique device identification (“UDI”) system. The UDI rule phased in the implementation of the UDI regulations over seven years, generally beginning with the highest-risk devices (i.e., Class III medical devices) and ending with the lowest-risk devices. Most compliance dates were reached as of September 24, 2018, with a final set of requirements for low-risk devices being reached on September 24, 2022, which will complete the phase in. The UDI regulations require “labelers” to include unique device identifiers (“UDIs”), with a content and format prescribed by the FDA and issued under a system operated by an FDA-accredited issuing agency, on the labels and packages of medical devices, and to directly mark certain devices with UDIs. The UDI regulations also require labelers to submit certain information concerning UDI-labeled devices to the FDA, much of which information is publicly available on an FDA database, the Global Unique Device Identification Database. The UDI regulations and subsequent FDA guidance regarding the UDI requirements provide for certain exceptions, alternatives and time extensions. For example, the UDI regulations include a general exception for Class I devices exempt from the Quality System Regulation (other than record-keeping requirements and complaint files). Regulated labelers include entities such as device manufacturers, repackagers, reprocessors and relabelers that cause a device’s label to be applied or modified, with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label, and include certain of our businesses.

~~We believe that we are substantially compliant with applicable UDI requirements.~~

Under the Controlled Substances Act, as a distributor of controlled substances, we are required to obtain and renew annually registrations for our facilities from the United States Drug Enforcement Administration (“DEA”) permitting us to handle controlled substances. We are also subject to other statutory and regulatory requirements relating to the storage, sale, marketing, handling and distribution of such drugs, in accordance with the Controlled Substances Act and its implementing regulations, and these requirements have been subject to heightened enforcement activity in recent times. We are subject to inspection by the DEA.

Certain of our businesses are also required to register for permits and/or licenses with, and comply with operating and security standards of, the DEA, the FDA, the United States Department of Health and Human Services, and various state boards of pharmacy, state health departments and/or comparable state agencies as well as comparable foreign agencies, and certain accrediting bodies depending on the type of operations and location of product distribution, manufacturing or sale. These businesses include those that distribute, manufacture and/or repackage prescription pharmaceuticals and/or medical devices and/or HCT/P products, or own pharmacy operations, or install, maintain or repair equipment. In addition, Section 301 of the National Organ Transplant Act, and a number of comparable state laws, impose civil and/or criminal penalties for the transfer of certain human tissue (for example, human bone products) for valuable consideration, while generally permitting payments for the reasonable costs incurred in procuring, processing, storing and distributing that tissue. We are also subject to foreign government regulation of such products. The DEA, the FDA and state regulatory authorities have broad inspection and enforcement powers, including the ability to suspend or limit the distribution of products by our distribution centers, seize or order the recall of products and impose significant criminal, civil and administrative sanctions for violations of these laws and regulations. Foreign regulations subject us to similar foreign enforcement powers. Furthermore, compliance with legal requirements has required and may in the future require us to institute voluntary recalls of products we sell, which could result in financial losses and potential reputational harm. Our customers are also subject to significant federal, state, local and foreign governmental regulation.

Certain of our businesses are subject to various additional federal, state, local and foreign laws and regulations, including with respect to the sale, transportation, storage, handling and disposal of hazardous or potentially hazardous substances, and safe working conditions.

~~Table of Contents~~

~~Certain of our businesses also maintain contracts with governmental agencies and are subject to certain regulatory requirements specific to government contractors.~~

~~Antitrust~~

The U.S. federal government, most U.S. states and many foreign countries have antitrust laws that prohibit certain types of conduct deemed to be anti-competitive. Violations of antitrust laws can result in various sanctions, including criminal and civil penalties. Private plaintiffs also could bring civil lawsuits against us in the United States for alleged antitrust law violations, including claims for treble damages.

~~Regulated Software; Electronic Health Records~~

The FDA has become increasingly active in addressing the regulation of computer software intended for use in health care settings. The 21st Century Cures Act (the “Cures Act”), signed into law on December 13, 2016, amended the device definition to exclude certain software, including clinical decision support software that meet certain criteria. In September 2019, the FDA issued draft and final guidance documents describing its interpretation of the statutory language regarding which types of clinical decision support tools and other software are exempt from regulation as medical devices. Certain of our businesses involve the development and sale of software and related products to support physician and dental practice management, and it is possible that the FDA or foreign government authorities could determine that one or more of our products is a medical device, which could subject us or one or more of our businesses to substantial additional requirements with respect to these products.

In addition, the European Parliament and the Council of the European Union have adopted a new pan-European General Data Protection Regulation (“GDPR”), effective from May 25, 2018, which increases privacy rights for individuals in Europe, extended the scope of responsibilities for data controllers and data processors and imposes increased requirements and potential penalties on companies offering goods or services to individuals who are located in Europe (“Data Subjects”) or monitoring the behavior of such individuals (including by companies based outside of Europe). Noncompliance can result in penalties of up to the greater of EUR 20 million, or 4% of global company revenues. Individual member states may impose additional requirements and penalties as they relate to certain things such as employee personal data. Among other things, the GDPR requires, with respect to data concerning Data Subjects, company accountability, consents from Data Subjects or other acceptable legal basis needed to process the personal data, prompt breach notifications within 72 hours, fairness and transparency in how the personal data is stored, used or otherwise processed, and data integrity and security, and provides rights to Data Subjects relating to modification, erasure and transporting of the personal data. The California Consumer Privacy Act (“CCPA”), signed into law on June 28, 2018, becomes effective January 1, 2020, and will require companies to institute additional protections on the collection, use and disclosure of certain “personal information” of California consumers. In addition to providing for enforcement by the California Attorney General, the CCPA also provides for a private right of action. Entities in violation of the CCPA may be liable for civil penalties. Other states, as well as the federal government, have increasingly considered the adoption of similar personal data privacy laws. While we believe we have substantially compliant programs and controls in place to comply with the GDPR and CCPA requirements, our compliance with these measures is likely to impose additional costs on us, and we cannot predict whether the interpretations of the requirements, or changes in our practices in response to new requirements or interpretations of the requirements, could have a material adverse effect on our business.

We also sell products and services that health care providers, such as physicians and dentists, use to store and manage patient medical or dental records. These customers, and we, are subject to laws, regulations and industry standards, such as the federal Health Insurance Portability and Accountability Act of 1996, as amended, and implement regulations (“HIPAA”) and the Payment Card Industry Data Security Standards, which require the protection of the privacy and security of those records, and our products may also be used as part of these customers’ comprehensive data security programs, including in connection with their efforts to comply with applicable privacy and security laws. Perceived or actual security vulnerabilities in our products or services, or the perceived or actual failure by us or our customers who use our products or services to comply with applicable legal or contractual data privacy and security requirements, may not only cause us significant reputational harm, but may

~~Table of Contents~~

~~also lead to claims against us by our customers and/or governmental agencies and involve substantial fines, penalties and other liabilities and expenses and costs for remediation.~~

Various federal initiatives involve the adoption and use by health care providers of certain electronic health care records systems and processes. The initiatives include, among others, programs that incentivize physicians and dentists, through Medicare’s MIPS, to use certified EHR technology in accordance with certain evolving requirements, including regarding quality, promoting interoperability, cost and improvement activities. Qualification for the MIPS incentive payments requires the use of EHRs that are certified as having certain capabilities designated in standards adopted by CMS and by the Office of the National Coordinator for Health Information Technology of the Department of Health and Human Services. These standards have been subject to change.

Certain of our businesses involve the manufacture and sale of certified EHR systems and other products linked to MIPS and other incentive programs. In order to maintain certification of our EHR products, we must satisfy these changing governmental standards. If any of our EHR systems do not meet these standards, yet have been relied upon by health care providers to receive federal incentive payments, as noted above, we are exposed to risk, such as under federal health care fraud and abuse laws, including the False Claims Act. For example, on May 31, 2017, the U.S. Department of Justice announced a $155 million settlement and 5-year corporate integrity agreement involving a vendor of certified EHR systems, based on allegations that the vendor, by misrepresenting capabilities to the certifying body, caused its health care provider customers to submit false Medicare and Medicaid claims for meaningful use incentive payments in violation of the False Claims Act. While we believe we are substantially in compliance with such certifications and with applicable fraud and abuse laws and regulations, and we have adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict whether changes in applicable law, or interpretation of laws, or changes in our practices in response to changes in applicable law or interpretation of laws, could have a material adverse effect on our business. Moreover, in order to satisfy our customers, our products may need to incorporate increasingly complex reporting functionality. Although we believe we are positioned to accomplish this, the effort may involve increased costs, and our failure to implement product modifications, or otherwise satisfy applicable standards, could have a material adverse effect on our business.

Other health information standards, such as regulations under HIPAA, establish standards regarding electronic health data transmissions and transaction code set rules for specific electronic transactions, such as transactions involving claims submissions to third party payers. Certain of our businesses provide electronic practice management products that must meet these requirements. Failure to abide by electronic health data transmission standards could expose us to breach of contract claims, substantial fines, penalties, and other liabilities and expenses, costs for remediation and harm to our reputation.

Additionally, as electronic medical devices are increasingly connected to each other and to other technology, the ability of these connected systems safely and effectively to exchange and use exchanged information becomes increasingly important. For example, on September 6, 2017, the FDA issued final guidance to assist industry in identifying specific considerations related to the ability of electronic medical devices to safely and effectively exchange and use exchanged information. As a medical device manufacturer, we must manage risks including those associated with an electronic interface that is incorporated into a medical device.

~~There may be additional legislative initiatives in the future impacting health care.~~

~~E-Commerce~~

Electronic commerce solutions have become an integral part of traditional health care supply and distribution relationships. Our distribution business is characterized by rapid technological developments and intense competition. The continuing advancement of online commerce requires us to cost-effectively adapt to changing technologies, to enhance existing services and to develop and introduce a variety of new services to address the changing demands of consumers and our customers on a timely basis, particularly in response to competitive offerings.

~~Table of Contents~~

Through our proprietary, technologically based suite of products, we offer customers a variety of competitive alternatives. We believe that our tradition of reliable service, our name recognition and large customer base built on solid customer relationships, position us well to participate in this significant aspect of the distribution business. We continue to explore ways and means to improve and expand our Internet presence and capabilities, including our online commerce offerings and our use of various social media outlets.

4942

Table of Contents

Results of Operations

The following table summarizes the significant components of our operating results for the three and nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 and cash flows for the nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 (in thousands):

			Three Months Ended				Nine Months Ended						Three Months Ended				Nine Months Ended
			September 28,		September 29,		September 28,		September 29,				September 26,		September 28,		September 26,		September 28,
			2019		2018		2019		2018				2020		2019		2020		2019
Operating results:	Operating results:										Operating results:
Net sales	Net sales		$	2,508,767	$	2,355,565	$	7,316,862	$	6,945,047	Net sales		$	2,840,146	$	2,508,767	$	6,953,416	$	7,316,862
Cost of sales	Cost of sales			1,747,600		1,633,206		5,036,574		4,785,231	Cost of sales			2,085,847		1,747,600		4,998,784		5,036,574
	Gross profit			761,167		722,359		2,280,288		2,159,816	Gross profit			754,299		761,167		1,954,632		2,280,288
Operating expenses:	Operating expenses:										Operating expenses:
	Selling, general and administrative			574,771		552,051		1,742,597		1,658,988	Selling, general and administrative			559,636		574,771		1,572,816		1,742,597
	Litigation settlements			-		38,488		-		38,488	Restructuring costs (credits)			6,992		(802)		27,713		15,764
	Restructuring costs (credits)			(802)		8,551		15,764		19,723		Operating income	$	187,671	$	187,198	$	354,103	$	521,927
		Operating income	$	187,198	$	123,269	$	521,927	$	442,617

Other expense, net	Other expense, net		$	(8,607)	$	(17,088)	$	(31,103)	$	(45,237)	Other expense, net		$	(10,516)	$	(8,607)	$	(24,138)	$	(31,103)
Net income from continuing operations	Net income from continuing operations			143,212		96,247		388,269		325,555	Net income from continuing operations			151,813		143,212		271,808		388,269
Income (loss) from discontinued operations	Income (loss) from discontinued operations			5,641		30,729		(5,576)		97,561	Income (loss) from discontinued operations			(29)		5,641		274		(5,210)
Net income attributable to Henry Schein, Inc.	Net income attributable to Henry Schein, Inc.			140,557		121,478		364,872		402,908	Net income attributable to Henry Schein, Inc.			141,697		140,557		261,161		364,872

																	Nine Months Ended
																	September 26,		September 28,
																	2020		2019
Cash flows:	Cash flows:										Cash flows:
Net cash provided by operating activities from continuing operations	Net cash provided by operating activities from continuing operations						$	525,180	$	269,395	Net cash provided by operating activities from continuing operations						$	248,414	$	525,180
Net cash used in investing activities from continuing operations	Net cash used in investing activities from continuing operations							(691,349)		(124,072)	Net cash used in investing activities from continuing operations							(93,956)		(691,349)
Net cash provided by (used in) financing activities from continuing operations								176,139		(219,894)
Net cash provided by financing activities from continuing operations											Net cash provided by financing activities from continuing operations							264,433		176,139

Plans of Restructuring

During the three ~~and nine~~ months ended September 26, 2020 and September 28, 2019, we recorded restructuring costs (credits) of $7.0 million and $(0.8) million. During the nine months ended September 26, 2020 and September 28, 2019, we recorded restructuring costs of ~~$(0.8)~~$27.7 million and $15.8 ~~million, respectively.~~million. The restructuring ~~credits in the three months ended September 28, 2019 were primarily attributable to a reduction in previously recorded estimated restructuring~~ costs ~~as of June 29, 2019.~~for these periods included costs for severance benefits and facility exit costs. The ~~total 2018~~ costs associated with ~~the actions to complete this restructuring were $54.4 million from continuing operations, consisting primarily~~these restructurings are included in a separate line item, “Restructuring costs” within our consolidated statements of ~~severance costs. As of June 29, 2019, the restructuring activities under this initiative are complete and we do not expect to incur any additional restructuring charges for the remainder of 2019.~~income.

5043

Table of Contents

Three Months Ended September ~~28, 2019~~26, 2020 Compared to Three Months Ended September ~~29, 2018~~28, 2019

Net Sales

Net sales for the three months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 were as follows (in thousands):

September 28,

% of

September 29,

% of

Increase

2019

Total

2018

Total

$

%
Health care distribution ^(1):

Dental

$
1,545,984

61.6
%

$
1,514,325

64.3
%

$
31,659

2.1
%

Medical

803,709

32.0

721,942

30.6

81,767

11.3

Total health care distribution

2,349,693

93.6

2,236,267

94.9

113,426

5.1

Technology and value-added services ⁽²⁾

137,331

5.5

119,298

5.1

18,033

15.1

Total excluding Corporate TSA revenue

2,487,024

99.1

2,355,565

100.0

131,459

5.6

Corporate TSA revenue⁽³⁾

21,743

0.9

-

-

21,743

-

Total

$
2,508,767

100.0
%

$
2,355,565

100.0
%

$
153,202

6.5

(1)
Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)
Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

(3)
Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health spin-off, which we expect to continue through August 2020.

			September 26,		% of		September 28,		% of		Increase
			2020		Total		2019		Total		$		%
Health care distribution ⁽¹⁾
	Dental		$	1,649,853	58.1	%	$	1,545,981	61.6	%	$	103,872	6.7	%
	Medical			1,027,146	36.2			803,709	32.0			223,437	27.8
		Total health care distribution		2,676,999	94.3			2,349,690	93.6			327,309	13.9
Technology and value-added services ⁽²⁾				138,355	4.9			137,334	5.5			1,021	0.7
		Total excluding Corporate TSA revenue		2,815,354	99.2			2,487,024	99.1			328,330	13.2
Corporate TSA revenue ⁽³⁾				24,792	0.8			21,743	0.9			3,049	14.0
		Total	$	2,840,146	100.0	%	$	2,508,767	100.0	%	$	331,379	13.2

(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

(3)	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which has been substantially completed as of October 2020.

The ~~6.5%~~13.2% increase in net sales for the three months ended September ~~28, 2019~~26, 2020 includes ~~7.6%~~an increase of 13.1% in local currency ~~growth (3.9%~~revenue (13.0% increase in internally generated revenue and ~~3.7%~~0.1% growth from acquisitions) ~~partially offset by a decrease~~and an increase of ~~1.1%~~0.1% related to foreign currency exchange. ~~Excluding~~Sales in the third quarter benefited from an approximate 291% increase in sales of personal protection equipment (PPE) and other COVID-19 related products, ~~under~~which accounts for nearly all the ~~transition services agreement with Covetrus, our net sales increased 5.6%, including local currency~~ growth ~~of 6.6% (3.0% increase~~ in ~~internally generated revenue and 3.6% growth from acquisitions) partially offset by a decrease of 1.0% related to foreign currency exchange.~~sales.

The ~~2.1%~~6.7% increase in dental net sales for the three months ended September ~~28, 2019~~26, 2020 includes ~~3.6%~~an increase of 6.6% local currency ~~growth (1.7%~~revenue (6.5% increase in internally generated revenue and ~~1.9%~~0.1% growth from acquisitions) ~~partially offset by a decrease~~and an increase of ~~1.5%~~0.1% related to foreign currency exchange. The ~~3.6%~~6.6% increase in local currency sales was attributable to an increase in dental consumable merchandise sales ~~growth~~ of ~~4.7% (2.3%~~9.4% (9.3% increase in internally generated revenue and ~~2.4%~~0.1% growth from acquisitions)~~. Growth~~, partially offset by a decrease in dental equipment sales and service revenues of 2.6%, all of which is attributable to the decrease in internally generated revenue. Dental equipment sales in the third quarter continued to recover as internal sales in local currencies in North America were ~~flat versus the prior year. On a local currency basis,~~essentially flat. International dental equipment sales experienced only a slight decline as practices resumed investments in traditional and ~~service revenues decreased~~high-technology capital equipment solutions. Although the COVID-19 pandemic adversely impacted our worldwide revenue beginning in ~~North America by 4.5%, but increased 7.9% internationally.~~mid-March as many dental offices progressively closed or began seeing a limited number of patients, our dental sales began to improve in the second half of the quarter ended June 27, 2020 and continuing into the quarter ended September 26, 2020 as dental practices resumed operating and patient traffic increased. Global dental sales in the third quarter benefited from an approximate 130% increase in sales of PPE, which accounts for nearly all the growth in dental sales.

The ~~11.3%~~27.8% increase in medical net sales for the three months ended September ~~28, 2019~~26, 2020 includes ~~11.4%~~an increase of 27.7% local currency ~~growth (5.3% increase in internally generated~~ revenue and ~~6.1% growth from acquisitions) partially offset by a decrease~~an increase of 0.1% related to foreign currency exchange. Economic conditions relating to the COVID-19 pandemic have had less of an impact on the performance of our medical group versus dental, in part due to continued strong sales of PPE, such as masks, gowns and face shields, and other COVID-19 related products, such as diagnostic test kits. Globally, our medical business experienced growth of sales of such products by approximately 600% compared to the prior year, which accounts for nearly all the growth in medical sales.

The ~~15.1%~~0.7% increase in technology and value-added services net sales for the three months ended September ~~28, 2019~~26, 2020 includes ~~15.8%~~an increase of 0.3% local currency ~~growth (4.9% increase~~revenue (1.3% decrease in internally generated revenue, ~~and 10.9%~~partially offset by 1.6% growth from acquisitions) ~~partially offset by a decrease~~and an increase of ~~0.7%~~0.4% related to foreign currency exchange. ~~Our technology sales in 2019 were bolstered by increased revenues with~~During the U.S. Department of Defense, which were $9.0 million versus $6.2 million in 2018. The local currency growth in technology and value-added services is affected by the revenue for certain products being recognized on a gross basis in the prior year. When excluding the effects of this change, internally generated revenue grew by 6.6%

5144

Table of Contents

quarter, in line with the resumption of dental practice operations, the trend for transactional software revenues improved as more patients visited dental practices worldwide.

Although dental and medical practices continued to re-open during the third quarter, patient volumes remain below pre-COVID-19 levels and certain regions in the U.S and internationally are experiencing an increase in COVID-19 cases. As such, there is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our net sales in future periods.

Gross Profit

Gross profit and gross margin percentages by segment and in total for the three months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 were as follows (in thousands):

		September 28,		Gross		September 29,		Gross		Increase					September 26,		Gross		September 28,		Gross		Increase / (Decrease)
		2019		Margin %		2018		Margin %		$		%			2020		Margin %		2019		Margin %		$		%
Health care distribution	Health care distribution	$	659,958	28.1	%	$	636,580	28.5	%	$	23,378	3.7	%	Health care distribution	$	653,204	24.4	%	$	659,955	28.1	%	$	(6,751)	(1.0)	%
Technology and value-added services	Technology and value-added services		100,554	73.2			85,779	71.9			14,775	17.2		Technology and value-added services		100,272	72.5			100,557	73.2			(285)	(0.3)
	Total excluding Corporate TSA revenues		760,512	30.6			722,359	30.7			38,153	5.3		Total excluding Corporate TSA revenues		753,476	26.8			760,512	30.6			(7,036)	(0.9)
Corporate TSA revenues	Corporate TSA revenues		655	3.0			-	-			655	-		Corporate TSA revenues		823	3.3			655	3.0			168	25.6
	Total	$	761,167	30.3		$	722,359	30.7		$	38,808	5.4		Total	$	754,299	26.6		$	761,167	30.3		$	(6,868)	(0.9)

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we realize substantially higher gross margin percentages in our technology segment than in our health care distribution segment. These higher gross margins result from being both the developer and seller of software products and services, as well as certain financial services. The software industry typically realizes higher gross margins to recover investments in research and development.

In connection with the completion of the Animal Health Spin-off (see Note 22-Discontinued Operations of the Notes to the Consolidated Financial Statements included under Item 1 for additional details), we entered into a transition services agreement with Covetrus, pursuant to which Covetrus purchases certain products from us. The agreement provides that these products will be sold to Covetrus at a mark-up that ranges from 3% to 6% of our product cost to cover handling costs. ~~We expect these~~These sales ~~to continue through August~~have been substantially completed as of October 2020.

Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in the mix of products sold as well as changes in our customer mix have been the most significant drivers affecting our gross profit margin. For example, sales of our private label products achieve gross profit margins that are higher than average. With respect to customer mix, sales to our large-group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the gross margin on sales to office-based practitioners, who normally purchase lower volumes at greater frequencies.

Health care distribution gross profit ~~increased $23.4~~decreased $6.8 million, or ~~3.7%~~1.0%, for the three months ended September ~~28, 2019~~26, 2020 compared to the prior year period, due primarily to the COVID-19 pandemic. Health care distribution gross profit margin decreased to 24.4% for the three months ended September 26, 2020 from 28.1% for the comparable prior year period. The overall ~~increase~~decrease in our health care distribution gross profit is attributable to ~~$23.5 million additional gross profit from acquisitions and $8.8 is attributable to growth in internally generated revenue. These increases were partially offset by $8.9~~an $85.2 million decline in gross profit due to the decrease in the gross margin ~~rates. Health care distribution gross profit margin decreased to 28.1% for the three months ended September 28, 2019 from 28.5% for the comparable prior year period.~~

~~Technology~~rates and ~~value-added services gross profit increased $14.8~~$1.4 million ~~or 17.2%, for the three months ended September 28, 2019 compared to the prior year period. The overall increase~~reduction in ~~our Technology and value-added services gross profit is attributable to $10.7 million additional~~ gross profit from acquisitions, ~~$3.6~~partially offset by an increase of $77.0 million from ~~growth in~~ internally generated ~~revenue, and $0.5million from increased gross margin rates~~. ~~Technology and value-added services gross~~revenue. Gross profit margin ~~increased to 73.2% for the three months ended September 28, 2019 from 71.9% for the comparable prior year period,~~was negatively affected by PPE products, primarily due to ~~increased~~significant adjustments recorded for PPE inventory and other COVID-19 related products caused by volatility of pricing and demand experienced during the quarter, which conditions may recur and adversely impact gross ~~margin rates from certain businesses acquired~~profit margins in future periods. During the quarter, we continued to earn lower vendor rebates, due to lower purchase volumes, during ~~2019.~~the year in our health care distribution segment, which also contributes to the lower gross profit margin.

5245

Table of Contents

Technology and value-added services gross profit decreased $0.3 million, or 0.3%, for the three months ended September 26, 2020 compared to the prior year period. The overall decrease in our Technology and value-added services gross profit is attributable to a $0.8 million decrease in internally generated revenue, primarily due to the COVID-19 pandemic and a decrease of $1.3 million from gross margin rates, partially offset by $1.8 million additional gross profit from acquisitions. Technology and value-added services gross profit margin decreased to 72.5% for the three months ended September 26, 2020 from 73.2% for the comparable prior year period primarily due to a decrease in the volume of our transactional revenue from eClaims and credit card processing.

Selling, General and Administrative

Selling, general and administrative expenses by segment and in total for the three months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 were as follows (in thousands):

				% of				% of									% of				% of
		September 28,		Respective		September 29,		Respective		Increase / (Decrease)					September 26,		Respective		September 28,		Respective		Decrease
		2019		Net Sales		2018		Net Sales		$		%			2020		Net Sales		2019		Net Sales		$		%
Health care distribution	Health care distribution	$	511,116	21.8	%	$	545,275	24.4	%	$	(34,159)	(6.3)	%	Health care distribution	$	505,370	18.9	%	$	511,116	21.8	%	$	(5,746)	(1.1)	%
Technology and value-added services	Technology and value-added services		62,853	45.8			53,815	45.1			9,038	16.8		Technology and value-added services		61,258	44.3			62,853	45.8			(1,595)	(2.5)
	Total	$	573,969	22.9		$	599,090	25.4		$	(25,121)	(4.2)		Total	$	566,628	20.0		$	573,969	22.9		$	(7,341)	(1.3)

Selling, general and administrative expenses (including restructuring ~~credits in the three months ended September 28, 2019 and litigation settlements and restructuring~~ costs in the three months ended September ~~29, 2018)~~26, 2020 and September 26, 2020) decreased ~~$25.1~~$7.3 million, or ~~4.2%~~1.3%, for the three months ended September ~~28, 2019~~26, 2020 from the comparable prior year period. The ~~$34.2~~$5.7 million decrease in selling, general and administrative expenses within our health care distribution segment for the three months ended September ~~28, 2019~~26, 2020 as compared to the prior year period was attributable to a reduction of ~~$44.3~~$16.9 million of operating costs, ~~(primarily due~~primarily as a result of cost-saving measures taken in response to ~~$38.5 million of litigation settlement costs recorded in~~ the ~~third quarter of 2018), and a $8.0 million decrease in restructuring costs~~COVID-19 pandemic, partially offset by ~~$18.1~~increases of $3.6 million of additional costs from acquired ~~companies.~~companies and an increase of $7.6 million in restructuring costs. The ~~$9.0~~$1.6 million ~~increase~~decrease in selling, general and administrative expenses within our technology and value-added services segment for the three months ended September ~~28, 2019~~26, 2020 as compared to the prior year period was attributable to ~~$8.8~~a reduction of $3.3 million of operating costs, primarily as a result of cost-saving measures taken in response to the COVID-19 pandemic, partially offset by an increase of $1.5 million of additional costs from acquired companies and an increase of ~~$1.6~~$0.2 million ~~of operating costs, partially offset by a $1.4 million decrease~~ in restructuring costs. As a percentage of net sales, selling, general and administrative expenses decreased to ~~22.9%~~20.0% from ~~25.4%~~22.9% for the comparable prior year ~~period.~~period, primarily due to the cost-saving measures taken in response to the COVID-19 pandemic, partially offset by an increase in restructuring costs. The cost savings achieved from measures taken in response to the COVID-19 pandemic are expected to diminish in future periods as most measures were temporary and ended during the third quarter of 2020.

As a component of total selling, general and administrative expenses, selling expenses ~~increased $18.5~~decreased $12.6 million, or ~~5.3%~~3.5% to ~~$365.2~~$345.7 million, for the three months ended September ~~28, 2019~~26, 2020 from the comparable prior year ~~period.~~period, primarily as a result of cost-saving measures taken in response to the COVID-19 pandemic. As a percentage of net sales, selling expenses decreased to ~~14.6%~~12.2% from ~~14.7%~~14.3% for the comparable prior year period.

As a component of total selling, general and administrative expenses, general and administrative expenses ~~decreased $43.6~~increased $5.3 million, or ~~17.3%~~2.4% to ~~$208.8~~$220.9 million, for the three months ended September ~~28, 2019~~26, 2020 from the comparable prior year period, primarily due to ~~$38.5 million of litigation settlement costs recorded~~an increase in ~~the third quarter of 2018 and a $9.4 million reduction of~~ restructuring costs. As a percentage of net sales, general and administrative expenses decreased to ~~8.3%~~7.8% from ~~10.7%~~8.6% for the comparable prior year period.

5346

Table of Contents

Other Expense, Net

Other expense, net, for the three months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 was as follows (in thousands):

		September 28,		September 29,		Variance					September 26,		September 28,		Variance
		2019		2018		$		%			2020		2019		$		%
Interest income	Interest income	$	3,943	$	3,928	$	15	0.4	%	Interest income	$	2,294	$	3,943	$	(1,649)	(41.8)	%
Interest expense	Interest expense		(12,373)		(20,430)		8,057	39.4		Interest expense		(11,111)		(12,373)		1,262	10.2
Other, net	Other, net		(177)		(586)		409	69.8		Other, net		(1,699)		(177)		(1,522)	(859.9)
	Other expense, net	$	(8,607)	$	(17,088)	$	8,481	49.6		Other expense, net	$	(10,516)	$	(8,607)	$	(1,909)	(22.2)

Interest ~~expense~~income decreased ~~$8.1~~$1.6 million primarily due to lower interest rates and reduced late fee income. Interest expense decreased $1.3 million primarily due to reduced interest expense resulting from decreased borrowings under our U.S trade accounts receivable securitization and lower interest rates, partially offset by increased borrowings under our bank credit lines. Other, net increased primarily due to certain litigation-related costs.

Income Taxes

For the three months ended September ~~28, 2019,~~26, 2020, our effective tax rate was ~~23.5%~~16.4% compared to ~~15.7~~% 23.5% for the prior year period. The difference between our effective tax rate and the federal statutory tax rate for the three months ended September 26, 2020, was primarily due to a U.S. federal income tax settlement, reached during the third quarter, which lowered income tax expense by approximately $15.6 million, as well as state and foreign income taxes and interest. The difference between our effective tax rate and the federal statutory tax rate for the three months ended September 28, 2019 primarily relates to state and foreign income taxes and interest expense. The difference between our effective tax rate and the federal statutory tax rate for the three months ended September 29, 2018 primarily relates to a provisional transition tax benefit of $10 million related to the Tax Act, as well as state and foreign income taxes and interest expense.

5447

Table of Contents

Nine Months Ended September ~~28, 2019~~26, 2020 Compared to Nine Months Ended September ~~29, 2018~~28, 2019

Net Sales

Net sales for the nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 were as follows (in thousands):

			September 28,		% of		September 29,		% of		Increase						September 26,		% of		September 28,		% of		Increase/(Decrease)
			2019		Total		2018		Total		$		%				2020		Total		2019		Total		$		%
Health care distribution ^(1):
Health care distribution ⁽¹⁾															Health care distribution ⁽¹⁾
	Dental		$	4,693,803	64.1	%	$	4,674,534	67.3	%	$	19,269	0.4	%	Dental		$	4,066,221	58.5	%	$	4,693,711	64.1	%	$	(627,490)	(13.4)	%
	Medical			2,184,927	29.9			1,976,367	28.5			208,560	10.6		Medical			2,445,644	35.2			2,184,927	29.9			260,717	11.9
		Total health care distribution		6,878,730	94.0			6,650,901	95.8			227,829	3.4			Total health care distribution		6,511,865	93.7			6,878,638	94.0			(366,773)	(5.3)
Technology and value-added services ⁽²⁾	Technology and value-added services ⁽²⁾			377,891	5.2			294,146	4.2			83,745	28.5		Technology and value-added services ⁽²⁾			375,547	5.4			377,983	5.2			(2,436)	(0.6)
		Total excluding Corporate TSA revenue		7,256,621	99.2			6,945,047	100.0			311,574	4.5			Total excluding Corporate TSA revenue		6,887,412	99.1			7,256,621	99.2			(369,209)	(5.1)
Corporate TSA revenue⁽³⁾	Corporate TSA revenue⁽³⁾			60,241	0.8			-	-			60,241	-		Corporate TSA revenue ⁽³⁾			66,004	0.9			60,241	0.8			5,763	9.6
		Total	$	7,316,862	100.0	%	$	6,945,047	100.0	%	$	371,815	5.4			Total	$	6,953,416	100.0	%	$	7,316,862	100.0	%	$	(363,446)	(5.0)


(1)	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.														Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

(2)	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.														Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

(3)	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health spin-off, which we expect to continue through August 2020.														Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which has been substantially completed as of October 2020.

The ~~5.4% increase~~5.0% decrease in net sales for the nine months ended September ~~28, 2019~~26, 2020 includes ~~7.3%~~a decrease of 4.4% in local currency ~~growth (3.9% increase~~revenue (5.1% decrease in internally generated revenue, ~~and 3.4%~~partially offset by 0.7% growth from acquisitions) ~~partially offset by~~and a decrease of ~~1.9%~~0.6% related to foreign currency exchange. Excluding sales of products under the transition services agreement with Covetrus, our net sales ~~increased 4.5%~~decreased 5.1%, including a decrease in local currency ~~growth~~revenue of ~~6.4% (3.0% increase~~4.5% (5.2% decrease in internally generated revenue, ~~and 3.4%~~partially offset by 0.7% growth from acquisitions) ~~partially offset by~~and a decrease of ~~1.9%~~0.6% related to foreign currency exchange. Sales for the nine months ended September 26, 2020 benefited from an approximate 142% increase in sales of PPE and other COVID-19 related products.

The ~~0.4% increase~~13.4% decrease in dental net sales for the nine months ended September ~~28, 2019~~26, 2020 includes ~~3.2%~~a decrease of 12.4% local currency ~~growth (1.9% increase~~revenue (12.7% decrease in internally generated revenue, ~~and 1.3%~~partially offset by 0.3% growth from acquisitions) ~~offset by~~and a decrease of ~~2.8%~~1.0% related to foreign currency exchange. The ~~3.2% increase~~12.4% decrease in local currency sales was attributable to a decrease in dental consumable merchandise ~~sales growth~~revenue of ~~4.3% (2.6% increase~~11.6% (12.0% decrease in internally generated revenue, ~~and 1.7%~~partially offset by 0.4% growth from acquisitions), ~~partially offset by~~and a decrease in dental equipment sales and service revenues of ~~0.5%~~15.4%, all of which is attributable to a decrease in internally generated revenue. ~~This decrease is primarily due~~The COVID-19 pandemic began to adversely impact our worldwide dental revenue beginning in mid-March as many dental offices progressively closed or began seeing a ~~decline~~limited number of patients. However, in ~~high-tech equipment~~the second half of the quarter ended June 27, 2020 and continuing into the quarter ended September 26, 2020 our dental sales began to improve as dental practices began to resume activities and patient traffic increased. Global dental sales for the nine months ended September 26, 2020 benefited from an approximate 66% increase in ~~North America.~~sales of PPE.

The ~~10.6%~~11.9% increase in medical net sales for the nine months ended September ~~28, 2019 includes~~26, 2020 is attributable to an increase of ~~10.7%~~11.9% local currency growth ~~(5.9%~~(10.8% increase in internally generated revenue and ~~4.8%~~1.1% growth from acquisitions) ~~partially offset~~. The COVID-19 pandemic began to adversely impact our medical revenue beginning in mid-March and continuing to a lesser extent into the third quarter, as medical offices began seeing a limited increase in the number of patients. Economic conditions relating to the COVID-19 pandemic have had less of an impact on the performance of our medical group versus dental, in part due to continued strong sales of PPE, such as masks, gowns and face shields, and other COVID-19 related products, such as diagnostic test kits. Globally, our medical business experienced growth of sales of such products during the nine months ended September 26, 2020 by ~~a decrease of 0.1% related~~approximately 295% compared to ~~foreign currency exchange.~~the prior year, and these products are the primary contributor to the increase in sales during this period.

Table of Contents

The ~~28.5% increase~~0.6% decrease in technology and value-added services net sales for the nine months ended September ~~28, 2019 includes 29.6%~~26, 2020 is attributable to a decrease of 0.6% in local currency ~~growth (2.2% increase~~revenue (4.2% decrease in internally generated revenue, ~~and 27.4%~~partially offset 3.6% growth from acquisitions) ~~partially offset by a decrease~~. During the second quarter and continuing into the third quarter, in line with the resumption of ~~1.1% related to foreign currency exchange. The local currency growth in technology and value-added services is affected by~~dental practice operations, the ~~revenue~~trend for ~~certain products being recognized on a gross basis in the prior year. When excluding the effects of this change, internally generated revenue grew by 3.9%~~transactional software revenues improved as more patients visited dental practices worldwide.

~~Table of Contents~~

Although dental and medical practices continued to re-open globally in the third quarter, patient volumes remain below pre-COVID-19 levels and certain regions in the U.S and internationally are experiencing an increase in COVID-19 cases. As such, there is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our net sales in future periods.

Gross Profit

Gross profit and gross margin percentages by segment and in total for the nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 were as follows (in thousands):

		September 28,		Gross		September 29,		Gross		Increase					September 26,		Gross		September 28,		Gross		Increase/(Decrease)
		2019		Margin %		2018		Margin %		$		%			2020		Margin %		2019		Margin %		$		%
Health care distribution	Health care distribution	$	2,004,218	29.1	%	$	1,958,377	29.4	%	$	45,841	2.3	%	Health care distribution	$	1,687,615	25.9	%	$	2,004,126	29.1	%	$	(316,511)	(15.8)	%
Technology and value-added services	Technology and value-added services		274,266	72.6			201,439	68.5			72,827	36.2		Technology and value-added services		265,040	70.6			274,358	72.6			(9,318)	(3.4)
	Total excluding Corporate TSA revenues		2,278,484	31.4			2,159,816	31.1			118,668	5.5		Total excluding Corporate TSA revenues		1,952,655	28.4			2,278,484	31.4			(325,829)	(14.3)
Corporate TSA revenues	Corporate TSA revenues		1,804	3.0			-	-			1,804	-		Corporate TSA revenues		1,977	3.0			1,804	3.0			173	9.6
	Total	$	2,280,288	31.2		$	2,159,816	31.1		$	120,472	5.6		Total	$	1,954,632	28.1		$	2,280,288	31.2		$	(325,656)	(14.3)

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we realize substantially higher gross margin percentages in our technology and value-added services segment than in our health care distribution segment. These higher gross margins result from being both the developer and seller of software products and services, as well as certain financial services. The software industry typically realizes higher gross margins to recover investments in research and development.

Health care distribution gross profit ~~increased $45.8~~decreased $316.5 million, or ~~2.3%~~15.8%, for the nine months ended September ~~28, 2019~~26, 2020 compared to the prior year period, due primarily to the COVID-19 pandemic. Health care distribution gross profit margin decreased to 25.9% for the nine months ended September 26, 2020 from 29.1% for the comparable prior year period. The overall ~~increase~~decrease in our health care distribution gross profit is attributable to ~~$52.4~~a $165.7 million ~~additional gross profit from acquisitions and $10.4 is attributable to growth~~decrease in internally generated ~~revenue. These increases were partially offset by~~revenue and a ~~$17.0~~$163.5 million decline in gross profit due to the decrease in the gross margin ~~rates. Health care distribution gross profit margin decreased to 29.1% for the nine months ended September 28, 2019 from 29.4% for the comparable prior year period.~~

Technology and value-added services gross profit increased $72.8 million, or 36.2%, for the nine months ended September 28, 2019 compared to the prior year period. The overall increase in our Technology and value-added services gross profit is attributable to $70.6rates, partially offset by $12.7 million additional gross profit from ~~acquisitions and $2.2 is attributable to growth in internally generated revenue. Technology and value-added services gross~~acquisitions. Gross profit margin ~~increased to 72.6% for the three months ended September 28, 2019 from 68.5% for the comparable prior year period,~~was negatively affected by PPE products, primarily due to ~~additional product offerings at higher~~significant adjustments recorded for PPE inventory and other COVID-19 related products caused by volatility of pricing and demand experienced during the quarter, which conditions may recur and adversely impact gross profit margins in future periods. Gross profit margin was also affected by fixed costs included in cost of goods sold that adversely affect gross margin rates when sales are lower. During the year, we continued to earn lower vendor rebates, due to lower purchase volumes, in our ~~Henry Schein One subsidiary~~health care distribution segment, which ~~was formed on July 1, 2018.~~

also contributes to the lower gross profit margin.

5649

Table of Contents

Technology and value-added services gross profit decreased $9.3 million, or 3.4%, for the nine months ended September 26, 2020 compared to the prior year period. The overall decrease in our Technology and value-added services gross profit is attributable to a decrease of $11.5 million in internally generated revenue, primarily due to the COVID-19 pandemic and a $9.0 million decline in gross profit due to the decrease in the gross margin rates, partially offset by $11.2 million additional gross profit from acquisitions. Technology and value-added services gross profit margin decreased to 70.6% for the nine months ended September 26, 2020 from 72.6% for the comparable prior year period primarily due to a decrease in the volume of our transactional revenue from eClaims and credit card processing.

Selling, General and Administrative

Selling, general and administrative expenses by segment and in total for the nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 were as follows (in thousands):

				% of				% of									% of				% of
		September 28,		Respective		September 29,		Respective		Increase / (Decrease)					September 26,		Respective		September 28,		Respective		Increase / (Decrease)
		2019		Net Sales		2018		Net Sales		$		%			2020		Net Sales		2019		Net Sales		$		%
Health care distribution	Health care distribution	$	1,576,996	22.9	%	$	1,599,399	24.0	%	$	(22,403)	(1.4)	%	Health care distribution	$	1,418,115	21.8	%	$	1,576,996	22.9	%	$	(158,881)	(10.1)	%
Technology and value-added services	Technology and value-added services		181,365	48.0			117,800	40.0			63,565	54.0		Technology and value-added services		182,414	48.6			181,365	48.0			1,049	0.6
	Total	$	1,758,361	24.0		$	1,717,199	24.7		$	41,162	2.4		Total	$	1,600,529	23.0		$	1,758,361	24.0		$	(157,832)	(9.0)

Selling, general and administrative expenses (including restructuring costs in the nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018, and litigation settlements in the nine months ended September 29, 2018) increased $41.2~~26, 2020) decreased $157.8 million, or ~~2.4%~~9.0%, for the nine months ended September ~~28, 2019~~26, 2020 from the comparable prior year period. The ~~$22.4~~$158.9 million decrease in selling, general and administrative expenses within our health care distribution segment for the nine months ended September ~~28, 2019~~26, 2020 as compared to the prior year period was attributable to a reduction of ~~$65.1~~$188.2 million of operating costs, ~~(primarily due~~primarily as a result of cost-saving measures taken in response to ~~$38.5 million of litigation settlement costs recorded in 2018) and a $3.1 million decrease in restructuring costs~~the COVID-19 pandemic, partially offset by ~~$45.8~~increases of $17.6 million of additional costs from acquired ~~companies.~~companies and an increase of $11.7 million in restructuring costs. The ~~$63.6~~$1.0 million increase in selling, general and administrative expenses within our technology and value-added services segment for the nine months ended September ~~28, 2019~~26, 2020 as compared to the prior year period was attributable to ~~$64.4~~an increase of $9.2 million of additional costs from acquired companies and an increase of $0.3 million in restructuring costs, partially offset by a ~~$0.8~~reduction of $8.5 million ~~decrease in restructuring~~of operating costs. As a percentage of net sales, selling, general and administrative expenses decreased to ~~24.0%~~23.0% from ~~24.7%~~24.0% for the comparable prior year period. The cost savings achieved from measures taken in response to the COVID-19 pandemic are expected to diminish in future periods as most of these measures were temporary and ended during the third quarter of 2020.

As a component of total selling, general and administrative expenses, selling expenses ~~increased $47.7~~decreased $104.1 million, or ~~4.5%~~9.6% to $ ~~1,112.2~~980.9 million, for the nine months ended September ~~28, 2019~~26, 2020 from the comparable prior year ~~period.~~period, primarily as a result of cost-saving measures taken in response to the COVID-19 pandemic. As a percentage of net sales, selling expenses decreased to ~~15.2%~~14.1% from ~~15.3%~~14.8% for the comparable prior year period.

As a component of total selling, general and administrative expenses, general and administrative expenses decreased ~~$6.5~~$53.7 million, or ~~1.0%~~8.0% to $ ~~646.2~~619.6 million, for the nine months ended September ~~28, 2019~~26, 2020 from the comparable prior year period, primarily ~~due~~as a result of cost-saving measures taken in response to ~~$38.5 million of litigation settlement costs recorded in~~ the ~~third quarter of 2018.~~COVID-19 pandemic. As a percentage of net sales, general and administrative expenses decreased to ~~8.8%~~8.9% from ~~9.4%~~9.2% for the comparable prior year period.

Our selling, general and administrative expenses for the nine months ended September 26, 2020 continued to be affected by certain estimates we made due to the adverse business environment brought on by the COVID-19 pandemic. For example, in the quarter ended March 28, 2020 we recorded incremental bad debt reserves of approximately $10 million for our global dental business. As of September 26, 2020, we have retained the $10 million incremental bad debt reserves due to the ongoing uncertainties in the markets we serve.

5750

Table of Contents

In the quarter ended March 28, 2020, we also recognized a net credit of approximately $17.5 million in stock-based compensation expense during the quarter due to our previous estimate that no performance shares granted in 2018, 2019 or 2020 will ultimately vest. Our assumptions regarding vesting of performance shares under our 2018, 2019 and 2020 LTIP remain largely unchanged from those as of March 28, 2020. Accordingly, we did not recognize any significant stock compensation expense related to performance shares during the nine months ended September 26, 2020.

During the quarter ended March 28, 2020, we recorded total impairment charges of approximately $6.1 million during the quarter related to prepaid royalty expenses and a customer relationship intangible asset.

Other Expense, Net

Other expense, net, for the nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018~~28, 2019 was as follows (in thousands):

		September 28,		September 29,		Variance					September 26,		September 28,		Variance
		2019		2018		$		%			2020		2019		$		%
Interest income	Interest income	$	12,368	$	11,105	$	1,263	11.4	%	Interest income	$	7,481	$	12,368	$	(4,887)	(39.5)	%
Interest expense	Interest expense		(41,459)		(54,569)		13,110	24.0		Interest expense		(29,409)		(41,459)		12,050	29.1
Other, net	Other, net		(2,012)		(1,773)		(239)	(13.5)		Other, net		(2,210)		(2,012)		(198)	(9.8)
	Other expense, net	$	(31,103)	$	(45,237)	$	14,134	31.2		Other expense, net	$	(24,138)	$	(31,103)	$	6,965	22.4

Interest income ~~increased by $1.3~~decreased $4.9 million primarily due to ~~increased investment~~lower interest rates and reduced late fee income. Interest expense decreased ~~$13.1~~$12.1 million primarily due to decreased borrowings under our U.S trade accounts receivable securitization and lower interest rates, partially offset by increased borrowings under our bank credit lines.

Income Taxes

For the nine months ended September ~~28, 2019,~~26, 2020, our effective tax rate was ~~23.9%~~20.0% compared to ~~21.8%~~23.9% for the prior year period. The difference between our effective tax ~~rates~~rate and the federal statutory tax rate for the nine months ended September 26, 2020, was primarily due to a U.S. federal income tax settlement, reached during the third quarter, which lowered income tax expense by approximately $15.6 million, as well as state and foreign income taxes and interest. The difference between our effective tax rate and the federal statutory tax rate for the nine months ended September 28, 2019 primarily relates to state and foreign income taxes and interest expense. The difference between our effective tax rates and the federal statutory tax rate for the nine months ended September 29, 2018 primarily relates to a provisional transition tax benefit of $10.0 million related to the Tax Act, as well as state and foreign income taxes and interest expense.

5851

Table of Contents

Liquidity and Capital Resources

Our principal capital requirements ~~include~~have included funding of acquisitions, purchases of additional noncontrolling interests, repayments of debt principal, the funding of working capital needs, purchases of fixed assets and repurchases of common ~~stock.~~stock (which have been temporarily suspended). Working capital requirements generally result from increased sales, special inventory forward buy-in opportunities and payment terms for receivables and payables. Historically, sales have tended to be stronger during the third and fourth quarters and special inventory forward buy-in opportunities have been most prevalent just before the end of the year, and have caused our working capital requirements to be higher from the end of the third quarter to the end of the first quarter of the following year.

The pandemic and the governmental responses to it had a material adverse effect on our cash flows in the second quarter. In the latter half of the second quarter and continuing into the third quarter, dental and medical practices began to re-open worldwide. However, patient volumes remain below pre-COVID-19 levels and certain regions in the U.S. and internationally are experiencing an increase in COVID-19 cases. As such, there is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our cash flows in future periods and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time.

As part of a broad-based effort to support plans for the long-term health of our business and to strengthen the our financial flexibility, we implemented cost reduction measures that included certain reductions in payroll, substantially decreased capital expenditures, reduced corporate spending and elimination of certain non-strategic targeted expenditures. As our markets have begun to recover we have ended most of those temporary expense-reduction initiatives during the third quarter. As the COVID-19 pandemic continues to unfold, we will continue to evaluate appropriate actions for its business.

We finance our business primarily through cash generated from our operations, revolving credit facilities and debt placements. Our ability to generate sufficient cash flows from operations is dependent on the continued demand of our customers for our products and services, and access to products and services from our suppliers.

Our business requires a substantial investment in working capital, which is susceptible to fluctuations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity, special inventory forward buy-in opportunities and our desired level of inventory. We anticipate future increases in our working capital requirements.

We finance our business to provide adequate funding for at least 12 months. Funding requirements are based on forecasted profitability and working capital needs, which, on occasion, may change. Consequently, we may change our funding structure to reflect any new requirements.

We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets, and our available funds under existing credit facilities provide us with sufficient liquidity to meet our currently foreseeable short-term and long-term capital needs. We have no off-balance sheet arrangements.

On February 7, 2019, we completed the Animal Health Spin-off. On the Distribution Date we received a tax free distribution of $1,120 million from Covetrus, which has been used to pay down our debt, thereby generating additional debt capacity that can be used for general corporate purposes, including share repurchases and mergers and acquisitions.

Net cash from continuing operations provided by operating activities was ~~$525.2~~$248.4 million for the nine months ended September ~~28, 2019,~~26, 2020, compared to net cash from continuing operations provided by operating activities of ~~$269.4~~$525.2 million for the comparable prior year period. The net change of ~~$255.8~~$276.8 million was primarily attributable to ~~increased~~lower net income, ~~decreases in~~lower distributions from equity affiliates, and increased working capital requirements, specifically an increase in inventories due to stocking of PPE and ~~increased~~other COVID-19 related products, and an increase in accounts receivable due to higher third quarter sales volume. These working capital increases were partially offset by greater growth in accounts payable and accrued expenses. The decrease in distributions from equity ~~affiliates.~~affiliates is the result of having sold our equity investment in Hu-Friedy Mfg. Co., LLC in the fourth quarter of 2019.

Table of Contents

Net cash from continuing operations used in investing activities was ~~$691.3~~$94.0 million for the nine months ended September ~~28, 2019,~~26, 2020, compared to ~~$124.1~~$691.3 million for the comparable prior year period. The net change of ~~$567.2~~$597.3 million was primarily attributable to ~~increased~~decreased payments for equity investments and business acquisitions.

Net cash from continuing operations provided by financing activities was ~~$176.1~~$264.4 million for the nine months ended September ~~28, 2019,~~26, 2020, compared to net cash ~~used in~~provided by financing activities of ~~$219.9~~$176.1 million for the comparable prior year period. The net change of ~~$396.0~~$88.3 million was primarily due to ~~a distribution~~increased net proceeds from bank borrowings and lower repurchases of our common stock, partially offset by proceeds received during the prior year related to the Animal Health Spin-off, proceeds from the Animal Health Share Sale, a reduction in acquisitions of noncontrolling interests in subsidiaries, and payments to the Henry Schein Animal Health Business partially offset by increased repayments of debt related to the Animal Health Spin-off and increased repurchases of our common stock.Spin-off.

~~Table of Contents~~

The following table summarizes selected measures of liquidity and capital resources (in thousands):

			September 28,		December 29,				September 26,		December 28,
			2019		2018				2020		2019
Cash and cash equivalents	Cash and cash equivalents		$	75,256	$	56,885	Cash and cash equivalents		$	533,495	$	106,097
Working capital⁽¹⁾	Working capital⁽¹⁾			1,207,050		956,393	Working capital⁽¹⁾			1,265,443		1,188,133

Debt:	Debt:						Debt:
	Bank credit lines		$	107,841	$	951,458	Bank credit lines		$	507,372	$	23,975
	Current maturities of long-term debt			109,188		8,280	Current maturities of long-term debt			110,015		109,849
	Long-term debt			872,229		980,344	Long-term debt			515,357		622,908
		Total debt	$	1,089,258	$	1,940,082		Total debt	$	1,132,744	$	756,732

Leases:	Leases:						Leases:
		Current operating lease liabilities	$	67,374	$	-	Current operating lease liabilities		$	62,914	$	65,349
		Non-current operating lease liabilities		182,505		-	Non-current operating lease liabilities			200,611		176,267

(1)							Includes $0 million and $127 million of accounts receivable which serve as security for U.S. trade accounts receivable securitization at September 26, 2020 and December 28, 2019 respectively.
(1)	Includes $419 million and $422 million of accounts receivable which serve as security for U.S. trade accounts receivable securitization at September 28, 2019 and December 29, 2018 respectively.

Our cash and cash equivalents consist of bank balances and investments in money market funds representing overnight investments with a high degree of liquidity.

Accounts receivable days sales outstanding and inventory turns

Our accounts receivable days sales outstanding from operations increased to 48.8 days as of September 26, 2020 from 45.3 days as of September 28, ~~2019 from 44.2 days as of September 29, 2018.~~2019. During the nine months ended September ~~28, 2019,~~26, 2020, we wrote off approximately ~~$4.4~~$5.0 million of fully reserved accounts receivable against our trade receivable reserve. Our inventory turns from operations ~~increased~~decreased to 4.7 as of September 26, 2020 from 4.9 as of September 28, ~~2019 from 4.4 as of September 29, 2018.~~2019. Our working capital accounts may be impacted by current and future economic conditions.

Bank Credit Lines

Bank credit lines consisted of the following:

		September 28,		December 29,			September 26,		December 28,
		2019		2018			2020		2019
Revolving credit agreement	Revolving credit agreement	$	75,000	$	175,000	Revolving credit agreement	$	-	$	-
364-day credit agreement						364-day credit agreement		500,000		-
Other short-term bank credit lines	Other short-term bank credit lines		32,841		376,458	Other short-term bank credit lines		7,372		23,975
Committed loan associated with Animal Health Spin-off			-		400,000
Total	Total	$	107,841	$	951,458	Total	$	507,372	$	23,975

The increase in the level of borrowings under our bank credit lines as of September 26, 2020 was attributable to potential cash requirements due to the impact of the COVID-19 pandemic.

Table of Contents

Revolving Credit Agreement

On April 18, 2017, we entered into a $750 million revolving credit agreement (the “Credit Agreement”)~~. This facility,~~, which matures in April ~~2022, replaced our $500 million revolving credit facility, which was scheduled to mature in September 2019.~~2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. We expect ~~that~~ the LIBOR rate ~~will~~to be discontinued at some point during ~~2021. We expect~~2021, which will require an amendment to ~~work with our lenders to identify a suitable replacement rate and amend~~ our debt agreements to reflect ~~this~~a new reference ~~rate accordingly.~~rate. We do not ~~believe that~~expect the discontinuation of LIBOR as a reference rate in our debt agreements ~~will~~to have a material adverse effect on our financial position or to materially affect our interest expense. ~~Additionally, the~~The Credit Agreement ~~provides,~~also requires, among other things, that we ~~are required to~~ maintain maximum leverage ~~ratios, and~~ratios. Additionally, the Credit Agreement contains customary representations, warranties and affirmative ~~covenants. The Credit Agreement also contains~~covenants as well as customary negative covenants, subject to negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive

~~Table of Contents~~

agreements. As of September ~~28, 2019~~26, 2020 and December ~~29, 2018,~~28, 2019, the borrowings on this revolving credit facility were ~~$75.0~~$0.0 million and ~~$175.0~~$0.0 million, respectively. As of September 26, 2020 and December 28, 2019, ~~and December 29, 2018,~~ there were ~~$9.6~~$9.5 million and ~~$11.2~~$9.6 million of letters of credit, respectively, provided to third parties under the credit facility.

On April 17, 2020, we amended the Credit Agreement to, among other things, (i) modify the financial covenant from being based on total leverage ratio to net leverage ratio, (ii) adjust the pricing grid to reflect the net leverage ratio calculation, and (iii) increase the maximum maintenance leverage ratio through March 31, 2021.

364-Day Credit Agreement

On April 17, 2020, we entered into a new $700 million 364-day credit agreement, with JPMorgan Chase Bank, N.A. and U.S. Bank National Association as joint lead arrangers and joint bookrunners. This facility matures on April 16, 2021. As of September 26, 2020, the borrowings on this credit facility were $500 million. We have the ability to borrow the remaining $200 million on a revolving basis as needed, subject to the terms and conditions of the credit agreement. The interest rate for borrowings under this facility will fluctuate based on our net leverage ratio. At September 26, 2020, the interest rate on this facility was 2.81%. The proceeds from this facility can be used for working capital requirements and general corporate purposes, including, but not limited to, permitted refinancing of existing indebtedness.

Other Short-Term Credit Lines

As of September ~~28, 2019~~26, 2020 and December ~~29, 2018,~~28, 2019, we had various other short-term bank credit lines available, of which ~~$32.8~~$7.4 million and ~~$376.5~~$24 million, respectively, were outstanding. At September ~~28, 2019~~26, 2020 and December ~~29, 2018,~~28, 2019, borrowings under all of ~~our~~these credit lines had a weighted average interest rate of ~~2.94%~~2.82% and ~~3.30%~~3.45%, respectively.

~~Committed Loan Associated with Animal Health Spin-off~~The decrease during the quarter ended September 26, 2020 in the weighted average interest rate under all of our credit lines was attributable to the Federal Reserve lowering borrowing rates during March 2020 in response to the COVID-19 pandemic.

Table of Contents

On May 21, 2018, we obtained a $400 million committed loan which matured on the earlier of (i) March 31, 2019 and (ii) the consummation of the Animal Health Spin-off. The proceeds of this loan were used, among other things, to fund our purchase of all of the equity interests in Butler Animal Health Holding Company, LLC (“BAHHC”) directly or indirectly owned by Darby Group Companies, Inc. (“Darby”) and certain other sellers pursuant to the terms of that certain Amendment to Put Rights Agreements, dated as of April 20, 2018, by and among us, Darby, BAHHC and the individual sellers party thereto for an aggregate purchase price of $365 million. As of December 29, 2018, the balance outstanding on this loan was $400 million and is included within the “Bank credit lines” caption within our consolidated balance sheet. At December 29, 2018, the interest rate on this loan was 3.38%. Concurrent with the completion of the Animal Health Spin-off on February 7, 2019, we re-paid the balance of this loan.

Long-term debt

Long-term debt consisted of the following:

September 28,

December 29,

2019

2018
Private placement facilities

$
621,217

$
628,189
U.S. trade accounts receivable securitization

350,000

350,000
Various collateralized and uncollateralized loans payable with interest

in varying installments through 2024 at interest rates

ranging from 2.56% to 10.5% at September 28,2019 and

ranging from 2.61% to 4.17% at December 29, 2018

5,995

6,491
Finance lease obligations payable through 2029 with interest rates

ranging from 1.64% to 19.13% at September 28,2019 and

ranging from 1.45% to 6% at December 29, 2018

4,205

3,944
Total

981,417

988,624
Less current maturities

(109,188)

(8,280)

Total long-term debt

$
872,229

$
980,344

~~Table of Contents~~

		September 26,		December 28,
		2020		2019
Private placement facilities		$	613,549	$	621,274
U.S. trade accounts receivable securitization			-		100,000
Note payable due in 2025 with an interest rate of 3.1%
	at September 26, 2020		1,438		-
Various collateralized and uncollateralized loans payable with interest,
	in varying installments through 2023 at interest rates
	ranging from 2.62% to 4.22% at September 26, 2020 and
	ranging from 2.56% to 10.5% at December 28, 2019		4,273		6,089
Finance lease obligations (see Note 7)			6,112		5,394
	Total		625,372		732,757
Less current maturities			(110,015)		(109,849)
	Total long-term debt	$	515,357	$	622,908

Private Placement Facilities

On June 23, 2020, we amended the private placement facilities to, among other things, (i) temporarily modify the financial covenant from being based on total leverage ratio to net leverage ratio until March 31, 2021, (ii) increase the maximum maintenance leverage ratio through March 31, 2021, but with a 1.00% interest rate increase on the outstanding notes if the net leverage ratio exceeds 3.0x, which will remain in effect until we deliver financials for a four-quarter period ending on or after June 30, 2021 showing compliance with the total leverage ratio requirement, and (iii) make certain other changes conforming to the Credit Agreement, dated as of April 18, 2017.

Table of Contents

The components of our private placement facility borrowings as of September ~~28, 2019~~26, 2020 are presented in the following table (in thousands):


		Amount of						Amount of
		Borrowing		Borrowing				Borrowing		Borrowing
Date of Borrowing		Outstanding		Rate		Due Date		Outstanding		Rate		Due Date
September 2, 2010		$	100,000	3.79	%	September 2, 2020
January 20, 2012(1)			50,000	3.45		January 20, 2024		$	14,286	3.09	%	January 20, 2022
January 20, 2012⁽¹⁾			21,429	3.09		January 20, 2022			50,000	3.45		January 20, 2024
December 24, 2012			50,000	3.00		December 24, 2024			50,000	3.00		December 24, 2024
June 2, 2014			100,000	3.19		June 2, 2021			100,000	3.19		June 2, 2021
June 16, 2017			100,000	3.42		June 16, 2027			100,000	3.42		June 16, 2027
September 15, 2017			100,000	3.52		September 15, 2029			100,000	3.52		September 15, 2029
January 2, 2018			100,000	3.32		January 2, 2028			100,000	3.32		January 2, 2028
September 2, 2020⁽²⁾									100,000	2.35		September 3, 2030
Less: Deferred debt issuance costs			(212)						(737)
		$	621,217					$	613,549


(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.	(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.						(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.
(2) On September 2, 2020, we refinanced our $100 million private placement borrowing at 3.79%, originally due on September 2, 2020, with a similar 10-year borrowing at 2.35% maturing on September 2, 2030.							(2) On September 2, 2020, we refinanced our $100 million private placement borrowing at 3.79%, originally due on September 2, 2020, with a similar 10-year borrowing at 2.35% maturing on September 2, 2030.

U.S. Trade Accounts Receivable Securitization

We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. Our current facility, which has a purchase limit of $350 million, ~~and~~ was ~~previously~~ scheduled to expire on April 29, 2022. On June 22, 2020, ~~has been~~the expiration date for this facility was extended to ~~April 29, 2022. The~~June 12, 2023. As of September 26, 2020 and December 28, 2019, the borrowings outstanding under this securitization facility were ~~$350~~$0 million ~~as of both September 28, 2019~~ and ~~December 29, 2018,~~$100 million, respectively. At September 26, 2020, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.22% plus 0.95%, for a combined rate of 1.17%. At December 28, 2019, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of ~~2.21%~~1.90% plus 0.75%, for a combined rate of ~~2.96%~~2.65%. ~~At December 29, 2018, the interest rate on borrowings~~

Borrowings under this facility are presented as a component of Long-term debt within our consolidated balance ~~sheet.~~sheets.

~~Table~~On June 22, 2020 we amended this facility to adjust certain covenant levels, in particular for the second and third quarters of ~~Contents~~2020.

Leases

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles, and certain equipment. Our leases have remaining terms of less than 1one year to approximately 16 years, some of which may include options to extend the leases for up to 10 years.As of September ~~28, 2019,~~26, 2020, our right-of-use assets related to operating leases were ~~$240.1~~$249.9 million and our current and non-current operating lease liabilities were ~~$67.4~~$62.9 million and ~~$182.5~~$200.6 million, respectively.

Table of Contents

Stock Repurchases

From ~~June 21, 2004~~March 3, 2003 through September ~~28, 2019,~~26, 2020, we repurchased ~~$3.2~~$3.6 billion, or ~~63,466,633~~75,563,289 shares, under our common stock repurchase programs, with ~~$75.0~~$201.2 million available as of September ~~28, 2019~~26, 2020 for future common stock share repurchases.

~~On October 30, 2019,~~As a result of the COVID-19 pandemic, as previously announced, we have temporarily suspended our ~~Board of Directors authorized the~~share repurchase ~~of up~~program in an effort to ~~an additional $400 million~~preserve cash and exercise caution during this uncertain period and due to certain restrictions related to financial covenants in ~~shares of~~ our ~~common stock.~~credit facilities.

Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the ~~Redeemable~~redeemable noncontrolling interests for the nine months ended September ~~28, 2019~~26, 2020 and the year ended December ~~29, 2018~~28, 2019 are presented in the following table:

		September 28,		December 29,			September 26,		December 28,
		2019		2018			2020		2019
Balance, beginning of period	Balance, beginning of period	$	219,724	$	465,585	Balance, beginning of period	$	287,258	$	219,724
Decrease in redeemable noncontrolling interests due to	Decrease in redeemable noncontrolling interests due to					Decrease in redeemable noncontrolling interests due to
	redemptions		(2,270)		(287,767)	redemptions		(12,636)		(2,270)
Increase in redeemable noncontrolling interests due to
Increase in redeemable noncontrolling interests due to business						Increase in redeemable noncontrolling interests due to business
	business acquisitions		73,975		4,655	acquisitions		25,955		74,865
Net income attributable to redeemable noncontrolling interests	Net income attributable to redeemable noncontrolling interests		10,618		15,327	Net income attributable to redeemable noncontrolling interests		7,253		14,838
Dividends declared	Dividends declared		(7,943)		(8,206)	Dividends declared		(7,272)		(10,264)
Effect of foreign currency translation loss attributable to	Effect of foreign currency translation loss attributable to					Effect of foreign currency translation loss attributable to
	redeemable noncontrolling interests		(4,912)		(11,330)	redeemable noncontrolling interests		(10,999)		(2,335)
Change in fair value of redeemable securities	Change in fair value of redeemable securities		(5,867)		41,460	Change in fair value of redeemable securities		5,141		(7,300)
Balance, end of period	Balance, end of period	$	283,325	$	219,724	Balance, end of period	$	294,700	$	287,258

Additionally, some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. Any adjustments to these accrual amounts are recorded in our consolidated ~~statement~~statements of income. For the nine months ended September ~~28, 2019~~26, 2020 and September ~~29, 2018,~~28, 2019, there were no material adjustments recorded in our consolidated ~~statement~~statements of income relating to changes in estimated contingent purchase price liabilities.

~~Table of Contents~~

Noncontrolling Interests

Noncontrolling interests represent our less than 50% ownership interest in an acquired subsidiary. Our net income is reduced by the portion of the subsidiaries net income that is attributable to noncontrolling interests.

Table of Contents

Critical Accounting Policies and Estimates

There have been no material changes in our critical accounting policies and estimates from those disclosed in Item 7 of our Annual Report on Form 10-K for the year ended December ~~29, 2018,~~28, 2019, except accounting policies adopted as of December ~~30, 2018~~29, 2019, which are discussed in Note 33-Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards of the Notes to the Consolidated Financial Statements included inunder Item 1.

~~Recently Issued Accounting Standards~~Our financial results for the nine months ended September 26, 2020 were affected by certain estimates we made due to the adverse business environment brought on by the COVID-19 pandemic. For example, in the quarter ended March 28, 2020 we recorded incremental bad debt reserves of approximately $10.0 million for our global dental business and continued to retain those incremental reserves through the quarter ended September 26, 2020. During the quarter ended March 28, 2020, we also recognized a net credit of approximately $17.5 million in stock-based compensation expense due to our estimate that no performance shares granted in 2018, 2019 or 2020 will ultimately vest. For the quarter ended September 26, 2020, we continued to estimate that no such performance-based shares will ultimately vest. Additionally in the quarter ended March 28, 2020, we recorded total impairment charges of approximately $6.1 million related to prepaid royalty expenses and a customer relationship intangible asset. We had no material impairment charges in the quarter ended September 26, 2020. Although our selling, general and administrative expenses for the nine months ended September 26, 2020 represent management's best estimates and assumptions that affect the reported amounts, our judgment could change in the future due to the significant uncertainty surrounding the macroeconomic effect of the COVID-19 pandemic.

~~In June 2016, the Financial Accounting Standards Board (“FASB”) issued~~ Accounting Standards Update (“ASU”) No. 2016-13, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2018. This ASU is required to be adopted using the modified retrospective basis, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance of this ASU is effective. Based upon the level and makeup of our financial asset portfolio, past loan loss activity and current known activity regarding our outstanding loans, we do not expect that this ASU will have a material impact on our consolidated financial statements.

~~In January 2017,~~For a discussion of accounting standards updates that have been adopted or will be adopted, see Note 3-Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards of the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other” (Topic 350) (“ASU 2017-04”). ASU 2017-04 eliminates step two from the goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of a reporting unit. ASU 2017-04 will require us to perform our annual goodwill impairment test by comparing the fair value of our reporting unitsNotes to the carrying value of those units. If the carrying value exceeds the fair value, we will be required to recognize an impairment charge; however, the impairment charge should not exceed the amount of goodwill allocated to such reporting unit. ASU 2017-04 is required to be implemented on a prospective basis for fiscal years beginning after December 15, 2019. We do not expect that the requirements of ASU 2017-04 will have a material impact on our consolidated financial statements.Consolidated Financial Statements included under Item 1.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our exposure to market risk from that disclosed in Item 7A of our Annual Report on Form 10-K for the year ended December ~~29, 2018.~~

28, 2019.

6458

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of management, including our principal executive officer and principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this quarterly report as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures were effective as of September ~~28, 2019~~26, 2020 to ensure that all material information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and that all such information is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

The combination of continued acquisition integrations and ~~systems~~system implementations undertaken during the quarter and carried over from prior quarters as well as changes to the operating methods of some of our internal controls over financial reporting due to the COVID-19 pandemic, when considered in the aggregate, represents a material change in our internal control over financial reporting.

During the quarter ended September ~~28, 2019,~~26, 2020, post-acquisition integration related activities continued for our global dental and North American ~~technology and~~ medical businesses acquired during prior quarters, representing aggregate annual revenues of approximately ~~$539~~$345 million. These acquisitions, the majority of which utilize separate information and financial accounting systems, have been included in our consolidated financial statements since their respective dates of acquisition.

Also, during the quarter ended September ~~28, 2019, post-implementation~~26, 2020, we completed the systems implementation activities related to a new CRM system ~~improvement activities continued~~ for a ~~new equipment system implemented during prior quarters for our~~ U.S. ~~dental~~technology business ~~representing~~having approximate aggregate annual revenues of ~~$783 million, as well as the implementation of a new ERP system for our dental business in China representing approximate aggregate annual revenues of $15~~$216 million.

All continued ~~acquisitions~~acquisition integrations and ~~systems~~system implementations ~~involved~~involve necessary and appropriate change-management controls that are considered in our ~~annual~~quarterly assessment of the design and operating effectiveness of our internal control over financial reporting.

In addition, as a result of a combination of continued governmental imposed and Company directed closures of some of our facilities due to the COVID-19 pandemic, we have had to maintain a number of changes to the operating methods of some of our internal controls. For example, moving from manual sign-offs and in-person meetings to electronic sign-offs and electronic communications such as email and telephonic or video conference due to out-of-office working arrangements. However, the design of our internal control framework and objectives over financial reporting remains unchanged and we do not believe that these changes have materially affected, or are reasonably likely to materially affect, the effectiveness of our internal control over financial reporting.

Limitations of the Effectiveness of Internal Control

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the internal control system are met. Because of the inherent limitations of any internal control system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

6559

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Beginning in January 2016, purported class action complaints were filed against Patterson Companies, Inc. (“Patterson”), Benco Dental Supply Co. (“Benco”) and Henry Schein, Inc. Although there were factual and legal variations among these complaints, eachFor a discussion of these complaints alleges, among other things, that defendants conspired to fix prices, allocate customers and foreclose competitors by boycotting manufacturers, state dental associations and others that deal with defendants’ competitors. On February 9, 2016, the U.S. District Court for the Eastern District of New York ordered all of these actions, and all other actions filed thereafter asserting substantially similar claims against defendants, consolidated for pre-trial purposes. On February 26, 2016, a consolidated class action complaint was filed by Arnell Prato, D.D.S., P.L.L.C., d/b/a Down to Earth Dental, Evolution Dental Sciences, LLC, Howard M. May, DDS, P.C., Casey Nelson, D.D.S., Jim Peck, D.D.S., Bernard W. Kurek, D.M.D., Larchmont Dental Associates, P.C., and Keith Schwartz, D.M.D., P.A. (collectively, “putative class representatives”) in the U.S. District Court for the Eastern District of New York, entitled In re Dental Supplies Antitrust Litigation, Civil Action No. 1:16-CV-00696-BMC-GRB. In the consolidated class action complaint, putative class representatives allege a nationwide agreement among Henry Schein, Benco, Patterson and non-party Burkhart Dental Supply Company, Inc. (“Burkhart”) not to compete on price. The consolidated class action complaint asserts a single count under Section 1Legal Proceedings, see Note 18–Legal Proceedings of the Sherman Act, and seeks equitable relief, compensatory and treble damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On September 28, 2018, the parties executed a settlement agreement that proposes, subject to court approval, a full and final settlement of the lawsuit on a classwide basis. Subject to certain exceptions, the settlement class consists of all persons or entities that purchased dental products directly from Henry Schein, Patterson, Benco, Burkhart, or any combination thereof, during the period August 31, 2008 through and including March 31, 2016. As a result, in our third quarter of fiscal 2018, we recorded a charge of $38.5 million, which was paid into a settlement fund in January 2019. On June 25, 2019, the district court granted final approvalNotes to the settlement, and entered final judgment dismissing the case. On July 16, 2019, Dr. William Roe, an unnamed class member that had objected to the settlement, filed a notice of appeal appealing the district court’s Final Judgment and Order Granting Motion for Final Approval of Class Settlement. On October 8, 2019, the class plaintiffs and the objector filed notice indicating that they had reached a settlement concerning the objection, which, once approved by the court, would resolve the objection. On October 24, 2019 the court approved the agreement between the objector and the plaintiffs.Consolidated Financial Statements included under Item 1.

On August 31, 2012, Archer and White Sales, Inc. (“Archer”) filed a complaint against Henry Schein, Inc. as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”) in the U.S. District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act. Archer alleges a conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit Archer’s distribution rights. On August 1, 2017, Archer filed an amended complaint, adding Patterson and Benco as defendants, and alleging that Henry Schein, Patterson, Benco and Burkhart conspired to fix prices and refused to compete with each other for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer. Archer seeks damages in an amount to be proved at trial, to be trebled with interest and costs, including attorneys’ fees, jointly and severally, as well as injunctive relief. On October 30, 2017, Archer filed a second amended complaint, to add additional allegations that it believes support its claims. The named parties and causes of action are the same as the August 1, 2017 amended complaint.

~~Table of Contents~~

affirmed the District Court’s order denying the motions to compel arbitration. On June 25, 2018, the Supreme Court of the United States granted defendants’ petition for writ of certiorari. On October 29, 2018, the Supreme Court heard oral arguments. On January 8, 2019, the Supreme Court issued its published decision vacating the judgment of the Fifth Circuit and remanding the case to the Fifth Circuit for further proceedings consistent with the Supreme Court’s opinion. On April 2, 2019, the District Court stayed the proceeding in the trial court pending resolution by the Fifth Circuit. The Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated. The Fifth Circuit issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel arbitration. Defendants filed a petition for rehearing en banc before the Fifth Circuit. The Fifth Circuit has not ruled on that petition. On October 1, 2019, the District Court set the case for trial on February 3, 2020. We intend to defend ourselves vigorously against this action.

IQ Dental alleges, among other things, that defendants conspired to suppress competition from IQ Dental and SourceOne for the marketing, distribution and sale of dental supplies and equipment in the United States, and that defendants unlawfully agreed with one another to boycott dentists, manufacturers and state dental associations that deal with, or considered dealing with, plaintiff and SourceOne. Plaintiff claims that this alleged conduct constitutes unreasonable restraint of trade in violation of Section 1 of the Sherman Act, New York’s Donnelly Act and the New Jersey Antitrust Act, and also makes pendant state law claims for tortious interference with prospective business relations, civil conspiracy and aiding and abetting. Plaintiff seeks injunctive relief, compensatory, treble and punitive damages, jointly and severally, and reasonable costs and expenses, including attorneys’ fees and expert fees. On December 21, 2017, the District Court granted the defendants’ motion to dismiss. On January 19, 2018, IQ Dental appealed the District Court’s order. On May 10, 2019, the U.S. Court of Appeals for the Second Circuit affirmed in part and reversed in part the District Court’s dismissal of the Complaint, holding that IQ Dental lacks antitrust standing to challenge the alleged boycott of SourceOne and state dental associations, but that it has standing to challenge injury related to the alleged direct boycott of its business. On June 29, 2019, the Second Circuit denied IQ Dental’s petition for rehearing or rehearing en banc. Proceedings in the District Court are ongoing. We intend to defend ourselves vigorously against this action.

On February 12, 2018, the United States Federal Trade Commission (“FTC”) filed a complaint against Benco Dental Supply Co., Henry Schein, Inc. and Patterson Companies, Inc. The FTC alleges, among other things, that defendants violated U.S. antitrust laws by conspiring, and entering into an agreement, to refuse to provide discounts to or otherwise serve buying groups representing dental practitioners. The FTC alleges that defendants conspired in violation of Section 5 of the FTC Act. The complaint seeks equitable relief only and does not seek monetary damages. We deny the allegation that we conspired to refuse to provide discounts to or otherwise serve dental buying groups and intend to defend ourselves vigorously against this action. A hearing before an administrative law judge began on October 16, 2018 and the hearing record was closed on February 21, 2019. On October 7, 2019, the administrative law judge issued his Initial Decision, finding in relevant part that the “evidence fails to prove a conspiracy involving Schein,” and dismissing the Complaint as to Schein. The Initial Decision will become the decision of the Commission on or about November 7, 2019 unless the Commission places the case on its own docket for review or stays the effective date of the decision.~~We believe this matter will not have a material adverse effect on our consolidated financial position, liquidity or results of operations.~~

~~Table of Contents~~

about Henry Schein’s business, operations and prospects during the Class Period, including matters relating to the issues in the antitrust class action and the FTC action described above, thereby causing the plaintiff and members of the purported class to pay artificially inflated prices for Henry Schein securities. The complaint sought unspecified monetary damages and a jury trial. Pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), the court appointed lead plaintiff and lead counsel on June 22, 2018 and recaptioned the putative class action as In re Henry Schein, Inc. Securities Litigation, under the same case number. Lead plaintiff filed a consolidated class action complaint on September 14, 2018. The consolidated class action complaint asserts similar claims against the same defendants (plus Timothy Sullivan) on behalf of the same putative class of purchasers during the Class Period. It alleges that Henry Schein’s stock price was inflated during that period because Henry Schein had misleadingly portrayed its dental-distribution business “as successfully producing excellent profits while operating in a highly competitive environment” even though, “in reality, [Henry Schein] had engaged for years in collusive and anticompetitive practices in order to maintain Schein’s margins, profits, and market share.” The complaint alleges that the stock price started to fall from August 8, 2017, when the company announced below-expected financial performance that allegedly “revealed that Schein’s poor results were a product of abandoning prior attempts to inflate sales volume and margins through anticompetitive collusion,” through February 13, 2018, after the FTC filed a complaint against Benco, Henry Schein and Patterson alleging that they violated U.S. antitrust laws. The complaint alleges violations of Section 10(b) of the Exchange Act and Rule 10b-5 and Section 20(a) of the Exchange Act. On September 27, 2019, the court issued a decision partially granting and partially denying defendants’ motion to dismiss the securities action. The court dismissed all claims against Messrs. Bergman and Paladino as well as the Section 10(b) claim against Henry Schein to the extent that that claim relied on the Company’s financial results and margins to allege a material misstatement or omission, and on the Company’s August 8, 2017 disclosure to allege loss causation. The court otherwise denied the motion as to Henry Schein and Mr. Sullivan. We intend to defend ourselves vigorously against this action. Henry Schein has also received a request under 8 Del. C. § 220 to inspect corporate books and records relating to the issues raised in the securities class action and the antitrust matters discussed above.

On May 3, 2018, a purported class action complaint, Marion Diagnostic Center, LLC, et al. v. Becton, Dickinson, and Co., et al., Case No. 3:18-cv-010509, was filed in the U.S. District Court for the Southern District of Illinois against Becton, Dickinson, and Co. (“Becton”); Premier, Inc. (“Premier”), Vizient, Inc. (“Vizient”), Cardinal Health, Inc. (“Cardinal”), Owens & Minor Inc. (“O&M”), Henry Schein, Inc., and Unnamed Becton Distributor Co-Conspirators. The complaint alleges that the defendants entered into a vertical conspiracy to force health care providers into long-term exclusionary contracts that restrain trade in the nationwide markets for conventional and safety syringes and safety IV catheters and inflate the prices of certain Becton products to above-competitive levels. The named plaintiffs seek to represent three separate classes consisting of all health care providers that purchased (i) Becton’s conventional syringes, (ii) Becton’s safety syringes, or (iii) Becton’s safety catheters directly from Becton, Premier, Vizient, Cardinal, O&M or Henry Schein on or after May 3, 2014. The complaint asserts a single count under Section 1 of the Sherman Act, and seeks equitable relief, treble damages, reasonable attorneys’ fees and costs and expenses, and pre-judgment and post-judgment interest. On June 15, 2018, an amended complaint was filed asserting the same allegations against the same parties and adding McKesson Medical-Surgical, Inc. as a defendant. On November 30, 2018, the District Court granted defendants’ motion to dismiss and entered a final judgment, dismissing plaintiffs’ complaint with prejudice. On December 27, 2018, plaintiffs appealed the District Court’s decision to the Seventh Circuit Court of Appeals. The parties argued the appeal on September 27, 2019 and are currently awaiting the Seventh Circuit’s ruling.

~~Table of Contents~~

around best practices for pain management, including the prescription of opioids and alternatives: (II) educating dentists and physicians, clinical associates, patients and patient networks on those best practices along with the risks of opioid addiction and alternative pain management treatment options for key indications; and ‎(III) offering grants to develop and offer training to dentists and physicians or other qualified professionals to qualify a practitioner for a waiver to prescribe or dispense buprenorphine medications. Henry Schein will pay $250,000 of Summit County’s expenses.

In addition to the County of Summit Action, Henry Schein and/or one or more of its affiliated companies have currently been named as a defendant in multiple lawsuits (currently less than one-hundred (100)), which allege claims similar to those alleged in the County of Summit Action. None of these other cases have been set for trial. These actions consist of some that have been consolidated within the MDL and are currently abated for discovery purposes, and others which remain pending in state courts and are proceeding independently and outside of the MDL. Of Henry Schein’s 2018 revenue of $9.4 billion from continuing operations, sales of opioids represented less than one-tenth of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions.

On October 9, 2018, a purported class action complaint entitled Kramer v. Henry Schein, Inc., Patterson Co., Inc., Benco Dental Supply Co., and Unnamed Co-Conspirators, was filed in the U.S. District Court for the Northern District of California. The complaint alleges that members of the proposed class, comprised of purchasers of dental services from dental practices in California, suffered antitrust injury due to an unlawful boycott, price-fixing or otherwise anticompetitive conspiracy among Henry Schein, Patterson and Benco. The complaint alleges that the alleged conspiracy overcharged California dental practices, orthodontic practices and dental laboratories on their purchase of dental supplies, which in turn passed on some or all of such overcharges to members of the California class purchasing dental services. Subject to certain exclusions, the complaint defines the class as “all persons residing in California purchasing and/or reimbursing for dental services from California dental practices on or after August 31, 2012.” The complaint alleges violations of California antitrust laws, including the Cartwright Act (Cal. Bus. and Prof. Code § 16720) and the Unfair Competition Act (Cal. Bus. and Prof. Code § 17200), and seeks a permanent injunction, actual damages to be determined at trial, trebled, reasonable attorneys’ fees and costs, and pre- and post-judgment interest. On December 7, 2018, an amended complaint was filed asserting the same claims against the same parties. On June 28, 2019, the court granted Defendants’ motions to dismiss with leave to amend. The parties subsequently stipulated to dismissal of the action with prejudice, pursuant to a settlement in which Henry Schein agreed to pay the plaintiff a de minimis amount. The court entered the stipulation of dismissal with prejudice and terminated the case on August 2, 2019.

On September 30, 2019, City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively) in the U.S. District Court for the Eastern District of New York, Case No. 2:19-cv-05530-FB-RLM. The complaint seeks to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February 8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein Animal

~~Table of Contents~~

Health Business with Vets First Choice in February 2019. The complaint alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly large customer in North America just before the Separation and Merger. The complaint seeks unspecified monetary damages and a jury trial. We intend to defend ourselves vigorously against this action.

As of September 28, 2019, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

~~Table of Contents~~

ITEM 1A. RISK FACTORS

~~There have been no material changes from~~In addition to the ~~risk~~other information set forth in this report, you should carefully consider the factors ~~disclosed~~discussed in ~~Part 1,~~ Item ~~1A, of~~1A. "Risk factors" in our Annual Report on Form 10-K for the year ended December ~~29, 2018.~~28, 2019. We provide an update to the following risk factor.

The recent COVID-19 pandemic and the responses of governments to it had, and may again have, a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. In the future, our business, results of operations, cash flows, financial condition and liquidity may be negatively impacted by the effects of other disease outbreaks, epidemics, pandemics, or similar wide spread public health concerns and other natural disasters.

The COVID-19 pandemic has had, and continues to have, an unprecedented impact on society, worldwide economic activity, and the health care sector (particularly, the dental market). As a global healthcare solutions company, the COVID-19 pandemic and the governmental responses to it had, and may again have, a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. In March and April 2020, the dental market was severely impacted by COVID-19, with many, if not a majority, of practices being closed or open on a limited basis only. Although dental practice openings and patient volume recovery in the United States and many other countries have rebounded faster than originally anticipated, they still remain below pre-COVID-19 levels, material uncertainty remains and the potential for one or more significant resurgences of COVID-19 could cause a significant reduction in dental practice openings and patient volume recovery, or further delay the return to normal operations. Even after COVID-19 has subsided, we may continue to experience material adverse impacts to our business, results of operations and cash flows as a result of, among other things, its global economic impact, including any recession that has occurred or may occur in the future, or a prolonged period of economic slowdown or the reluctance of patients to return for elective dental or medical care.

The impacts and potential impacts from the COVID-19 pandemic include, but are not limited to:

• Significant reductions in demand or significant volatility in demand for certain of our products. For example, in March and April 2020, many dental offices in the United States performed only emergency procedures, and rescheduled wellness exams and elective procedures. Dental offices in other countries also have experienced closures or restricted operations, as have medical offices around the world. Such closures and restrictions impacted our customers’ spending with us and had, and if reinstated may again have, a material adverse effect on our business, results of operations and cash flows. Although dental practice openings and patient volume recovery have rebounded faster than originally anticipated, capacity constraints in offices and demand-side factors may again lead to reductions in demand or significant volatility in demand for our products. Additionally, significant reduction in demand for certain of our products or customers’ decisions to delay the purchase of large equipment may result in us having increased inventory;

• Shortage of Certain Personal Protective Equipment (PPE). Supply chain disruptions for PPE and an increased demand for these products has resulted, and may continue to result, in backorders of certain PPE and a potential scarcity in raw materials to make certain PPE. Prices for certain PPE have been volatile. Although we have expanded our sourcing in critical product categories, added substitute products, and adapted our transportation model to shorten lead-times in product delivery, among other improvements, we still may not be able to supply our customers with the quantity of certain PPE products they demand, which may lead to our customers seeking alternative sources of supply. Furthermore, healthcare professionals’ inability to obtain a sufficient quantity of certain PPE from us and other suppliers could limit capacity at such offices, which could again result in material

Table of Contents

adverse impacts on our business, results of operations and cash flows, and could materially adversely affect our financial condition and liquidity. Conversely, we recorded significant charges in the third quarter for PPE inventory due to volatility of pricing for PPE, and, depending upon the course of the pandemic, if PPE pricing or demand decreases, our margins and the value of certain our PPE inventory could be further negatively impacted in future periods, which could result in a material adverse impact on our business, results of operations and cash flows;

• Reduction in Peoples’ Ability and Willingness to be in Public. Although some restrictions recommended by several public health organizations, and implemented by many local governments, to slow and limit the transmission of COVID-19 (including business closures and restrictions, stay-at-home and similar measures) have been lifted or partially lifted, ongoing social distancing ordinances and similar restrictions, and the potential for one or more significant resurgences of COVID-19 may result in the re-imposition of governmental social distancing and other restrictions, and/or cause people to be less willing to go to elective medical and dental appointments, which could again materially adversely affect demand for our products. A lengthened period of materially suppressed demand could again cause material adverse impacts on our business, results of operations and cash flows and could materially adversely affect our financial condition and liquidity;

• Potential delays in customer payments, or defaults on our customer credit arrangements. We generally sell products to customers with payment terms. If customers’ cash flows or operating and financial performance deteriorate, or if they are unable to make scheduled payments or obtain credit, they may not be able to pay, or may delay payment to us. Likewise, for similar reasons, suppliers may restrict credit or impose more stringent payment terms. The inability of current and/or potential customers to pay us for our products and/or services or any demands by suppliers for more stringent payment terms may materially adversely affect our business, results of operations, cash flows, financial condition and liquidity and may limit the amounts we can borrow under our trade accounts receivable securitization;

• Impact on third parties’ ability to meet their obligations to us; impact on our ability to meet obligations to third parties. Failure of third parties on which we rely, including our suppliers, contract manufacturers, distributors, contractors (including third party shippers), banks, joint venture partners and external business partners, to meet their obligations to us, or significant disruptions in their ability to do so, which may be caused by their own financial or operational difficulties, or by travel restrictions and border closures, may materially adversely affect our business, results of operations, cash flows, financial condition and liquidity. Certain of our contracts with supply partners contain minimum purchase requirements or include rebate provisions if we satisfy certain sales or purchasing targets that, in certain cases we have not been able to satisfy and in other cases we may not be able to fully satisfy, due to the impact of the COVID-19 pandemic. Rebate income recognized to date this year is less than rebates earned over the same period last year. Our failure to satisfy such contractual provisions or renegotiate more favorable terms could materially adversely affect our business, results of operations and cash flows;

• Negative impact on our workforce and impact of adapted business practices. The spread of COVID-19 has caused us to implement temporary cost reduction measures (including a payroll cost reduction plan centered around furloughs, reduced pay and work hours, voluntary unpaid time off, suspension of the 401(k) match, and job reductions), most of which have now ended, modify our business practices (including employee travel, employee work locations, and cancellation of physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees. As the COVID-19 pandemic continues to unfold, we will continue to evaluate appropriate actions for our business. Many of our employees shifted abruptly to working remotely and continue to do so. An extended period of modified pay and business practices and remote work arrangements could have a negative impact on employee morale, strain our business continuity plans, introduce operational risk (including but not limited to cybersecurity risks), and impair our ability to efficiently operate our business;

• Significant changes in political conditions. Significant changes in political conditions in markets in which we purchase and distribute our products have occurred and are expected to continue at least during the pendency of the pandemic, including quarantines, governmental or regulatory actions, closures or other restrictions that limit or close our operating facilities, restrict our employees’ ability to travel or perform necessary business functions, or

Table of Contents

otherwise constrain the operations of our business partners, suppliers, or customers, which may materially adversely affect our business, results of operations, cash flows, financial condition and liquidity;

• Potential impact on our ability to meet obligations under credit facilities. Although we recently entered into amendments to our material credit facilities to, among other things, extend the maturity dates and temporarily provide additional flexibility under certain covenants, an extended negative impact of COVID-19 on our business, results of operations, cash flows, financial condition and liquidity could impact our ability to meet our obligations under credit facilities or outstanding long term debt, which contain maximum leverage ratios, and customary representations, warranties and affirmative covenants;

• Volatility in the financial markets. Volatility in the financial markets may materially adversely affect the availability and cost of credit to us;

• Refocusing management resources to mitigate effects of COVID-19. Our management is focused on mitigating the effects of COVID-19, which has required, and may continue to require for the duration of the pandemic, a large investment of time and resources across the Company, and may delay certain strategic and other plans which could materially adversely affect our business;

• Potentialincreased costs associated with our self-insured medical insurance programs. We may incur significant employee health care costs under our self-insurance medical insurance programs if a large number of our employees and/or their covered family members become ill from COVID-19; and

• Reputational risk associated with response to COVID-19. If we do not respond appropriately to the COVID-19 pandemic, or if customers do not perceive our response to be adequate, we could suffer damage to our reputation and our brands, which could materially adversely affect our business.

The impact of COVID-19 may also exacerbate other risks discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 28, 2019, any of which could have a material adverse effect on us.

More generally, in the future our business, results of operations, cash flows, financial condition and liquidity may be negatively impacted by the effects of other disease outbreaks, epidemics, pandemics, similar wide spread public health concerns, and other natural disasters.

Table of Contents

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of equity securities by the issuer

Our share repurchase program announced on ~~June 21, 2004,~~March 3, 2003, originally allowed us to repurchase up to ~~$100~~two million of shares pre-stock splits (eight million shares post-stock splits) of our common stock, which represented approximately ~~3.5%~~2.3% of the shares outstanding at the commencement of the program. As summarized in the table below, subsequent additional increases totaling ~~$3.2~~$3.7 billion, authorized by our Board of Directors, to the repurchase program provide for a total of ~~$3.3~~$3.8 billion of shares of our common stock to be repurchased under this program.

Date of

Amount of Additional

Authorization

Repurchases Authorized

October 31, 2005

$
100,000,000

March 28, 2007

100,000,000

November 16, 2010

100,000,000

August 18, 2011

200,000,000

April 18, 2012

200,000,000

November 12, 2012

300,000,000

December 9, 2013

300,000,000

December 4, 2014

300,000,000

November 30, 2015

400,000,000

October 18, 2016

400,000,000

September 15, 2017

400,000,000

December 12, 2018

400,000,000

Date of	Amount of Additional
Authorization	Repurchases Authorized
June 21, 2004	$	100,000,000
October 31, 2005		100,000,000
March 28, 2007		100,000,000
November 16, 2010		100,000,000
August 18, 2011		200,000,000
April 18, 2012		200,000,000
November 12, 2012		300,000,000
December 9, 2013		300,000,000
December 4, 2014		300,000,000
November 30, 2015		400,000,000
October 18, 2016		400,000,000
September 15, 2017		400,000,000
December 12, 2018		400,000,000
October 30, 2019		400,000,000

As of September ~~28, 2019,~~26, 2020, we had repurchased approximately ~~$3.2~~$3.6 billion of common stock ~~(63,466,633~~(75,563,289 shares) under these initiatives, with ~~$75.0~~$201.2 million available for future common stock share repurchases.

~~The following table summarizes repurchases~~As a result of the COVID-19 pandemic, as previously announced, we have temporarily suspended our ~~common stock under our stock~~share repurchase program ~~during~~in an effort to preserve cash and exercise caution in this uncertain period and due to certain restrictions related to financial covenants in our credit facilities.

During the fiscal quarter ended September ~~28, 2019.~~26, 2020, we did not make any repurchases of our common stock. The maximum number of shares that could be purchased under this program is determined at the end of each month based on the closing price of our common stock at that time. The maximum number of shares that could be repurchased as of August 1, 2020, August 29, 2020, and September 26, 2020 were 2,927,561, 3,028,466 and 3,422,542, respectively.

Total Number

Maximum Number

Total

of Shares

of Shares

Number

Average

Purchased as Part

that May Yet

of Shares

Price Paid

of Our Publicly

Be Purchased Under
Fiscal Month

Purchased (1)

Per Share

Announced Program

Our Program (2)
6/30/19 through 8/2/19

40,000

$
69.29

40,000

2,586,437
08/03/19 through 08/31/19

721,574

61.47

721,574

2,046,215
09/01/19 through 09/28/19

810,335

63.04

810,335

1,198,470

1,571,909

1,571,909

(1) All repurchases were executed in the open market under our existing publicly announced authorized program.

(2) The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the closing price of our common stock at that time.

ITEM 5. OTHER INFORMATION

On October ~~30, 2019, our~~29, 2020, the Compensation Committee of the Board of Directors ~~authorized~~approved an amendment to the ~~repurchase~~Henry Schein, Inc. Supplemental Executive Retirement Plan (“SERP”), which reinstates our ability to make book-entry contributions to the SERP in the contribution percentage designated by the Compensation Committee, effective as of upJanuary 1, 2021. Our executive officers are eligible to ~~an additional $400 million~~participate in ~~shares~~the SERP.

The above summary is qualified in its entirely by reference to the full text of ~~our common stock.~~

the SERP amendment, which is attached hereto as Exhibit 10.2 and incorporated herein by reference.

7163

Table of Contents

ITEM 6. EXHIBITS

Exhibits.

	10.1	Henry Schein, Inc. 2020 Recovery Performance Plan. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 12, 2020.)**
	10.2	Amendment Number Three to the Henry Schein, Inc. Supplemental Executive Retirement Plan, amended and restated effective as of January 1, 2014.**+
	31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of ~~2002~~2002.+.+
	31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of ~~2002~~2002.+.+
	32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.++
	101.INS	Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL ~~document.+~~document+
	101.SCH	Inline XBRL Taxonomy Extension Schema Document+
	101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document+
	101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document+
	101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document+
	101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document+
	104	The cover page of Henry Schein, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September ~~28, 2019,~~26, 2020, formatted in Inline XBRL (included within Exhibit 101 attachments).+

+ Filed or furnished herewith.

** Indicates management contract or compensatory plan or agreement.

7264

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	Henry Schein, Inc.
	(Registrant)


	By: /s/ Steven Paladino
	Steven Paladino
	Executive Vice President and
	Chief Financial Officer
	(Authorized Signatory and Principal Financial
	and Accounting Officer)

Dated: November ~~5, 2019~~2, 2020

7365